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Abstract 
 
The Broad Institute is a research collaboration of MIT, Harvard University and affiliated hospitals, and 
the Whitehead Institute for Biomedical Research.  Its scientific mission is to “(1) create tools for genomic 
medicine and make them broadly available to the scientific community and (2) apply these tools to propel 
the understanding and treatment of disease.”  The Broad Institute contains the world’s largest high-
throughput genome sequencing center, which contributed approximately one third of the sequence for the 
Human Genome Project (HGP) completed in 2003.1 
 
The Molecular Biology Production Group (MBPG) is the most upstream part of the Broad Institute’s 
genome sequencing operation. This group is responsible for incoming DNA quality control, construction 
of DNA Libraries, and production of agar plates containing E.coli cell colonies (with many of copies of 
DNA). In this way, MPBG scales up raw DNA to a quality and quantity necessary for the subsequent 
high-volume, automated genome sequencing process.  
 
While most of the genome sequencing process at the Broad Institute had already been highly 
industrialized, MBPG had not yet undergone such a transformation and was still operated more like a 
laboratory than a manufacturing group. This low level of operations capability resulted in a highly 
variable output from MBPG processes in terms of quantity, physical quality, and data quality. 
Additionally, the MBPG processes were not well understood or measured, yet had a very significant 
effect on downstream processes in the genome sequencing center. 
 
Thus, the goal of this thesis was to create a framework for improving the operations capability of a 
molecular biology laboratory in a high throughput genome sequencing center.  This framework defined an 
operations strategy of maximizing quality in MBPG, characterized the group’s sources of quality 
problems, implemented lean manufacturing and production forecasting in MBPG, and defined future 
opportunities for MBPG to implement Six Sigma and RFID.  This thesis work resulted in significant 
quality improvements in MBPG as well as a much more industrial approach to the management of the 
laboratory’s operations.  More broadly, this thesis work can be applied to the operations capability 
improvement of any high-throughput laboratory in the biotechnology and pharmaceutical industry. 
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1 Introduction 
 
Rapid advancements in genome science and previews of its potential applications have prompted experts 
to predict that biotechnology will be the most influential science of the 21st century.  Breakthroughs in the 
areas of biological techniques, process automation, information technology, and computational methods 
have enabled this modern study of genomics.  With these tools, the biotechnology industry can access 
cellular DNA, generate large quantities of information on biological processes, and derive scientific 
insights from these massive data sets.  This thesis focuses on how operations management tools have been 
applied to advance the field of genomics, specifically to improve the operations capability of a molecular 
biology laboratory in a high throughput genome sequencing center. 
 
A primary contributor to these advances in genomics has been the Broad Institute of MIT and Harvard, 
formerly known as the Whitehead Institute Center for Genomic Research.  The Broad Institute is a 
research collaboration of MIT, Harvard University and affiliated hospitals, and the Whitehead Institute 
for Biomedical Research.  Its scientific mission is to “(1) create tools for genomic medicine and make 
them broadly available to the scientific community and (2) apply these tools to propel the understanding 
and treatment of disease.”  The Broad Institute contains the world’s largest high-throughput genome 
sequencing center, which contributed approximately one third of the sequence for the Human Genome 
Project (HGP) completed in 2003.2 
 
During the completion of the HGP in the 1990s and early 2000s, the purpose of the Broad Institute’s 
sequencing operation was to rapidly scale-up or “industrialize” the genome sequencing process.  This 
industrialization of sequencing refers to its transition from being a highly skilled craft performed by a few 
very well-educated biologists to a large-scale, coordinated production process involving over one hundred 
technicians, engineers, managers, and scientists.  In order to achieve scale, speed, and efficiency, the 
sequencing process was deconstructed into simpler, repetitive steps, utilizing high-volume process 
automation and operations management tools.  Complementing this work structure, the organization 
divided itself around individual processes, resulting in a layered hierarchy of departments and sub-
departments traditionally found in most manufacturing plants.  The Broad Institute effectively created the 
world’s premier genome sequencing factory, one of the first applications of manufacturing-style 
management to biotechnology research and development (R&D) processes. 
 
The Molecular Biology Production Group (MBPG) is the most upstream part of the Broad Institute’s 
genome sequencing center. This group is responsible for incoming DNA quality control, construction of 
DNA Libraries, and production of agar plates containing E.coli cell colonies (with many of copies of 
DNA). In this way, MPBG scales up raw DNA to a quality and quantity necessary for the subsequent 
high-volume, automated genome sequencing process. The MBPG operations include the most complex 
molecular biology procedures and require the most highly skilled technicians at the Broad Institute.  
 
While most of the genome sequencing process at the Broad Institute had already been highly 
industrialized, MBPG had not yet undergone such a transformation and was still operated more like a 
laboratory than a manufacturing group. Additionally, MBPG had been challenged over the last two years 
since the completion of the HGP in transitioning from a high-volume, low-mix project environment (one 
long project with only human DNA) to a low-volume, high-mix project environment (many short projects 
with DNA from many different organisms).  These challenges and low level of operations capability had 
resulted in a highly variable output from MBPG processes in terms of quantity, physical quality, and data 
                                                 
2
 Source: The Broad Institute website, <http://www.broad.mit.edu/>. 
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quality.  Additionally, the MBPG processes were not very well understood or measured, yet had a very 
significant effect on the downstream processes in the genome sequencing center.  
 
Therefore, the goal of this thesis was to create a framework for improving the operations capability of a 
molecular biology laboratory in a high throughput genome sequencing center.  This framework defined an 
operations strategy of maximizing quality in MBPG, characterized the group’s sources of quality 
problems, implemented lean manufacturing and production forecasting in MBPG, and defined future 
opportunities for MBPG to implement Six Sigma and RFID.  This thesis work resulted in significant 
quality improvements in MBPG as well as a much more industrial approach to the management of the 
laboratory’s operations.  It also resulted in an understanding across the Broad Institute that the operations 
strategy of MBPG should be to maximize quality, and that all subsequent operations capability 
improvement projects should be performed with this sole objective in mind.  Finally, this thesis work 
served as an introduction of lean manufacturing to the Broad Institute’s genome sequencing operations, 
and this methodology has now taken hold in the organization and spread to other groups beyond MBPG. 
 
More broadly, the results of this thesis work can be applied to the operations capability improvement of 
any high throughput laboratory in the biotechnology and pharmaceutical (also referred to as “biopharma”) 
industry.  As an increasing number of high throughput technologies are introduced into biopharma R&D 
organizations, many managers are challenged with how to operate their laboratories like a production 
group in a traditional manufacturing plant.  The Broad Institute has been on the forefront of addressing 
this new management challenge given its role in creating the first example of “industrial scale biology” 
with the genome sequencing operations it created for the HGP.  Whereas previous LFM thesis work 
completed at the Broad Institute (Scott Rosenberg in 2003, Julia Chang in 2004, and Kazunori Maruyama 
in 2005) had focused on increasing throughput and/or reducing costs through the use of operations 
management tools, this thesis demonstrates how these same tools can be used to increase quality.   
 
The thesis proceeds as follows: 
 
Chapter 2, Genomics & Molecular Biology Background provides a brief explanation of genomics, 
DNA sequencing operations, and molecular biology as requisite background information for the thesis.  A 
short history of the Human Genome Project is also discussed. 
 
Chapter 3, Business Context for Genome Sequencing discusses the structure and history of the genome 
sequencing industry, including both the public and private sector.  An overview of the structure, purpose, 
and history of the Broad Institute within this industry is also analyzed.   
 
Chapter 4, Molecular Biology Production Group Overview describes the department at the Broad 
Institute that was the focus of this LFM internship and thesis work, the Molecular Biology Production 
Group.  It is described in terms of process capabilities, organizational structure, and cost structure.   
 
Chapter 5, Initial Audit of MBPG Operations Capability provides a data-driven audit of the initial 
operations capability in MBPG at the beginning of this thesis work. This chapter includes a historical 
production data analysis, a quality management systems review, an inventory management systems 
review, and a forecasting and production scheduling systems review. 
 
Chapter 6, MBPG Operations Strategy and Project Approach proposes an optimal operations 
strategy for MBPG, taking into account the local objectives within the group and the global objectives of 
the Broad Institute’s sequencing operations.  The appropriate operations management tools are then 
selected to address different areas of improvement in the operations capability of MBPG. 
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Chapter 7, Lean Manufacturing Implementation describes a five-month lean manufacturing and 
process reengineering implementation in MBPG.  These methodologies were used to reduce the most 
severe forms of process variability, rationalize and improve workflow, and establish a baseline level of 
continuous improvement in the MBPG team.  Specifically, the goals, methodology, results, and metrics of 
the implementation are discussed. 
 
Chapter 8, Production Forecasting Implementation describes a three-month long production 
forecasting implementation in MBPG.  A forecasting tool was applied to improvements in inventory 
management, materials requirement planning (MRP), labor utilization, and supply chain visibility. 
 
Chapter 9, Opportunities for Six Sigma identifies future implementation opportunities for Six Sigma in 
MBPG.  This approach is needed to understand and reduce the intrinsic process variability in MBPG. 
 
Chapter 10, Opportunities for RFID identifies future implementation opportunities in MBPG and the 
rest of the Broad Institute for radio frequency identification (RFID) technology.  
 
Chapter 11, Organizational Change and Leadership Analysis examines this thesis work from the 
three perspectives of organizational processes – strategic design, political, and cultural.  This chapter also 
includes a project leadership assessment, evaluation of the change process, and recommendations for 
continued success in MBPG. 
 
Chapter 12, Conclusions ties the results and discussion of the preceding chapters together and offers 
some perspectives on how the framework developed in this thesis can be applied to the operations 
capability improvement of any high-throughput laboratory in the biopharma industry. 
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2 Genomics and Molecular Biology Background 
 
This chapter provides a brief explanation of genomics, molecular biology, and DNA sequencing 
operations.  A short history of the Human Genome Project is also discussed.  The objective of this chapter 
is to provide the reader with a sufficient technical background in genomics and molecular biology to 
understand the remaining chapters of the thesis. 
 
2.1 The Human Genome Project 
Completed in 2003, the Human Genome Project (HGP) was the largest scientific and technological 
enterprise in the history of biology. Costing more than $3 billion and stretching over 13 years, the HGP 
involved two U.S. government agencies, a major non-profit funding source in England, and scientists 
from six countries. While simpler organisms had previously been sequenced, the HGP represented a 
significant increase in both genomic size and complexity.  It began in 1990 with the simple but ambitious 
goal of sequencing the entire genetic makeup of the human species.  Other more specific goals included: 
• Identify all the 20,000-25,000 genes in human DNA 
• Determine the sequences of the 3 billion chemical base pairs that make up human DNA 
• Store this information in publicly-available databases 
• Improve tools for data analysis 
• Transfer related technologies to the private sector 
• Address the ethical, legal, and social issues that may arise from the project.3 
 
Primary sequencing responsibility fell on large genome centers at the Whitehead Institute (now the Broad 
Institute), Washington University, Baylor University, and the Sanger Center in Great Britain, with dozens 
of smaller centers around the world also contributing.   The HGP has been likened to other famous 
technical projects, such as the Manhattan Project and the Apollo Space Program. While much smaller in 
scale, the HGP was still a huge public project with a $3 billion price tag. This cost included about $2 
billion from the National Institutes of Health (NIH) and $1 billion from the Department of Energy (DOE).   
The full level of HGP funding was actually several hundred million more, since the Wellcome Trust, a 
large philanthropy group in England, became a joint sponsor after the HGP was under way. These figures 
easily place the HGP as the biggest science project ever in the biotechnology field.4 
 
In the course of completing the final HGP sequence, an interim working draft of the human sequence was 
published simultaneously with a companion publication of the human sequence generated by Celera 
Genomics Corporation.  For much of the research community, this represented a fulfillment of the major 
objectives of the HGP.  A startling finding of this first draft was that the number of human genes appeared 
to be significantly fewer than previous estimates, which ranged from 50,000 genes to as many as 140,000.  
The full sequence was completed and published in April 2003, timed to coincide with the fiftieth 
anniversary of the discovery of DNA by Watson and Crick.  Throughout these thirteen years, the Broad 
Institute’s genome sequencing center served as the flagship of the HGP, generating more than one-third, 
or 1.2 billion bases, of the final sequence. 
 
During the thirteen years that comprised the HGP project, the underlying gene sequencing technologies 
were revolutionized in both technique and process speed.  With the process technology and speed that 
exists at the Broad Institute in 2004, two entire Human Genome Projects could be completed within one 
single year.  Another way to state this rapid progress is that using 1985 technology at today’s sequencing 
                                                 
3
 Source: HGP Information Website, <http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml>. 
4
 Source: Lambright, W. Henry, “Managing ‘Big Science’: A Case Study of the Human Genome Project.”   
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scale would require approximately 200 times more employees, 1000 times more floor space, and 100 
times more power.5  This great increase in the efficiency of genome sequencing has followed fairly 
closely to Moore’s Law, as depicted in Figure 1 below. 5 
 
Though the HGP is finished, analyses of the information it created will continue for many years.  This 
historical initiative has created a foundation of genetic knowledge upon which decades of future medical 
research will be built.  Scientists have already begun to conduct wide cross-genomic comparisons 
between humans and other species to determine which genes have been preserved through evolution and 
which are uniquely human. From a medical perspective, doctors have begun to use HGP data to develop 
tests that determine whether a person is at risk for certain diseases or how well a patient will respond to 
certain drugs or medical treatments.  
 
Beyond the medical and scientific ramifications, the momentous societal implications of possessing the 
detailed genetic information made possible by the HGP were recognized from the outset. Thus, another 
major component of the HGP was devoted to the analysis of the ethical, legal and social implications 
(ELSI) of this newfound genetic knowledge, and the subsequent development of policy options for public 
consideration.  This ELSI work continues today at the NIH. 
 
One final important feature of the HGP project was the federal government's long-standing dedication to 
the transfer of technology to the private sector. By licensing technologies to private companies and 
awarding grants for innovative research, the project accelerated the multibillion-dollar biotechnology 
industry and fostered the development of many new applications such as: 
• Medicine – Individualized diagnostics, drugs, and therapies 
• Agriculture and Livestock – Tougher, healthier, and more nutritious crops and animals  
• Industrial Processes – Cleaner and more efficient manufacturing of chemicals, pulp and paper, 
textiles, food, fuels, metals, and minerals 
• Environmental Biotechnology – Biodegradable products, new energy resources, environmental 
diagnostics, and less hazardous toxic site cleanups 
• DNA Fingerprinting – Identification of humans and other animals, plants, and microbes;  
detection of and resistance to harmful agents used in biological warfare 
 
 
Figure 1. Annual cost of sequencing a mammalian genome, showing a Moore’s Law type efficiency increase.5 
                                                 
5
 Source: Nicol, Robert, Presentation at the Broad Institute, October 12, 2004. 
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2.2 Genomics Background 
DNA, or deoxyribonucleic acid, is the genetic building block and hereditary material upon which all 
known life regulates its daily function and long-term evolution.  Long, active sequences of DNA, called 
genes, are translated into proteins during cell activity. Proteins then regulate all of the basic functions in 
life, such as forming structural cell elements, catalyzing chemical reactions in the body, and regulating the 
creation and behavior of other proteins (see Figure 2). 
 
The information in DNA is stored as a code made up of four chemical bases: adenine (A), guanine (G), 
cytosine (C), and thymine (T). DNA bases pair up with each other, A with T and C with G, to form units 
called base pairs. Thus, a sequence of “GAATC” bonds to its complementary sequence “CTTAG.” Each 
base is also attached to a sugar molecule and a phosphate molecule. Together, a base, sugar, and 
phosphate are called a nucleotide. Nucleotides are arranged in two long strands that form a spiral called a 
double helix. The structure of the double helix is like a ladder, with the base pairs forming the ladder's 
rungs and the sugar and phosphate molecules forming the vertical sidepieces of the ladder (see Figure 3).  
This double helix structure of DNA was first recognized by James Watson and Francis Crick in 1953. 
 
An organism’s entire DNA sequence is called a genome, and a human genome consists of about three 
billion base pairs.  The sequence, or order, of these bases determines the information available for 
building and maintaining an organism, similar to how letters of the alphabet appear in a certain order to 
form words and sentences.  While one individual’s genome does differ slightly from another individual’s, 
a vast majority of the sequence within a species is identical.  Even between species, the DNA sequences 
have considerable commonality.  For example, more than 99% of the DNA sequence is the same in all 
people, and the human genome differs from the chimpanzee genome by roughly 1%.6    
 
Every cell contains a complete copy of an individual’s entire genetic makeup. Inside the nucleus of each 
cell are 46 chromosomes, each with an average length of 130 million base pairs. These 46 chromosomes 
are arranged in 23 pairs of mostly identical chromosomes, and one chromosome in each pair is derived 
from each parent. Slight differences between the genes in these parental chromosomes are what cause 
individuals to demonstrate varying degrees of each parent’s characteristics. 
 
 
Figure 2. Relationship among DNA, genes, chromosomes, genomes, cells, and proteins.7 
                                                 
6
 Source: Chang, Julia L, “Control and Optimization of E. Coli Picking Process for DNA Sequencing.” 
7
 Source: US Dept. of Energy, <http://www.ornl.gov/TechResources/Human_Genome/publicat/primer2001/1.html>. 
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Figure 3. The structure of DNA.8 
 
Differences among individuals are a complex function of variations in both their genetics and the 
environment in which they are raised. The genetic variation comes from the tendency of genetic material 
to mutate and recombine over many generations. The differentiation process of mutation is rare but 
influential. On average, human beings differ genetically by no more than one in 1000 base pairs, and 
mutation is the source of this very small 0.1% difference. A second differentiation process, 
recombination, plays a more significant role in human diversity. Recombination occurs when DNA from 
one chromosome is exchanged with similar DNA in the other chromosome in the same pair. Mutation and 
recombination, along with environmental conditions that favor some genes over others, are responsible 
for the wide genetic diversity observable in the world.9 
 
In total, the human genome consists of over three billion DNA base pairs and almost 30,000 genes. For 
many years after the discovery of DNA by Watson and Crick, scientists could sequence only a few DNA 
base pairs at a time. In the 1980’s, it became possible to sequence hundreds and thousands of base pairs. 
Finally, in the 1990’s, genome centers like the Broad Institute applied advances in DNA science and high-
volume process technologies to sequence entire genomes. This ambitious, but ultimately successful, 
gamble turned into the large-scale DNA sequencing operation described in the following sections.9  The  
successful operation of large-scale sequencing centers continues today, and this thesis is part of their 
journey for continuous improvement in the quality, cost, and speed of sequencing a genome. 
 
2.3 Molecular Biology Background 
Molecular biology involves the study of molecules that carry out all life-sustaining processes in an 
organism and transmit those processes across generations.  This field consists of three broad classes of 
phenomena – structural, biochemical, and functional.  The structural phenomena are the material entities 
that make up living cells, including small molecules (water, ions, etc.), medium-sized molecules (ATP, 
NADH, etc.), macromolecules (proteins, polynucleotides, etc.), and organelles (ribosomes, mitochondria, 
etc.).  The biochemical phenomena are the physical interactions in which the structural phenomena are 
                                                 
8
 Source: US National Library of Medicine, <http://www.mydna.com/genes/genetics/genetics101/ 
genetics_dnagene.html>. 
9
 Source: Rosenberg, Scott A, “Managing a Data Analysis Production Line: An Example from the Whitehead/MIT 
Center for Genomic Research.” 
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involved.  Finally, the functional organization deals with the order governing the way in which all these 
entities and interactions work together to accomplish tasks and satisfy needs of the cell. 10 
 
In the context of the genome sequencing operation at the Broad Institute, the topics within molecular 
biology of most interest are ligation, transformation, and the polymerase chain reaction (PCR).  The 
following sub-sections go into detail on each of these three topics 
 
2.3.1 Ligation 
Molecular biologists frequently need to combine two different pieces of DNA together to form one piece 
of DNA.  The term “recombinant DNA” refers to this concept of recombining DNA fragments from 
different sources into a new and hopefully useful DNA molecule. Joining linear DNA fragments together 
with covalent bonds is referred to as “ligation.”11 
 
Typically, a strand of DNA with a known sequence is combined together with a strand of DNA with an 
unknown sequence in order to produce a long DNA strand with a “reference” section and a “to be 
determined” section.  These unknown strands are usually referred to as “fragments,” and the known 
strands are usually referred to as a “vector.”  Ligation is utilized to combine both ends of a fragment with 
both ends of a vector to create a single, circular piece of DNA called a “plasmid.” 
 
Figure 4 illustrates the steps of the ligation of two DNA molecules.  This ligation reaction requires the 
following three ingredients in addition to water:  
 
 
Figure 4. Ligation of two DNA molecules with complementary single-stranded “sticky” ends.12 
                                                 
10
 Source: ISCID Encyclopedia of Science and Philosophy, “Molecular Biology and Teleology.” 
11
 Source: Austgen et al, “DNA Ligation.” 
12
 Source: Lodish et al, Molecular Cell Biology, 5th ed. 
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• Two or more fragments of DNA that have complementary single-stranded “sticky” ends – 
The ends of these DNA molecules are called sticky because several bases are not bound to their 
complementary base and are thus open to reacting to a complementary base on another strand of 
DNA.  For example, if one DNA fragment has a sticky end of “---AATC” and another DNA 
fragment has a sticky end of “TTAG---“, then a ligation reaction can occur. 
• ATP-containing buffer – Adenosine triphosphate (ATP) is the energy currency of the cell, and it 
transfers energy from chemical bonds to energy-absorbing reactions within the cell.  
• T4 DNA ligase – The reaction enzyme used in ligation is T4 DNA ligase. This enzyme will ligate 
DNA fragments having overhanging, cohesive ends that are annealed together. 
 
2.3.2 Transformation 
One of the great strengths of molecular biology is the ability to manipulate genetic material, such as in the 
ligation reaction described above.  Utilizing these genetic manipulations require large quantities of DNA, 
and one of the easiest ways to produce large amounts of DNA is to place the desired DNA into bacteria, 
grow and harvest the bacteria, and then isolate the DNA.  This process is called transformation and is 
illustrated in Figure 6.13 
 
Bacteria, such as E. coli, can maintain external DNA inside them as plasmids, which are circles of DNA 
containing a gene that allows the bacteria to grow in the presence of an antibiotic.  Transformation begins 
with treating “competent” bacteria cells to take plasmid (created through the ligation reaction) up inside 
their cell walls.  One of two processes can be used to insert the DNA into the bacteria cells – heat 
shocking or electroporation.  In heat shocking, the cells are pulsed with a blast of heat in the presence of 
calcium chloride (CaCl2), causing their cell walls to momentarily open up, pass the DNA through, and 
then close up again without destroying the cell.  In electroporation, the cells are pulsed with a very short 
electrical charge, which has the same effect of passing DNA into the cell during the brief moment 
between the opening and closing the cell wall.13 
 
After the introduction of plasmid, the competent bacteria cells are spread out in agar plates that contain 
both nutrients for the cells to grow as well as an antibiotic.  The cells that have taken up the plasmid will 
be resistant to this antibiotic and will then replicate on the agar plate, forming a cell colony.  The cells that 
have not taken up the plasmid will succumb to the antibiotic, die off, and not replicate.  Thus, the final 
transformation products are many, many cell colonies that contain many, many copies of the same DNA 
plasmid as illustrated in Figure 5. 
 
2.3.3 Polymerase Chain Reaction 
PCR (polymerase chain reaction) was a revolutionary discovery in the fields of molecular biology and 
genetics and continues to be applied today in many fields of biology.  PCR is used for making a huge 
number of copies of a gene.  While the transformation process described in the previous example is one 
way of amplifying the number of DNA copies, PCR provides an even greater amplification beyond 
transformation and is vital to the operation of high through-put genome sequencing centers. 
 
                                                 
13
 Source: Sciences Education Foundation, “Recombinant DNA Labs: Basic Tools For The Molecular Biologist - 
Teachers Guide: Bacterial Transformation.” 
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Figure 5.  Illustration of an agar plate with grown cell colonies containing DNA plamids.14 
 
 
Figure 6. Ligation and Transformation processes used to create many copies of a DNA plasmid.15 
                                                 
14
 Source: Chang, Julia L, “Control and Optimization of E. Coli Picking Process for DNA Sequencing.”  
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There are three major steps that occur during one cycle of a PCR – denaturation, annealing, and 
elongation.  This cycle is typically repeated 30 or 40 times (see Figure 7). PCR is conducted in an 
automated thermal cycler, which can heat and cool the reaction mixture in a very short time. 
 
The denaturation step is conducted at 94°C.  During this step, double-stranded DNA melts and opens up 
into two pieces of single stranded DNA.  In addition, all enzymatic reactions stop during this step, 
including the elongation from a previous cycle.16 
 
The annealing step is conducted at 54°C.  Primers, or short pieces of single-stranded DNA, were added at 
the beginning of the PCR.  These primers are bouncing around in the reaction medium, and bonds are 
constantly formed and broken between the primers and the single-stranded DNA created during 
denaturation. The more stable bonds last a little bit longer (primers that fit exactly) and on that little piece 
of double stranded DNA (template and primer), polymerase can attach and start copying the DNA.16 
 
The final step, elongation, is conducted at 72°C, the ideal working temperature for polymerase, an 
enzyme. The polymerase begins adding nucleotides to the primer and eventually makes a complementary 
copy of the single-stranded DNA template. If the template contains an A nucleotide, the enzyme adds on 
a T nucleotide to the primer. If the template contains a G, it adds a C to the new chain, and so on until the 
end of the DNA strand. This completes one PCR cycle, resulting in two copies of each double-stranded 
DNA fragment that entered the denaturation step.  Subsequent cycles of the PCR quickly amplify the 
number of copies of this originally double-stranded DNA fragment (see Figure 7).16 
 
 
Figure 7. The basics of the Polymerase Chain Reaction (PCR) .17 
                                                                                                                                                             
15
 Source: Lodish et al, Molecular Cell Biology, 5th ed. 
16
 Source: Vierstraete, Andy, “Principle of the PCR.” 
17
 Source: Lodish et al, Molecular Cell Biology, 5th ed. 
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2.4 Genome Sequencing Operations 
Modern state-of-the-art genome sequencing operations operate with a divide-and-conquer strategy.  This 
strategy involves first breaking up large DNA samples into small segments, then determining the exact 
DNA sequence of the small segments, and finally assembling the segment sequences into the entire 
composite sequence of the original sample.  This approach to sequencing is conducted in large-scale 
genome sequencing operations that operate like traditional manufacturing plants with the caveat that the 
final product is not physical but rather informational (i.e. a genome database). 
 
As mentioned previously, the genome of a mammal is about three billion base pairs in length.  Current 
technology allows sequencing segments that are 4,000 to 40,000 base pairs in one read.  However, 
dividing just one long piece of DNA into its smaller segments is not enough to sequence the entire 
genome.  The small segments must overlap each other enough to allow assembly, a computer-aided 
process of fitting together thousands of segments into a single sequence.  The redundancy required to 
ensure enough overlap for assembly of the entire genome is referred to as “coverage.”  Currently, the 
Broad Institute utilizes “4-6 X coverage,” meaning that, in total, four to six copies of an entire genome are 
sent through the genome sequencing process to produce one final sequence. 
 
The physical process inside a genome sequencing operation is broken down into six main steps – 
Genomic DNA, Plasmid Library, Plating & Preparation, Sequencing Reaction, Detection, and Finishing 
(see Figure 8).  These steps are organized into different departments and groups in different genome 
sequencing centers.  The Broad Institute’s structure for its sequencing operations is a typical organization 
and is depicted below in Figure 9. 
 
  
 
 
 
Figure 8. Six main steps in modern DNA Sequencing Operations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Process flow for The Broad Institute’s DNA Sequencing Operations. 
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The first step, Genomic DNA, involves preparing purified DNA samples for subsequent cloning into a 
suitable vector.  DNA samples are usually provided to sequencing centers by scientists at external 
universities or national research laboratories that specialize in extracting samples of DNA from the 
organism currently being studied.  These DNA samples are sent to the sequencing center where they then 
go through several quality assurance steps to determine the quantity, size, and quality of the DNA.  The 
DNA is then hydrodynamically sheared to produce random small fragments in the appropriate size range.   
 
The next step, Plasmid Library, involves the creation of DNA plasmid libraries according to the ligation 
process described in section 2.3.1 above.  Each random small DNA fragment is combined with an 
appropriate vector to form a circular piece of DNA.  The size range of the DNA fragment and the type of 
vector used in this step are determined by the nature of the genome and the sequencing strategy.  The 
most common sizes for the DNA fragments are 4000 base pairs (4kb libraries), 10,000 base pairs (1kb 
libraries), and 40,000 base pairs (fosmid libraries). 
 
The Plating & Preparation step involves the insertion of DNA plasmid libraries into E.coli cells according 
to the transformation process described in section 2.3.2 above.  These cells are then coated onto agar 
plates which select for only those cells that have taken up plasmids.  After sixteen hours of incubation, the 
transformed, plated cells grow into solid colonies visible to the eye (see Figure 5).  Each individual 
colony is then picked off of the agar plate by high-speed robotic instruments into a single well of a 384-
well library storage plate.  From this point forward in the process, each DNA clone is individually tracked 
by barcode.  An LFM thesis completed in 2004 by Julia Chang (“Control and Optimization of E.coli 
Picking Process for DNA Sequencing”) focused on understanding and reducing the variability in this 
automated picking process at the Broad Institute. The final part of the Plating & Preparation step is to run 
the DNA through a “templify” process that rapidly and efficiently produces many copies of circular DNA. 
 
During the fourth step, Sequencing Reaction, the DNA clones are placed in a solution containing special 
DNA base pairs that are tagged with a fluorescent dye. By raising the temperature of the solution, the 
plasmid DNA can be induced to separate according to the PCR described in section 2.3.3 above. When 
the temperature is lowered, an enzyme in the solution reconstructs the double-stranded structure by 
grabbing base pairs from the surrounding solution. Whenever the enzyme selects a dyed base pair, 
however, the reconstruction process stops, leaving a DNA segment that is prematurely terminated by a 
dyed A, T, G, or C. After many PCR cycles, the end result is a nested set of DNA fragments representing 
terminations at each base in the sequence (see Figure 10). 
 
 
 
Figure 10. Dye-tagged DNA fragments representing terminations at each base in the sequence.18 
                                                 
18
 Source: the National Human Genome Research Institute, Animated Educational Toolkit, 
<http://www.genome.gov/Pages/Education/Kit/main.cfm>. 
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The resulting solution of dye-terminated segments is the input to the fifth step, Detection, which is the last 
of the physical laboratory steps of the genome sequencing process. The solution of dyed plasmid 
segments is placed at one end of a long capillary. A charge causes the DNA to migrate through this 
capillary, with smaller, lighter segments moving faster than larger, heavier segments.  At the end of the 
capillary, a laser illuminates the dyed base pairs at the end of each DNA molecule that emerges. A sensor 
detects the continuously varying illumination and records it in a data file. A piece of software then 
analyzes this data and makes a final determination of each base-pair in the sequence.  An LFM thesis 
completed in 2005 by Kazunori Maruyama (“DNA Sequencing Technology: Improvement of 
Electrophoretic Sequencing Process & Analysis of Sequencing Tool Industry”) focused on improving the 
cost and throughput of this detection process at the Broad Institute. 
 
Finishing represents the final stage of the DNA sequencing process, where highly skilled analysts analyze 
and fix any broken, uncertain, or problematic sections of the final genome sequence.  Wherever the 
detection software cannot find DNA sequence for a region, a gap exists that must be closed.  Human 
analysts, called finishers, attempt to close these gaps through a variety of laboratory techniques.  An LFM 
thesis completed in 2003 by Scott Rosenberg (“Managing a Data Analysis Production Line: An Example 
from the Whitehead/MIT Center for Genomic Research”) focused on improving the throughput and 
workflow control policies of the finishing department at the Broad Institute during a period of time where 
finishing was the bottleneck for the completion of the HGP. 
 
Upon completion of the Genomic DNA, Plasmid Library, Plating & Preparation, Sequencing Reaction, 
Detection, and Finishing steps of the genome sequencing process, the final product, a complete genome, 
is released.  This product is in the form of a database that is made publicly available on government 
websites.  Articles describing the key findings in each completed genome are also typically published in 
prestigious journals such as Nature and Science.  The published results of the Human Genome Project, 
the most important product of modern genome sequencing operations, can be found online at the Human 
Genome Resources website (http://www.ncbi.nlm.nih.gov/genome/guide/human/). 
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3 Business Context for Genome Sequencing 
 
This chapter discusses the structure, purpose, history, and future of the genome sequencing industry, 
including both the public and private sector.  An overview of the structure, purpose, and history of the 
Broad Institute within this industry is also analyzed, focusing on its sources of competitive advantage.  
The objective of this chapter is to provide the reader with an understanding of the current business and 
funding climate of the genome sequencing industry. 
 
3.1 Genome Sequencing Industry Analysis 
The genome sequencing industry has undergone an incredible cycle of boom, bust, and then stabilization 
over the last 10-15 years, primarily fueled by the excitement and anticipation of the completion of the 
Human Genome Project.  While the medical benefit and success of genomics has never been called into 
question, the success of genomics in financial markets and public funding arenas has not yet been clearly 
established.  This section provides a brief analysis of the genome sequencing industry, focusing on the 
main buyers, competitors, and suppliers.  Figure 11 illustrates the landscape of this industry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Overview of the suppliers, competitors, and buyers participating in the genome sequencing industry. 
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3.1.1 Buyers for Genome Sequencing Services 
The main sources of demand in the genome sequencing industry are from public funding sources and 
private endowments.  Since most genome sequencing projects produce large datasets that are used in 
biomedical research on therapies that won’t hit the market for 10-20 years, the near-term economic value 
is lacking to fuel large sources of demand from private industry.  Thus, the government and charitable 
organizations are needed to step in and fund this longer-range research.  This funding is given out in large 
annual or project-specific grants that the public genome sequencing centers compete with each other for 
based on capability, cost, timeline, and quality. 
 
The primary funding source in the U.S. for genome sequencing is the National Human Genome Research 
Institute (NHGRI), which was established in 1989 to carry out the role of the National Institutes of Health 
(NIH) in the Human Genome Project.  The NHGRI collaborated with the United States Department of 
Energy (DOE) to initiate and fund the HGP, and the NHGRI director, Francis Collins, served as the 
HGP’s international leader.  NHGRI directs and supports work on the sequencing of the human genome; 
funds research on the genome's structure, function, and role in health and disease; and supports studies on 
the ethical, legal and social implications (ELSI) of genome research. With an annual budget of 
approximately $480 million, the NHGRI provides the majority of genome sequencing grants and has 
funded the completion of the human, mouse, chimpanzee, honey bee, marsupial, chicken, rat, kangaroo, 
dog, and bovine genomes.19 
 
A secondary funding source in the U.S. for genome sequencing is the Department of Energy (DOE), 
which created the Joint Genome Institute (JGI) in 1997 to unite the expertise and resources in genome 
mapping, DNA sequencing, technology development, and information sciences pioneered at the DOE 
genome centers at Lawrence Berkeley National Laboratory, Lawrence Livermore National Laboratory, 
and Los Alamos National Laboratory. The DOE was a co-leader and co-financier of the HGP along with 
the NHGRI.  With an annual budget of approximately $66M, the JGI is now the sole recipient of the 
DOE’s genomics-related budget, and no other public genome sequencing centers receive DOE funding.  
The JGI has sequenced the genomes of the puffer fish, sea squirt, frog, green alga, diatom, cottonwood 
tree, more than 60 microbial genomes, and a host of agriculturally important plant pathogens.20 
 
The largest source of private funding for genome sequencing work is the Wellcome Trust in England, 
established in 1936 and with an endowment of around £10 billion. The Wellcome Trust is an independent 
charity funding research to improve human and animal health, and it is the UK’s largest non-
governmental source of funds for biomedical research.  The Sanger Institute was established by the 
Wellcome Trust in 1992 as part of the global HGP effort and provided 30% of the final sequence.  With 
an annual budget of approximately £400M, the Sanger Institute is the sole recipient of the Wellcome 
Trust’s genomics-related budget, and it has contributed to the sequences for the human, mouse, zebrafish, 
malaria, sleeping sickness, typhoid, tuberculosis, fission yeast, and roundworm.21 
 
A final and small source of funding for genome sequencing work is the large pharmaceutical and 
biotechnology (biopharma) companies. They will periodically purchase sequencing projects from the 
private sequencing centers or their own internal sequencing laboratories.  During the 1990s, many private 
sequencing companies flourished from actual and expected demand for their services by the biopharma 
firms.  However, this demand quickly slowed in the late 1990s as the biopharma companies created their 
own internal sequencing capabilities and researchers realized the payoffs from genomics would be much 
farther out in the future.  Consequentially, many private sequencing centers went bankrupt or drastically 
                                                 
19
 Source: NHGRI website, <http://www.genome.gov/>. 
20
 Source: DOE Joint Genome Initiative website, <http://www.jgi.doe.gov/>. 
21
 Source: Wellcome Trust website, <http://www.wellcome.ac.uk/>. 
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changed their business models away from sequencing services.  Thus, this source of demand is not very 
important when analyzing the current state of the genome sequencing industry. 
 
3.1.2 Competitors in the Genome Sequencing Industry 
During the HGP, the primary and much publicized competition in the genome sequencing industry was 
between the public genome centers funded by the NHGRI, DOE, and Wellcome Trust and the private 
sequencing effort of Celera Genomics.  The public and private efforts faced off in a direct competition to 
complete the human genome sequence first.  This competition was publicly declared a tie in early 2001 
with the joint publication of a draft sequence of the human genome.   
 
In the years since the completion of the HGP, the competitive landscape has changed quite dramatically 
in the industry.  While all the major public genome centers continue to operate today, most of the private 
genome sequencing companies have ceased to exist or have radically changed their business models away 
from sequencing.  As mentioned in the previous section, the economic value for sequencing is quite long-
term and, thus, government and charitable funding organizations are needed.  With this constraint on 
demand, only the public genome sequencing centers will continue to thrive in the future of this industry 
along with internal sequencing laboratories of the large biopharma companies.  The rest of this section 
briefly summarizes the key competitors. 
 
In 2001 there were 16 major genome sequencing centers in the U.S. and abroad.  Five of these formed the 
core of the HGP effort: the Broad Institute (formerly called the Whitehead Institute Center for Genomic 
Research), Baylor College of Medicine, Washington University in St. Louis, the Joint Genome Institute, 
and the Sanger Institute in England.  Known as the G-5, these centers completed 85% of the sequence in 
the HGP and continue today as the largest public genome sequencing centers in the world.22 
 
The Broad Institute was formed in 2003 from the former Whitehead Institute Center for Genomic 
Research along with several laboratories and centers at MIT, Harvard, and Harvard Hospitals.  In the late 
1990’s, the Broad gained worldwide recognition for contributing one third of the sequence for the HGP, 
and it continues to operate the world’s largest genome center.  The Broad employs 250 people, including 
scientists and medical researchers from Whitehead, MIT, and Harvard.23  See Section 3.2 for more 
information on the Broad Institute. 
 
The Baylor College of Medicine established its human genome sequencing center (BCM-HGSC) in 1996 
when the NHGRI designated Baylor College of Medicine as one of six pilot programs for the final phase 
of the Human Genome Project. In 1999, the Center was selected as one of three sites in the U.S. from the 
pilot program chosen to complete the final phase of the HGP.  Today, the BCM-HGSC employs more 
than 200 staff and operates 77 sequencing machines 24 hours a day, seven days a week. 24 
 
The Genome Sequencing Center at the Washington University Medical School focuses on the large scale 
generation and analysis of DNA sequence. Founded in 1993, the center played a leadership role in the 
HGP, constructing the clone map and contributing 25% of the finished sequence.   Washington University 
currently employs approximately 150 people in its sequencing center.25 
 
The Joint Genome Institute (JGI) was created by the DOE in 1997 to unite the expertise and resources in 
at the DOE genome centers at Lawrence Berkeley National Laboratory, Lawrence Livermore National 
                                                 
22
 Source: Lambright, W. Henry, “Managing ‘Big Science’: A Case Study of the Human Genome Project.”   
23
 Source: The Broad Institute website, <http://www.broad.mit.edu/>. 
24
 Source: BCM-HGSC website, <http://www.hgsc.bcm.tmc.edu/>. 
25
 Source: Genome Sequencing Center at Washington Univ. Medical School website, <http://genome.wustl.edu/>. 
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Laboratory, and Los Alamos National Laboratory. In 1999, the University of California, which manages 
these three national labs for the DOE, consolidated activities and facilities for JGI's 160 employees in 
what is known now as the Production Genomics Facility (PGF). The JGI has an annual budget of 
approximately $60 million funded predominantly by the DOE.26 
 
The Sanger Institute is a genome research center set up in 1992 by the Wellcome Trust and the Medical 
Research Council in order to further our knowledge of genomes, and in particular to play a substantial 
role in the sequencing and interpretation of the human genome.  The Sanger Institute has grown to a staff 
of about 600 in 2001 and has an annual budget of approximately £400M.  Since its inception, the Institute 
has increased output of finished DNA sequence by a factor of over 100 and was a leading contributor of 
finished sequence to the HGP.27 
 
Moving out of the public domain in the genome sequencing industry, the history of the private sequencing 
centers has been dominated by Celera Genomics.  Founded in 1998 by Dr. J Craig Venter and Applera 
Corporation (parent of Applied Biosystems, a key industry supplier discussed in Section 3.1.3 below), 
Celera had the primary mission of sequencing and assembling the human genome within three years, well 
ahead of schedule of the public HGP.  Celera’s hope was to extract commercial value from “owning” the 
rights to the first human genome sequence.  The company eventually compromised with the public HGP 
effort to declare a tie in early 2001 with the joint publication of a draft sequence of the human genome.  
Since then, Celera has experienced a dramatic decline in its stock price, significant layoffs and capacity 
reduction in its sequencing center, and a drastic change in its business model.  Celera is now engaged in 
the discovery and development of targeted therapies for cancer, autoimmune and inflammatory diseases, 
leveraging its expertise and capabilities in genomics.28 
 
Two other well known private genome sequencing companies were Human Genome Sciences (HGSI) and 
Incyte Genomics.  Both have experienced similar fates to Celera Genomics and are now attempting 
dramatic shifts in their business models.  HGSI had originally attempted to patent individual genes as it 
sequenced them, and the company is now positioned as a mid-stage drug discovery company with a 
pipeline of cancer, lupus, rheumatoid arthritis and hepatitis C therapies derived from its proprietary 
genomic technology.29  Incyte had also attempted to patent individual genes, but it too is now focused on 
drug discovery with therapies that treat HIV inflammatory disorders, cancer and diabetes.30  Neither 
HGSI nor Incyte operate a significant genome sequencing center today. 
 
The final competitor of note in this industry are the small to medium size genome sequencing laboratories 
that have been set up inside many of the large pharmaceutical and biotechnology companies.  As 
genomics grew in importance as a future platform for the discovery of new medical therapies, these 
companies, particularly Merck, Pfizer, and Novartis, began to develop their own internal sequencing 
expertise focused on different therapeutic areas.  The widespread availability of cost-effective sequencing 
technologies created during the publicly-funded HGP was a key enabler in allowing these pharmaceutical 
and biotechnology companies to set up internal small-scale sequencing operations.  These internal labs 
have mostly eliminated any sources of demand from biopharma companies on the public or private 
sequencing centers. 
 
                                                 
26
 Source: DOE Joint Genome Initiative website, <http://www.jgi.doe.gov/>. 
27
 Source: The Sanger Institute website, <http://www.sanger.ac.uk/>. 
28
 Source: Celera Genomics website, <http://www.celera.com/>. 
29
 Source: HGSI website, <http://www.hgsi.com/>. 
30
 Source: Incyte website, <http://www.incyte.com/>. 
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3.1.3 Suppliers to the Genome Sequencing Industry 
Of all the constituents in the genome sequencing industry, the suppliers have extracted the greatest 
amount of value and have become the most successful businesses related to this industry.  Whereas the 
benefit of genome sequencing is long-term in nature, the competing public and private sequencing centers 
still have sizeable short-term needs for sequencing tools, equipment, reagents, consumables, intellectual 
property, and DNA samples.  The suppliers to this industry fulfill these needs and are separated into three 
main vendor categories – tools, reagents, and DNA samples. 
 
The tools vendors supply the equipment, tools, IP, and other infrastructure needed to build out and 
maintain a large-scale genome sequencing center.  They supply products such as DNA sequencers, 
laboratory automation equipment, and imaging systems.  Most of these vendors follow the classic “razor 
and razor blade” business strategy where they sell low-margin equipment followed on by recurring sales 
of high-margin consumables.  Most also surround their products with strong IP that provide them with 
near monopolies in key genomics technologies.   The most dominant tools vendor is Applied Biosystems 
(ABI), which makes the DNA sequence detectors that account for the largest capital expenditure in all 
genome sequencing centers. 31  ABI has had a strained relationship with its customers at the public 
sequencing centers since it co-founded Celera Genomics in 1998 to directly compete against the public 
HGP.  Another key tools vendor is Affymetrix, which makes the GeneChip system, a “lab-on-a-chip” 
technology for acquiring, analyzing and managing complex genomic information.32 
 
Another highly successful set of businesses can be found in the reagent vendor segment of the genome 
sequencing industry.  These suppliers provide the critical biological and chemical reagents to run a large-
scale genomics center, along with consumables such as pipette tips, tubes, plates, and gloves.  Many of 
these reagents are sold with high margins and in a steady replenishment stream.  The reagent vendor 
market has been undergoing a great deal of consolidation over the last few years and is currently 
dominated by Invitrogen and General Electric’s Amersham Biosciences division.  Invitrogen is a supplier 
of research kits and reagents that simplify and improve gene cloning, gene expression and gene analysis 
techniques, and the company has completed several acquisitions of smaller rivals in the last three years.33  
GE entered this market in 2004 with the $9.5 billion acquisition of Amersham Biosciences, a U.K. based 
leader in diagnostic imaging agents and life sciences.34   
 
The final key suppliers to the genome sequencing industry are the multitude of DNA sample providers.  
These research universities and government laboratories from around the world supply the critical 
samples of DNA needed for each project completed in a genome sequencing center.  For each major 
genome project, the grant-receiving sequencing center will collaborate with one or a few of the world’s 
expert scientists in the organism whose genome is to be sequenced.  Those experts will retrieve DNA 
samples from these organisms and ship the small DNA samples to the sequencing center.  These suppliers 
are typically assigned and bound to a sequencing center per the terms of the grant awarded for an 
individual genome sequencing project. 
 
3.2 Overview of the Broad Institute 
The Eli and Edythe L. Broad Institute was established in 2003 as a research collaboration of the 
Massachusetts Institute of Technology (MIT), Harvard University and affiliated hospitals, and the 
Whitehead Institute for Biomedical Research.  It is the one of the best-funded genomic research 
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 Source: Applied Biosystems website, <http://www.appliedbiosystems.com/>. 
32
 Source: Affymetrix website, <http://www.affymetrix.com/index.affx>. 
33
 Source: Invitrogen website, <http://www.invitrogen.com>. 
34
 Source: GE Health Care website, <http://www.gehealthcare.com>. 
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organizations in the world, with 250 employees.  The Broad Institute is currently located in several 
laboratory facilities within the Kendall Square biotech cluster in Cambridge, MA, and will be moving into 
a new, state-of-the-art building in this same area in 2006. Most of the Broad’s funding comes in the form 
of research grants from the National Human Genome Research Institute, a division of the National 
Institutes of Health (NIH) in Washington D.C.   
 
The Broad Institute was created in June 2003, when philanthropists Eli & Edythe Broad of Los Angeles 
donated $100M to create an institute to fulfill the genome's promise for medicine.  Both MIT and Harvard 
each matched this $100M donation, creating a new $300M organization bringing together a multitude of 
genomics-related research groups from MIT, Harvard, Harvard Hospitals, and the Whitehead Institute.  
MIT administers the Broad Institute on behalf of these other groups.  The Broad Institute has the 
following stated mission:35 
• Our scientific mission is: 
o To create tools for genomics medicine and make them broadly available to the scientific 
community 
o To apply these tools to propel the understanding and treatment of disease 
• Our organizational mission is: 
o To enable collaborative projects that cannot be accomplished solely within the traditional 
setting of individual laboratories 
o To empower scientists through access to cutting-edge tools 
 
The largest group within the Broad Institute is the large-scale genome sequencing center formerly known 
as the Whitehead Institute Center for Genomic Research (WICGR).  In the 1990s and early 2000s, 
WICGR gained worldwide recognition for contributing one third of the sequence for the HGP.  The 
former WICGR group within the Broad Institute was the focus of this thesis as well as several previous 
LFM thesis’ in 1999-2004.  In addition to genome sequencing, the Broad Institute now houses three other 
research platforms – molecular profiling, genetic analysis, and chemistry.  These four platforms support 
four high-level research programs focused on cell components, chemical biology, cancer genomics, and 
medical and population genomics.  Figure 12 illustrates the Broad Institute’s organizational chart. 
 
The competitive advantage of the Broad Institute’s sequencing operation has been its ability to rapidly 
scale-up or “industrialize” the genome sequencing process.  In order to achieve scale, speed, and 
efficiency, the sequencing process was decomposed into many simpler, repetitive steps, utilizing high-
volume process automation and operations management tools.  Complementing this work design, the 
organization divided itself around individual processes, with many sub-teams performing small, repetitive 
pieces of the larger process.  The resulting organization consisted of a layered reporting hierarchy of 
departments and sub-departments traditionally found in most manufacturing plants and organizations.  
The Broad Institute effectively created the world’s premier DNA sequencing factory, one of the first 
applications of manufacturing-style management to biotechnology R&D processes. 
 
Each sequencing operations department has a manager, and most of the sub-departments have a 
coordinator or supervisor. The technicians, who are roughly analogous to the floor-level operators in a 
manufacturing plant, work closely together and report up to these coordinators and managers.  However, 
due to the reporting structure, facility layout, and job design, teams and sub-teams interact infrequently, 
resulting in weak relationships across groups.  Figure 13 is an organizational chart for just the sequencing 
operations at the Broad Institute and depicts in fuller detail the Molecular Biology Production Group 
(MBPG) – the department most relevant to this thesis.   
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 Source: The Broad Institute website, <http://www.broad.mit.edu/>. 
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Figure 12. Organizational structure of the Broad Institute.36 
 
 
Figure 13. Organizational structure of the sequencing operations at the Broad Institute. 
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 Source: Maruyama, Kazunori, “DNA Sequencing Technology : Improvement of Electrophoretic Sequencing 
Process & Analysis of Sequencing Tool Industry.” 
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4 Molecular Biology Production Group Overview 
 
This chapter describes the Molecular Biology Production Group (MBPG), the most upstream part of the 
genome sequencing center at the Broad Institute.  MBPG is described in terms of its process capabilities, 
organizational structure and cost structure.  The objective of this chapter is to provide the reader with an 
operational description of the department that is the focus of this LFM internship and thesis work. 
 
4.1 Process Capabilities 
MBPG is the most upstream part of the Broad Institute’s genome sequencing process. Obtaining DNA 
sequence data requires several molecular biology steps to prepare the DNA samples for large scale 
automated sequencing, and MBPG oversees these critical process steps.  This group is responsible for 
three primary processes – (1) incoming DNA quality control, (2) construction of DNA Libraries, and (3) 
production of agar plates containing E.coli cell colonies with many of copies of DNA inside them. In this 
way, MPBG scales up raw DNA to a quality and quantity necessary for the subsequent high-volume, 
automated genome sequencing process. Figure 14 summarizes the MBPG processes along with the team 
organization within MBPG, and Appendix A contains detailed process flow diagrams for MBPG. 
 
MBPG contains a unique mix of high-skilled job-shop processes and low-skilled, high-volume 
manufacturing line processes.  Effectively executing both types of processes is a significant challenge.  
Additionally, MBPG had been challenged over the last two years since the completion of the HGP in 
transitioning from a high-volume, low-mix project environment (one long project with only human DNA) 
to a low-volume, high-mix project environment (many short projects with DNA from many different 
organisms).  Unfortunately, prior to this thesis work, the design and management of MBPG’s processes 
had not yet been re-optimized for these new operational requirements. 
 
 
 
Figure 14. Processes and sub-departments within the Molecular Biology Production Group. 
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4.1.1 Incoming DNA Quality Control 
The first process conducted within MBPG is incoming DNA quality control (referred to as the “Genomic 
DNA” step in Section 2.4 and Figure 8).  This work is performed by the “DNA Preparation” team in 
MBPG.  The DNA Preparation team receives DNA samples from external laboratories (as explained in 
Section 3.1.3 above) and either places them into refrigerated storage or immediately performs the 
following three quality control tests on the DNA samples: 
 
• Fractionation Gel – This QC tests serves as a visualization tool and proxy for the quality of the 
DNA sample.  Since DNA is a polymer, the incoming sample can contain a range of different 
molecule sizes.  For the Broad Institute, longer molecules of DNA indicate a higher quality 
sample that will perform better in downstream processes. In a fractionation gel, the DNA is 
placed inside an agarose gel medium in a liquid buffer solution.  A voltage is then placed across 
the gel medium for approximately two hours, and the DNA will travel through the gel in the 
direction of the voltage.  Shorter molecules of DNA will travel farther than longer molecules of 
DNA.  A “DNA ladder” solution containing several known lengths of DNA is run next to the 
DNA sample.  After the two hours, the DNA is stained with an UV-sensitive die, and the 
distribution of molecule lengths in the sample can be determined from comparing its final 
position in the gel to the DNA ladder. 
 
• Pico Green Assay – This QC test measures the quantity and concentration of the DNA sample 
(in picograms per microliter).  The DNA sample is stained with a pico green die and then 
fluoresced with UV light.  The samples fluorescence intensity is compared to known standards to 
calculate the sample’s DNA concentration. 
 
• Spectrophotometer Reading – This QC test also measures the quantity and concentration of the 
DNA sample (in picograms per microliter).  It is typically run on a sample only at the request of 
an external collaborator.  Otherwise, MBPG relies on the pico green assay for its DNA 
quantification tool.  In this test, the DNA sample is placed in a spectrophotometer where its peak-
height reading is taken at two different wavelengths.  The ratio of the peak heights at these two 
wavelengths is then compared to known standards to calculate the sample’s DNA concentration. 
 
After completing these three QC tests, the final step in this first MBPG process is to shear the DNA to 
one of three required sizes, depending on which type of DNA library will be constructed from the sample.  
A hydrodynamic shearing machine is used to produce random small fragments in the size ranges of 4000 
base pairs (4kb libraries), 10,000 base pairs (10kb libraries), and 40,000 base pairs (fosmid libraries).  
This sheared DNA is then held as work-in-progress (WIP) inventory in a -20°C freezer in the MBPG 
laboratory area.   
 
4.1.2 Construction of DNA Libraries (Ligation) 
The second process conducted within MBPG is construction of DNA libraries (referred to as the “Plasmid 
Library” step in Section 2.4 and Figure 8).  These libraries are created according to the ligation technique 
explained in detail in Section 2.3.1, and the “Ligation” team in MBPG is responsible for this work.    See 
Appendix A for detailed process flow diagrams of the ligation process performed in MBPG. 
 
The ligation team pulls sheared DNA samples from a WIP inventory in MBPG and then begins the 5-6 
day long ligation process.  Three different types of libraries are produced in varying quantities as dictated 
by the scientific needs of each genome sequencing project.  The highest volume libraries are the “4kb 
libraries,” which are constructed from DNA with an average size of 4000 base pairs. The second highest 
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volume libraries are the “10kb libraries,” which are constructed from DNA with an average size of 10,000 
base pairs.  Both the 4kb and 10kb libraries are processed through ligation in an almost identical manner. 
 
The lowest volume libraries are the “fosmid libraries,” which are constructed from DNA with an average 
size of 40,000 base pairs.  They are processed through the ligation and transformation steps in a slightly 
different biological technique than the 4kb and 10kb libraries. However, for the purposes of this thesis, 
the fosmid libraries are assumed to be processed in the same manner as all other libraries.  All completed 
libraries are held as WIP inventory in a -20°C freezer in the MBPG laboratory area. 
 
4.1.3 Production of Agar Plates with E.coli Cell Colonies (Transformation) 
The final process conducted within MBPG is the production of agar plates that contain E.coli cell 
colonies with many copies of DNA inside them (referred to as the “Plating & Preparation” step in Section 
2.4 and Figure 8).  These agar plates are created according to the transformation technique explained in 
detail in Section 2.3.2, and the “Transformation” team in MBPG is responsible for this work.    See 
Appendix A for detailed process flow diagrams of the transformation process performed in MBPG. 
 
The transformation team pulls DNA libraries from a WIP inventory and then performs the daily 
transformation process.  The transformation process is where the Broad Institute begins its high-volume 
genome sequencing process.  Whereas the DNA Preparation and Ligation team handle approximately 4-6 
DNA samples per week, the Transformation team produces between 150-180 agar plates per day.   
 
The transformation team is also the interface between MBPG and the downstream Core Sequencing 
department.  Every day, the agar plates produced by the Transformation team are placed in a warm room 
to grow the cell colonies over night.  Every morning, the grown agar plates are pulled back out of the 
warm room and handed-off from the transformation team to the picking team in Core Sequencing.  Due to 
this one day lag between transformation and picking, the MBPG transformation team works on a Sunday 
through Thursday work schedule rather than the Monday through Friday schedule of all other Broad 
employees.  In summary, the transformation process is completed to a much more constant and higher 
volume production schedule than the other two processes in MBPG.   
 
4.2 Organizational Structure 
The MBPG processes include the most complex molecular biology procedures and require the most 
highly skilled technicians at the Broad Institute.  MBPG resembles a highly skilled job shop as compared 
to other sequencing operations departments which resemble a more traditional manufacturing line.  As 
mentioned previously, the competitive advantage of the Broad Institute has been its ability to rapidly 
scale-up or industrialize the DNA sequencing process.  While the other departments in sequencing 
operations at the Broad Institute had already been highly industrialized, MBPG had not yet undergone 
such a transformation and still operated more like a laboratory than a manufacturing or production group. 
 
The organizational structure of MBPG falls along the lines of its three main process capabilities described 
above in Section 4.1.  MBPG has a total staff of 16 people divided into three teams called DNA 
Preparation, Ligation, and Transformation that all report up through one MBPG manager (see the 
organizational chart for MBPG included in Figure 13).  The MBPG manager is a very experienced 
scientist and laboratory manager with a prestigious PhD and Post-Doc educational background.  This 
manager joined the Broad Institute in late 2003 as the MBPG manager and reports directly to the director 
of sequencing operations.  This director has been with the Broad Institute since 2001, is an alumnus of the 
Leaders for Manufacturing (LFM) program at MIT, and was the sponsor of this LFM internship and 
thesis work. 
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The transformation team consists of four laboratory technicians and one coordinator (i.e. a supervisor).  
The technicians all have bachelor’s degrees in a science field and have been working in MBPG for 
several years.  The coordinator supervises the daily work of the transformation team and also provides 
technical trouble-shooting assistance.  The coordinator is one of the most experienced employees at the 
Broad Institute and had been promoted into this supervisory role from one of the transformation 
technician positions.  Since the transformation process is the least technically complicated in MBPG, the 
members of the transformation team in general have the lowest technical skills in MBPG. 
 
The ligation team consists of four laboratory technicians and one coordinator.  The technicians all have 
bachelor’s or master’s degrees in a science field and perform process improvement and research work in 
addition to their ligation process responsibilities.  The coordinator supervises the daily work of this team 
and also provides technical trouble-shooting assistance.  The coordinator is a younger employee at the 
Broad Institute and had been quickly promoted into this supervisory role from one of the ligation 
technician positions.  Since the ligation process is the most technically complicated in MBPG, the 
members of the ligation team have the highest technical skills in MBPG. 
 
The DNA preparation team consists of five laboratory technicians and no coordinator.  The technicians all 
have bachelor’s degrees in a science field and have been working in MBPG for many years.  The team 
had a coordinator up through early 2004, and since that time the team has been jointly supervised by the 
ligation and transformation team coordinators.  Since the DNA preparation processes are the most highly 
variable in MBPG, the members of the DNA Preparation team in general have the broadest set of 
technical skills and also the least standardized daily workflows in MBPG. 
 
An additional department to mention in this section is the Molecular Biology Development (MBD) group. 
This department is tightly linked with MBPG and is responsible for next generation molecular biology 
process technology development.  MBD is managed by the most senior molecular biology scientist at the 
Broad Institute, who had in the past developed all the processes used in MBPG and had also managed 
MBPG for several years. This department also employs one senior technician who used to work in 
MBPG.  MBD is co-located in the same laboratory space as MBPG, and the two teams interact quite 
frequently in the same way that process development engineers and manufacturing engineers interact in a 
traditional manufacturing organization.  The MBPG and MBD managers both report up to the director of 
sequencing operations and are parallel to one another on the Broad Institute organizational chart. 
 
4.3 Cost Structure 
While specific cost numbers can not be documented in this thesis for MBPG or the Broad Institute’s 
sequencing operations due to confidentiality reasons, a qualitative description of the cost structure of 
MBPG relative to the rest of the genome sequencing process is useful.  The cost structure of MBPG can 
be analyzed from the perspective of labor, materials, capital, and total costs. 
 
In terms of labor, employees in the Broad Institute’s sequencing operations earn roughly equivalent 
salaries across all departments.  MBPG has a total staff of 16 as compared to approximately 90 total 
employees in sequencing operations. Thus, MBPG accounts for approximately 18% of the total labor 
costs for the Broad Institute’s sequencing operations. 
 
In terms of material costs, two reagents used downstream from MBPG in the Core Sequencing 
department account for the vast majority (approximately 80%) of the Broad’s annual material spend.  The 
materials used in MBPG are relatively inexpensive and account for only about 10% of the total material 
costs for the Broad Institute’s sequencing operations. 
 
MIT Thesis – Matthew R. Vokoun  Page 31 of 132 
In terms of capital costs, the Detection department dominates the capital investment needs of the Broad 
Institute. This department contains 96 Applied Biosystems DNA sequence detectors, each costing several 
hundreds of thousands of dollars.  Consistent with Theory of Constraints, these detectors are by design 
the bottleneck of the entire sequencing process.  In addition, the Core Sequencing department has 
significant capital investments in process automation equipment.  MBPG is a very low capitally intensive 
operation and only accounts for approximately 5% of the total capital costs for the Broad Institute. 
 
Combining the labor, material, and capital costs together, a clear picture is painted of how MBPG is the 
lowest cost department in the Broad Institute’s sequencing operations.  From discussions with the 
directors at the Broad Institute, MBPG typically consumes only 10% of the total cost to sequence a large 
mammalian genome such as the human, dog, or mouse.  Core Sequencing and Detection together account 
for 70%, and Finishing accounts for the remaining 20%.  Figure 15 depicts this cost breakdown. 
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Figure 15. Cost breakdown for a typical genome sequencing project at the Broad Institute. 
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5 Initial Audit of MBPG Operations Capability 
 
This chapter provides a data-driven audit of the initial operations capability in MBPG at the beginning of 
this LFM internship.  Included are a historical production data analysis, a quality management systems 
review, an inventory management systems review, and a forecasting and production scheduling systems 
review.  The objective of this chapter is to educate the reader on the operational situation in MBPG prior 
to the completion of this thesis work and LFM internship. 
 
5.1 Historical Production Data Analysis 
From the perspective of the entire genome sequencing process at the Broad Institute, the two primary 
products of the MBPG group are (1) DNA libraries and (2) sets of agar plates with cell colonies 
containing copies of a DNA library. This second product, the grown agar plates, is the product that exits 
MBPG into the downstream Core Sequencing department which conducts the rest of the high throughput 
sequencing process.  Thus, in order to analyze the initial level of performance of MBPG, it was useful to 
analyze the variability of the quality in this agar plate output to Core Sequencing.   
 
After cell colonies are grown overnight on the agar plates produced by the MBPG transformation team, 
the Core Sequencing department sends the plates through the picking process (see Figure 9).  The quality 
of the agar plates serve as an internal quality metric (meaning inside the Broad Institute’s genome 
sequencing operations) for MBPG and is evaluated with the following two criteria: 
 
• White Count – This measurement refers to the number of white-colored, grown cell colonies on 
an agar plate.  The white count represents the number of E.coli cells that effectively took up a 
DNA library during the transformation process and also the “potency” or quality of the DNA 
library itself.  It is measured in two primary methods – the first is a manual visual count by an 
experienced Transformation employee, and the second is an automated count by the robot that 
performs the picking process in Core Sequencing.  An informal target of 3000 white counts per 
agar plate has been established between MBPG and Core Sequencing.  However, actual white 
counts can very by several thousand, and MBPG does not understand its Ligation and 
Transformation processes well enough yet to control this output variable accurately. 
 
• Glycerol Yield – During the picking process in Core Sequencing, a grown cell colony is picked 
off the agar plate by a robot and placed into one well of a 384-well plastic plate containing 
glycerol, an organic solvent.  These plates are green in color and called “glycerol plates” at the 
Broad Institute.  The glycerol yield refers to the number of glycerol plates that can be filled up 
from picking one agar plate (glycerol yield = picked glycerol plates ÷ agar plates).  Not all the 
grown colonies indicated by the white count can be picked, so the glycerol yield represents how 
many actual cell colonies have been passed on to the downstream processes after picking. 
 
To analyze the performance of MBPG relative to these metrics, data was gathered on the average white 
count and glycerol yield for each 4kb DNA library transformed and picked from January through June of 
2004.  Only 4kb libraries were analyzed as their performance is closely equivalent to that for 10kb and 
Fosmid libraries.  For each measurement, the average and standard deviation where calculated, and the 
data was then plotted in a standard control chart including upper control limits (UCL) and lower control 
limits (LCL).  Figure 16 displays the control chart for white counts, and Figure 17 displays the control 
chart for glycerol yield.  These control charts were then tested against the seven standard tests for process 
control shown in Figure 18.   
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Figure 16. Control chart for the white counts of 4kb libraries transformed and picked from January to June of 2004. 
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Figure 17. Control chart for the glycerol yield of 4kb libraries transformed and picked from January to June of 2004. 
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Figure 18. Seven standard tests for process control.37 
 
The application of the seven standard tests for process control to the white counts and glycerol yield data 
show that MBPG’s processes are not well controlled.  The white counts control chart fails four of the 
seven tests, and the glycerol yield control chart fails three of the tests.  These test results are summarized 
below in Table 1, Figure 19, and Figure 20.  The primary takeaway from this historic analysis of two 
internal quality metrics is that the process output from MBPG to the downstream portion of the genome 
sequencing process is not well understood, highly variable, and not under adequate process control. 
 
Table 1.  Process control test results for white counts and glycerol yield. 
Test No. Test Name White Counts Result Glycerol Yield Result 
1 Outside UCL / LCL Fail Fail 
2 2 of 3 between 2σ & 3σ Pass Pass 
3 4 of 5 beyond 1σ Fail Fail 
4 9 in a row above / below µ Fail Pass 
5 6 in a row with up / down trend Pass Pass 
6 14 alternates in row Pass Pass 
7 15 in a row within ± 1σ Fail Fail 
 
In addition to the internal quality metrics of white counts and glycerol yield, the operation of MBPG and 
the Broad Institute is evaluated with one important external quality metric – the quality of the genome 
sequence data published.  The Broad Institute’s reputation is dependent on the very high quality of the 
data it produces, and any problem with this data in the past has been considered the most severe quality 
issue possible.  MBPG plays a key role in preventing these quality issues as it receives all DNA samples 
and starts each DNA sample along its path through the Broad’s physical and informational processes.   
 
While few external quality problems have ever arisen in the Broad’s history, a few very notable incidents 
have happened, primarily due to mix-ups of DNA samples resulting in published sequence for one 
organism containing sequence from a DNA sample of another organism.  Two such incidents had 
occurred previous to this thesis work, and both had resulted in notable scientists from other research 
organizations notifying the head of the Broad Institute of the quality issues, causing some reputation 
damage to the Broad.  MBPG had played a role in each of these crucial external quality problems in 
causing the initial mix-up in DNA samples from different organisms and projects.  Therefore, as 
problematic as the internal quality metrics have been shown to be in this historic production analysis, a 
more pressing historical operations challenge for MBPG has been its role in contributing to two severe 
external quality problems. 
                                                 
37
 Source: Roemer, Thomas, “Quality Lecture” notes, Course 15.760, MIT Sloan School of Management. 
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Figure 19. Failed process control tests on the white counts control chart from January to June of 2004. 
 
 
 
Figure 20. Failed process control tests on the glycerol yield control chart from January to June of 2004. 
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5.2 Quality Management Systems 
The quality management systems in MBPG are primarily classified as “inspecting quality into the 
process.”  This statement refers to enforcing quality through post-processing inspections rather than 
through proactive process control techniques for preventing quality issues from occurring in the first 
place. Since the molecular biology processes used in MBPG are relatively new technologies and still 
difficult to perform, a deep understanding of the intrinsic variability and quality constraints in these 
processes is lacking.  Additionally, most of the work in MBPG requires highly skilled, highly educated, 
and experienced scientists and laboratory technicians, rather than on-the-job trained lower-level workers.  
Thus, quality is achieved in MBPG through precise attention to detail in each process and significant 
quality assurance testing and analysis both during and after each process. 
 
To describe the quality management systems in MBPG prior to the completion of this thesis work, the 
quality testing in each MBPG process described in Section 4.1 will be analyzed.  Starting with the 
incoming DNA quality control processes performed by the DNA Preparation team, the primary quality 
focus is on external, incoming work rather than on the work performed within this MBPG team.  Thus, 
very little QA analysis is done on the output of the DNA Preparation team’s work.  The employees on this 
team self-inspect the quality of their work, mostly through viewing the success or failure of each process 
step they conduct.  Overall, the internal quality management system in the DNA Preparation process is 
not very sophisticated, relying mostly on the skill and training of the employees. 
 
The quality management systems for the ligation or DNA library construction process in MBPG are 
significantly more advanced.  Quality is assured in this process through two primary mechanisms – (1) 
measuring DNA yield throughout the process and (2) test runs of each DNA library through the 
downstream transformation, sequencing, and detection processes.  The first mechanism uses the pico 
green assay described in Section 4.1.1 to determine the amount of DNA present after the most important 
steps in the ligation process.  This DNA quantity is the most important process variable in ligation and 
should be used to determine the optimal settings of each reaction in the ligation process.  However, a 
major problem with the execution of this quality management system is that the MBPG employees 
perform all the pico green tests at the end of the ligation process rather than during the process as they 
should be doing.  This issue is a major flaw in MBPG’s quality management of the ligation process. 
 
The second quality management mechanism in the ligation process involves sending a sample from each 
DNA library through the rest of the genome sequencing process at the Broad Institute.  The library is 
transformed in MBPG, then sent through the Core Sequencing department, and finally processed through 
the Detection equipment to assemble its DNA sequence.  This full-process testing ensures that the DNA 
library performs “normally” through the rest of the process and also contains a DNA sequence that 
appears to be from the same organism as it should (by comparing to smaller genome data sets available 
for that organism at other research locations).  Only after successfully completing this test sequencing is a 
DNA library officially released for use in production sequencing.  The results of this test are reflected in a 
“Library Pass Rate” metric tracked by the MBPG management team.  Thus, this quality management 
system effectively prevents any quality mistakes from the DNA preparation and ligation processes to pass 
downstream into actual genome sequence data released from the Broad Institute.  However, this quality 
assurance comes at a high cost of labor, materials, and capacity consumption of all downstream resources. 
 
The final MBPG process, transformation, relies heavily on visual inspection for its quality assurance.  
Well-trained technicians perform each step of the transformation process and self regulate the quality of 
each process step.  As mentioned in Section 4.1.3, the agar plates created by the transformation team are 
handed-off the next day to the picking team in the Core Sequencing department.  A formalized hand-off 
process was created between these two teams to visually inspect each agar plate for contamination, lack 
of cell colony growth, and other quality problems.  Any plate not passing these visual quality tests is not 
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further processed and discarded.  The results of this test are reflected in an “Agar Plate Pass Rate” metric 
tracked by the MBPG management team.   
 
A final area of quality management to describe is the assurance of quality for the raw materials consumed 
in MBPG’s processes (not including DNA samples).  These raw materials are supplied to MBPG by the 
Materials department at the Broad Institute.  Materials performs all quality assurance testing on these raw 
materials before releasing them to MBPG, and this department also provides value-added services to 
MBPG such as breaking down large lots of raw materials into single-use quantities.  Thus, very little 
quality assurance is performed in MBPG on raw materials as this service is provided by the Broad 
Institute’s Materials department. 
 
5.3 Inventory Management Systems 
MBPG employees two different inventory management systems – one for its DNA samples and one for 
the general materials it consumes as it processes the DNA samples.  MBPG is solely responsible for the 
DNA inventory, but it relies heavily on the Materials department to manage the materials inventory.  
These two inventory systems are described below and illustrated in Figures 21 and 22. 
 
DNA inventory exists in four different states in MBPG – (1) DNA samples, (2) sheared DNA, (3) DNA 
libraries, and (4) agar plates containing DNA.  These inventory states have the following characteristics: 
 
• DNA RM Inventory – This inventory represents the DNA samples received at the Broad 
Institute from external labs and universities. 
o Inventory Level: The level of this inventory is highly variable and has no target level.  As 
the Broad Institute performs more and more sequencing projects, this inventory is 
expected to grow substantially in size and complexity. 
o Location: -20ºC or 4ºC freezers in the MBPG lab area. 
o Comments: 
 Incoming DNA is usually processed right away. 
 “Extra” DNA is stored as RM samples if it is not needed in MBPG’s processes. 
 DNA samples are held forever or until fully consumed. 
 A new IT system is being implemented in 2005 to better manage this inventory. 
 
• Sheared DNA WIP Inventory – This inventory represents the sheared DNA created by the DNA 
preparation team and then passed on to the ligation team. 
o Inventory Level: This inventory has no limit on its level as these sheared DNA samples 
take up very little space and usually are quickly consumed by the ligation team. 
o Location: -20ºC freezer in the MBPG lab area. 
o Comments: 
 Target maximum and minimum buffer levels do not exist for this inventory. 
 A buffer is usually kept so that the ligation team can pull from inventory. 
 This inventory is sometimes discarded every few years to save space. 
 
• DNA Library WIP Inventory – This inventory represents the completed DNA libraries. 
o Inventory Level: This inventory has no limit on its level as these DNA libraries take up 
very little space and sometimes need to be reused months or years after they are created. 
o Location: -20ºC freezer in the MBPG lab area. 
o Comments: 
 Manual storage location tracking of this inventory is done by coordinators. 
 DNA libraries are mostly stored forever. 
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Figure 21. DNA inventory management system used in MBPG. 
 
 
 
 
Figure 22. Materials inventory management system used in MBPG. 
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• Agar Plate WIP – This inventory represents the agar plates created by the transformation team. 
o Inventory Level: One day of demand for the picking process (150-180 plates/day) is held. 
o Location: Warm room in the Core Sequencing (CS) lab area. 
o Comments: 
 Plates must dwell in the warm room for at least 18 hours after transformation. 
 Plates are kept in the warm room overnight and then handed off to CS. 
 If plates are not used the next day in picking, the CS team will store them in a 
cold room overnight and pick them the next day. 
 
Materials inventory is primarily managed for MBPG by the Materials department.  This department 
orders material from suppliers, receives and inspects the material shipped from suppliers, performs value-
added processing, and then delivers material to inventory mini-marts in MBPG.  One value-added process 
involves combining multiple materials into a ready-to-use form for MBPG, and the other value-added 
process involves breaking down bulk materials into single-use sizes.  An example of the former is 
placing agar solution into empty plastic plates to create the agar plates used in MBPG.  An 
example of the latter is breaking a large bottle of a chemical buffer into small little test tubes 
each containing the precise small volume needed in a specific MBPG process step. 
 
The vast majority of materials needed by MBPG are stored in the Materials lab area.  Only a few days of 
inventory is held on-hand in the MBPG lab area in the form of small material mini-marts.  These mini-
marts are replenished on a daily or weekly basis by members of the Materials team according to labeled 
minimum inventory levels.  The MBPG employees pull materials from these mini-marts on an as-needed 
basis throughout the work day.  Inventory levels in these mini-marts have historically been defined by 
rough estimates of consumption and safety stock requirements as well as physical lab space limitations.  
From the perspective of the Broad Institute’s ERP system (called OPM), inventory visibility ends when 
Materials delivers items into the MBPG mini-marts. 
 
Materials inventory exists in three different states for MBPG – (1) bulk raw materials, (2) prepared raw 
materials, and (3) MBPG mini-marts.  These inventory states have the following characteristics: 
 
• Bulk RM Inventory – This inventory represents the materials in the state they are received at the 
Broad Institute from suppliers. 
o Inventory Level: One to two months of inventory is normally held in this state. 
o Location: Freezers and storage rooms in the Materials lab area. 
o Comments: 
 Bulk inventory is held shortly before further value-added processing. 
 Inventory targets are determined by calculations in the ERP system. 
 Inventory levels are tracked in the ERP system. 
 All on-site inventory is owned by the Broad Institute (i.e. no VMI). 
 
• Prepared RM Inventory – This inventory represents the materials after value-added processing 
is completed by the Materials department. 
o Inventory Level: One to three weeks of inventory is normally held in this state. 
o Location: Freezers and storage rooms in the Materials lab area. 
o Comments: 
 Most materials have quality assurance testing performed on them by Materials. 
 Some RM’s are combined to form ready-to-use materials. 
 Some RM’s are broken down from bulk form to single-use sizes. 
 Inventory levels are tracked in the ERP system 
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• MBPG Mini-Marts – This inventory represents the on-hand inventory in the MBPG lab area. 
o Inventory Level: Three to ten days of inventory is normally held in this state. 
o Location: Freezers and mini-marts in the MBPG lab area. 
o Comments: 
 Mini-Marts with visual inventory target levels sit in the MBPG lab area. 
 Materials department replenishes the mini-marts on a daily or weekly basis. 
 MBPG employees pull inventory from mini-marts for consumption. 
 Inventory targets are determined by usage rate and safety stock targets. 
 Inventory levels are NOT tracked in the ERP system. 
 
5.4 Forecasting and Production Scheduling Systems 
The forecasting and production scheduling systems in MBPG prior to the completion of this thesis work 
were very minimal. For the most part, the managers in MBPG manually forecasted and scheduled the 
work that needed to be completed for the next one to two weeks.  These forecasts were then 
communicated to MBPG employees in daily and weekly work assignments from MBPG management.  
Very little visibility into future MBPG demand and production schedules were known within the 
department or communicated to the downstream Core Sequencing department or supporting Materials 
department. 
 
Within MBPG, the transformation team operates to a different production schedule than the ligation and 
DNA preparation teams.  As mentioned previously in this thesis, the Detection department at the Broad 
Institute is the most capitally expensive part of the genome sequencing process and the bottleneck for the 
entire operation.  Therefore, in accordance with the operations management principles from Theory of 
Constraints (TOC), all processes upstream of detection are scheduled so as to never starve this bottleneck.  
The Broad Institute has implemented this scheduling principle into its ERP system, taking the forecasted 
production work for detection and back-scheduling all processes in the Core Sequencing department and 
the transformation team in MBPG.  The transformation team is included in this production schedule due 
to its one-day processing lag before Core Sequencing processing.  Thus, the MBPG managers are handed 
a transformation forecast and production schedule that they must meet in order to keep all the downstream 
processes running with minimal inventory buffers.  This forecast is created in the ERP system and 
reviewed with MBPG in a weekly meeting for all the sequencing operations managers and coordinators. 
 
The ligation and DNA preparation teams are de-coupled from the transformation production schedule 
because their work does not directly flow downstream in a just-in-time manner.  These two teams produce 
small products in very low volumes that then support many weeks of transformation and Core Sequencing 
work – i.e. one DNA library can support weeks or months of downstream processes.  Thus, the ligation 
and DNA preparation teams work according to schedules manually created by the MBPG managers.  
These schedules typically only cover the current and next weeks and are subject to frequent and drastic 
changes.  In general, MBPG’s scheduling goal is to push all incoming DNA through DNA preparation 
and ligation as quickly as possible, and then hold a large buffer of DNA library inventory.  Knowledge of 
which DNA libraries are needed in future weeks for transformation also impacts the priority in which one 
DNA library is produced over another.  However, the overall forecasting and production scheduling 
system for DNA preparation and ligation was very unstable, error-prone, short-sighted, and reactionary.  
These system issues not only caused problems for the MBPG employees but also made the supporting 
work of the Materials department very difficult. 
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6 MBPG Operations Strategy and Project Approach 
 
This chapter proposes an optimal operations strategy for MBPG, taking into account the group’s local 
objectives and the global objectives of the Broad Institute’s sequencing operations.  The appropriate 
operations management tools are then selected to address different areas of operations capability 
improvement in MBPG.  The objective of this chapter is to provide the reader with the strategic 
background behind the programs implemented during this thesis work and LFM internship. 
 
6.1 MBPG Operations Strategy Selection 
The broadly stated purpose of this thesis work and LFM internship was to improve the operations 
capability of a molecular biology laboratory in a high throughput genome sequencing center such as the 
Broad Institute.  Thus, several operational improvement projects needed to be completed.  However, 
conducting standard improvement projects without a guiding rationale would most likely leave MBPG in 
a worse operational condition.  Therefore, an MBPG operations strategy was first needed to serve as this 
guiding rationale, and all subsequent improvements would be made with this operations strategy in mind. 
 
Broadly stated, the operations strategy of any firm is focused on one of four goals – (1) minimize cost, (2) 
maximize throughput, (3) maximize flexibility, or (4) maximize quality.38   The operational characteristics 
and business strategy of the firm dictate which of these goals should dominate its operations strategy.  
Additionally, the operations strategy of the various departments can be different from the overall 
operations strategy of the firm, as long as all these operational strategies are tied in to the firm’s overall 
business strategy.  At the Broad Institute, the overall business strategy is to drastically reduce the cost to 
sequence a genome while maintaining the current high level of quality.  Consequently, the operations 
strategy of most of the Broad Institute’s genome sequencing process is to minimize cost and maximize 
throughput.  However, as argued in this section, this operations strategy is not ideal for MBPG. 
 
The sequencing operations process flow diagram is recreated below in Figure 23 with observations added 
on the material and capital cost drivers.  As described in Section 4.3, two reagents downstream from 
MBPG are the primary material cost drivers, accounting for approximately 80% of annual material spend.  
Also mentioned in Section 4.3, the capital cost driver for the sequencing process is the DNA sequencers 
used in Detection.  Consistent with Theory of Constraints, these detectors are by design the bottleneck of 
the entire sequencing process.  All processes upstream from these detectors have excess capacity by 
design.  One final observation is that the Broad Institute’s final product is purely informational, and its 
public reputation is directly associated with the quality of data it publishes.  Any mistakes in this 
published data would extract an enormous and immeasurable cost on the Broad Institute.  
 
Combining the information provided from this process flow diagram along with the fact that MBPG 
accounts for only 10% of the total cost to sequence a genome (see Figure 15 and Section 4.3), enough 
operational characteristics of MBPG are understood to formulate its operations strategy.  The following 
key observations on MBPG summarize its important operational characteristics: 
 
• Relative cost for MBPG to the rest of the Broad Institute is very low. 
• MBPG is upstream from the bottleneck. 
• MBPG is upstream from the primary material and capacity cost drivers. 
• Excess capacity (relative to the bottleneck) has been designed into MBPG. 
• Quality of final information product is highly dependent on MBPG quality. 
                                                 
38
 Source: Pyke, David, “A Framework for Operations Strategy.” 
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Figure 23. Process flow for DNA Sequencing Operations with observations on material and capital cost drivers. 
 
These operational characteristics quickly point to what the operations strategy for MBPG should NOT 
focus on – minimize cost, maximize flexibility, or maximize throughput.  Any effort in reducing MBPG’s 
costs will have little overall impact given the low 10% relative cost of MBPG to the rest of the 
sequencing process.  Any effort to maximize flexibility would not be useful as MBPG’s role is to perform 
standard, repetitive processes.  Finally, any effort on maximizing MBPG throughput would also have no 
impact because the Broad Institute’s genome sequencing process can only operate as fast as its bottleneck 
in the downstream Detection department. 
 
The operations strategy for MBPG is, therefore, to maximize quality.  Any operational improvement 
project completed during or after this thesis work should be focused on achieving this strategy.  
Specifically, MBPG should always seek to maximize its quality through the following goals: 
 
• Eliminate the potential to pass errors downstream – All quality problems that leave MBPG 
will pass through the sequencing process’ material cost drivers and consume time on the 
bottleneck.  Thus, MBPG’s operations strategy must minimize sending errors downstream. 
• Minimize process variability – All process variability signals from MBPG are passed 
downstream where they can get amplified and create significant problems in the parts of the 
process that are expensive and capacity constrained. 
• Maintain high data integrity – The final product for the Broad Institute is purely informational 
(a genome database), so the data extracted from MBPG is more important than its physical 
processes.  Thus, MBPG must always ensure very high data quality. 
 
Another way to view the operations strategy for MBPG is with the Cost of Quality (COQ) framework.  
The COQ is defined the amount of money a firm loses because its product or service was not done right in 
the first place.  COQ is also defined as the current cost of resolving existing failures in a process.  MBPG 
can be viewed as having a very high Cost of Quality since any mistake it makes will significantly cost the 
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Broad Institute from (1) consuming expensive materials, (2) consuming bottleneck process time, and (3) 
damaging the organization’s external reputation from publishing low quality data. 
 
6.2 Potential MBPG Sources of Quality Problems 
Now that the operations strategy for MBPG has been defined as maximizing quality, the next important 
analysis is to determine which sources of quality problems are of highest importance to MBPG.  While an 
analysis of the frequency of occurrence for a wide range of quality problems exiting MBPG would be a 
proper place to begin, this analysis option was not viable.  The data needed to perform this analysis were 
not available or easily generated during the course of this thesis work. Additionally, MBPG’s quality 
management systems ensure that almost 100% of its quality issues are caught through internal QA testing 
before reaching any downstream processes.  Therefore, an analysis of the potential sources of quality 
problems in MBPG based on the observations of the employees in the department proved to be a more 
effective and appropriate approach.   
 
To gather data on the potential sources of quality problems, several interviews were conducted with the 
technicians, coordinators, and manager in MBPG along with the director of sequencing operations.  These 
interviews focused on generating a list of the sources of quality problems that could potentially occur 
along with a ranking of the magnitude of effect each quality problem would have.  In other words, each 
problem was scored on the basis of how large its negative impact would be on MBPG and the rest of the 
Broad Institute.  This information was presented back to all the MBPG employees in the form of a Pareto 
diagram which ranked the sources of quality problems from highest to lowest in terms of the magnitude 
of impact each would have if they occurred.  Follow-on interviews changed or confirmed the problems 
included on the diagram, their relative ranking, and their relative order of magnitude.  The final version of 
the Pareto diagram appears in Figure 24, and the final list of potential MBPG sources of quality problems 
is listed below in order of impact: 
 
• DNA sample mix-ups – MBPG handles DNA samples from multiple organisms and genome 
projects at the same time.  Each sample looks identical (a small plastic tube with a clear solution 
of DNA inside).  Switching a DNA sample would be hard to visually detect and would lead to a 
very serious destruction in the quality of the published sequence data from the Broad Institute. 
• Poor adherence to protocols – MBPG has frequent improvements to the protocols used in its 
processes, yet it suffers from poor compliance to these protocols due to poor training and 
communication of these new procedures.  Thus, MBPG employees sometimes perform improper 
procedures, directly impacting the quality of MBPG products. 
• Undetected equipment failures – MBPG has experienced several equipment failures in the past 
that went undetected for several days.  No good mechanism for tracking products to the pieces of 
equipment they were processed through existed in MBPG, so it was nearly impossible for MBPG 
to know which products had been negatively impacted by these equipment failures. 
• Lab disorganization and uncleanliness – Poor organization and cleanliness in the MBPG lab 
area made for a poor working environment and wasted precious lab floor space.  Additionally, 
DNA samples and sequencing is very sensitive to contamination of other DNA, proteins, or cells, 
and this contamination is more likely to occur in a poorly cleaned and organized lab. 
• Priority and schedule changes – Frequent changes in the MBPG production schedule led 
employees to waste effort and materials on unneeded work, release work downstream in the 
incorrect order, and experience unnecessary process disruptions and instability. 
• Type of DNA – All of the processes in MBPG were developed and optimized during the Human 
Genome Project when only human DNA was processed.  Now, MBPG processes DNA samples 
from over twenty different organisms, and the variability of behavior of different DNA in 
MBPG’s processes is observable but not well understood. 
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Figure 24. Pareto diagram of the potential sources of quality problems in MBPG. 
 
• Intrinsic biological variability – Due to the relatively small duration of time the biotechnology 
field has existed, the true intrinsic variability of most biotech processes is not well understood 
when compared to the field of chemistry.  Thus, understanding the mechanisms behind variability 
in molecular biology process is a challenge for this area of science and not just MBPG. 
• Equipment-to-equipment variability – Most of the processes in MBPG rely on automated 
pieces of equipment to run thermal reactions, mix samples, and dispense reagents.  While the 
variability of behavior between two pieces of the same types of equipment is observable in 
MBPG, it is not yet well understood or characterized. 
• Within equipment variability – For all of the critical pieces of equipment in MBPG, no gage 
R&R studies have yet been performed to understand the sources of variability within an 
individual piece of equipment.  Employees in MBPG have observed such variability though. 
• Raw material variability – Similar to the other variability items listed above, MBPG has 
observed variability of behavior between different lots of the same raw materials, but this 
variability is not yet well understood or characterized. 
 
6.3 Solutions to Potential MBPG Quality Problems 
Now that the operations strategy for MBPG has been defined as maximizing quality and the sources of 
potential quality problems in MBPG have been identified, the final important analysis is to select the 
appropriate operations management tools to address each quality problem.  The selection of solutions was 
accomplished through conversations among the author, the thesis research advisors from MIT, and the 
director of sequencing operations at the Broad Institute (an alumnus of the MIT Leaders for 
Manufacturing program).  Based on the expertise of this group of people, the following operations 
management tools were selected to address the issues most important to the operations strategy of MBPG. 
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The quality problems in the Pareto diagram in Figure 24 separate naturally into two groups of five items 
each.  The five left-most quality problems – DNA sample mix-ups, improper procedures, undetected 
equipment failures, lab disorganization and uncleanliness, and priority and schedule changes – are all 
sources managed into the process by the policies, workflow design, and organizational design of MBPG.  
In other words, these sources of quality problems have nothing to due with the actual molecular biology 
processes performed in MBPG.  On the other hand, the five right-most quality problems – type of DNA, 
intrinsic biological variability, equipment-to-equipment variability, within equipment variability, and raw 
material variability – are all directly associated with or intrinsic to the process and product technologies.  
Interestingly, the quality problem sources managed into MBPG have a much larger potential effect than 
the problems sources intrinsic to the actual work performed. The five left-most quality problems are the 
classic “low hanging fruit” on the tree of operations capability improvement opportunities in MBPG. 
 
The four most important of the “managed in” sources of quality problems – DNA sample mix-ups, 
improper procedures, undetected equipment failures, and lab disorganization and uncleanliness – were 
identified as classic problems addressed in basic lean manufacturing and process reengineering 
implementations.  The opportunity to use lean and process reengineering in MBPG was quickly identified 
near the beginning of this thesis work and was considered the highest importance work as it addressed the 
four most important concerns in MBPG’s operations strategy to maximize quality. 
 
The one remaining “managed in” source of quality problems – priority and schedule changes – was 
identified as being readily addressed by the implementation of a basic production forecasting process and 
spreadsheet tool in MBPG.  The manager and coordinators could implement this basic production 
forecasting along with assistance from the supporting Materials department. 
 
Finally, the five “intrinsic” sources of quality problems – type of DNA, intrinsic biological variability, 
equipment-to-equipment variability, within equipment variability, and raw material variability – were 
identified as classic problems addressed with the Six Sigma methodology.  Six Sigma could be utilized to 
understand, reduce, and control these sources of variability.  Due to time and resource constraints, this Six 
Sigma work was determined to be out of the scope of this thesis work, but it will be addressed in the 
future during a follow-on LFM internship in MBPG in 2005-2006 (see Chapter 9 for more details). 
 
The selection of operations management solutions to each of the sources of potential quality problems in 
MBPG described above is summarized below in Table 2 and Figure 25. 
 
 
Table 2.  Selections for solutions to the sources of potential quality problems in MBPG. 
Source of Potential Quality Problem Type of Problem Operations Management Solution 
DNA sample mix-ups 
Improper procedures 
Undetected equipment failures 
Lab disorganization and uncleanliness 
Managed In Lean Manufacturing &  Process Reengineering 
Priority and schedule changes Managed In Production Forecasting Process & Tool 
Type of DNA 
Intrinsic biological variability 
Equipment-to-equipment variability 
Within equipment variability 
Raw material variability 
Intrinsic Six Sigma 
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Figure 25. Operations management solutions to the potential sources of quality problems in MBPG. 
 
6.4 Approach and Timeline for Thesis Work 
As this chapter described, the initial thesis work was to define an operations strategy for MBPG, 
determine which opportunities for operations capability improvement best fit with this operations 
strategy, and then select the appropriate operations management tools to address these opportunities.  The 
remaining thesis work was focused on completing two projects to address the most important potential 
sources of quality problems in MBPG.  The first project, a lean manufacturing and process reengineering 
implementation, was completed in July through November of 2004 and is described in Chapter 7.  The 
second project, a production forecasting process and tool implementation, was completed in October 
through December of 2004 and is described in Chapter 8.  The overall timeline of this thesis work is 
illustrated below in Figure 26. 
 
The Six Sigma work identified in this section was determined to be out of the scope of this thesis work 
due to time and resource constraints.  However, the opportunities for Six Sigma were documented during 
this internship and are included in Chapter 9.  Finally, a side project came up during this thesis work 
focused on potential applications of RFID technology in MBPG.  While this project was not completed 
during the timeframe of this thesis work, the opportunities for RFID were documented and are included in 
Chapter 10. 
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Figure 26. Timeline for LFM internship and thesis work completed in 2004 in MBPG at the Broad Institute. 
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7 Lean Manufacturing Implementation 
 
This chapter describes a five-month lean manufacturing and process reengineering implementation 
completed in MBPG during July through November of 2004.  Brief overviews of lean manufacturing and 
process reengineering are first provided.  Then, the chapter shows how these tools were applied in MBPG 
to reduce the most severe forms of process variability, rationalize and improve workflow, and establish a 
baseline level of process understanding and continuous improvement in the MBPG team.  The objective 
of this chapter is to specifically discuss the implementation’s goals, methodology, results, and metrics. 
 
7.1 Lean Manufacturing Overview 
Lean Manufacturing (or simply just “Lean”) is a business initiative focused on reducing waste in 
manufactured products and their related processes.  The central belief in Lean is that the cause of poor 
performance in any organization is wasteful activity. Lean is a time-based strategy and uses a narrow 
definition of waste (non-value-adding work) as any task or activity that does not produce value from the 
perspective of the end customer.  Increased competitive advantage comes from assuring every task is 
focused on rapid transformation of raw materials into finished product.39 
 
Lean Manufacturing started as the Toyota Production System (TPS), developed by the Toyoda (now 
Toyota) Motor Car Company.  Lean Manufacturing and TPS are also sometimes called Just-in-Time (JIT) 
manufacturing.  Toyota started as a manufacturer of looms for manufacturing cloth, branched into 
bicycles before WWII, and eventually started to manufacture engines, small delivery vehicles, trucks, and 
cars.  Poor management decisions almost bankrupt the company in these early days, forcing the original 
management to either resign or significantly change their ways.  39 
 
Toyota went on an aggressive improvement program to work their way back from near oblivion, and thus 
the motivations for Lean Manufacturing were established.  Tools and techniques soon started to emerge 
that eased the problems with the old, inefficient ways, and allowed Toyota to achieve its Lean 
Manufacturing goals.  Toyota looked for inspiration to Henry Ford (inventor of the assembly line), 
Frederick Taylor (inventor of industrial engineering), and W. Edwards Deming (father of modern quality 
management).  Based on these early beginnings, the techniques were refined, honed, and improved in all 
areas to become today’s TPS or Lean Manufacturing.39 
 
With the invasion of the North American automobile market by Toyota in the 1970's, the American 
automotive industry was in for major de-stabilization.  American automotive manufacturers looked for an 
explanation as to how Toyota could manufacture a car, ship it to North America, and sell it faster and 
cheaper than domestically made vehicles.  The quality of the Toyota vehicles also increased at a rapid 
rate.  In short, American companies had assumed and accepted the mass production theory and honed it to 
perfection.  Toyota had used mass production as a starting point and evolved it further into TPS, enabling 
the company to maintain significant cost and quality competitive advantages that continue today.39 
 
Today, Lean Manufacturing is being used world-wide in a wide array of organizations, including 
manufacturers, banks, service organizations, research laboratories, and hospitals.  Toyota suggests that it 
takes a smart person at least 20 years to complete full training, attitude, knowledge and comprehension of 
Lean Manufacturing in their work venue.  However, the most significant savings can be achieved in the 
first several months, as the amount of "low hanging fruit" available in most organizations is staggering.39 
                                                 
39
 Source: Lean Manufacturing Website, <http://www.pqa.net/ProdServices/leanmfg/lean.html>. 
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Lean Manufacturing typical results in reduced overhead operating costs, shortened lead times, reduced 
inventory levels, increased sales and profits, and lowered on-the-job employee frustration.  This 
operations management tool provides a strategic approach to integrated improvements through value 
stream mapping and the focus on maximizing the value-adding-to-waste ratio.  It directly promotes and 
advocates radical breakthrough innovation, while also emphasizing fast response to obvious improvement 
opportunities.  Finally and most importantly, Lean addresses workplace culture and resistance to change 
through direct team involvement at all levels of the organization.40 
 
Lean Manufacturing has developed many standard tools and principles.  Rather than provide an 
exhaustive description of each, the rest of this section will focus on the three tools used in the lean 
manufacturing implementation in MBPG – 5S, workstations, and kanban. 
7.1.1 5S 
5S is a methodology for organizing workplaces and keeping them clean, and it forms the core of TPS and 
Lean Manufacturing.  The name 5S originates from the five Japanese words describing the process to 
obtain an orderly workplace – Seiri, Seiton, Seiso, Seiketsu, Shitsuke.  Today, these five words have been 
translated into the 5S methodology used at the beginning of any lean manufacturing implementation –
Sort, Straighten, Shine, Standardize, and Sustain.  Each of the 5S’s is described below: 
 
• Sort – Sorting through the contents of an area and removing unnecessary items. 
• Straighten – Straightening necessary items for easy and efficient access, and then keeping them 
that way.  Also called “set in order.”   
• Shine – Cleaning everything, keeping it clean, and maintaining area and equipment as it should 
be.  Also called “sweep.”   
• Standardize – Creating guidelines for keeping the area organized and clean, and then making the 
standards obvious. 
• Sustain – Educating and communicating to make sure everyone maintains 5S standards. 
 
The purpose of 5S is much more than just simple housekeeping.  5S allows workers to provide input in 
order to improve their own workplace.  It cleans and organizes areas around machinery and equipment. It 
also creates a safer work environment, removes clutter, creates a labeling system for ease of recognition, 
introduces audit procedures, and creates a more inviting work place.  The improvements in organization, 
layout, and standardization from 5S lead to higher productivity, fewer defects, and a much safer 
workplace.  The initial deliverable from implementing 5S is an organized and clean workplace, and the 
long-term deliverable is that workers adapt ongoing responsibility to maintain 5S. 
 
7.1.2 Workstations 
Pull production is a basic tenet of Lean Manufacturing. In a pull environment, downstream activities, such 
as assembly, signal their needs to upstream activities, such as material handling. The same principles 
apply to a lean workstation.  Factory employees pull parts and access assembly tools in the workstation 
when and where they need them on a just-in-time basis. 
 
Workstations (or workcells) are at the heart of Lean Manufacturing.  They increase productivity and 
quality, while at the same time simplifying material flow, management and even accounting systems.  On 
the surface, lean workstations may appear simple. However, beneath this deceptive simplicity are 
sophisticated socio-technical systems.  The proper functioning of a workstation depends on subtle 
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 Source: Lean Manufacturing Website, <http://www.pqa.net/ProdServices/leanmfg/lean.html>.  
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interactions of people and equipment. Each element must fit with the others in a smoothly functioning, 
self-regulating and self-improving operation. 
 
Lean workstations are designed for minimal wasted motion, which refers to any unnecessary time and 
effort required to assemble a product. Excessive twists or turns, uncomfortable reaches or pickups, and 
unnecessary walking are all components of wasted motion.  Lean workstations focus on critical employee 
issues and concerns, such as safety, ergonomics, getting parts efficiently and finding tools quickly.  
 
7.1.3 Kanban 
Kanban is a Japanese noun, meaning “visible record”. This word has come to represent an array of 
different production and inventory control systems which signal the following: what parts to manufacture, 
when to start manufacturing, when to stop manufacturing, how many parts to manufacture, and where to 
deliver finished goods.  A kanban manages the flow of material so that production occurs only when the 
customer demands a product.41    
 
The purpose of a kanban system is to provide a limit on inventory in the pipeline.  With a properly 
implemented Kanban, inventory tends to be reduced to less than 30% of the initial level while 
maintaining the same order fill rate, shorter lead times for customer orders, and the same customer service 
level.  Additionally, kanbans lead to workers being more in-control of their job and less frustrated.41 
 
7.2 Process Reengineering Overview 
Business process reengineering (BPR) involves the restructuring and transformation of a business process 
by fundamentally rethinking and redesigning it to achieve dramatic improvements in cost, quality, and 
speed.  BPR was one of the most influential management movements of the 1990’s, and, like the quality 
movement of the 1980’s, it put management attention squarely on operations and business processes.  The 
ideas behind BPR were developed by Michael Hammer and James Champy in their 1993 best-selling 
book entitled Reengineering the Corporation. 
 
At the heart of process reengineering is the idea of discontinuous thinking, leading to the recognition and 
breaking away from the outdated rules and fundamental assumptions that underlie operations.  BPR 
emulates this idea with the four general themes of a process orientation, a creative use of information 
technology, ambition, and rule-breaking.  Reengineering teams approach existing processes with the 
questions of “why?” and “what if?” and create new processes, facility layouts, and organizational 
structures that provide dramatic levels of operational improvements.   
 
Hammer and Champy originally formulated nine principles of reengineered or re-thought processes, and 
these principles continue to be applied in any process reengineering work.42  These nine principles are: 
 
(1) Process steps performed in their natural order – Refers to following the natural work 
precedence rather than the artificial one introduced by the linearity imposed by task 
specialization. 
(2) Reduced checks and controls – Eliminate non-value-added tasks that place unnecessary 
demands on limited resources. 
                                                 
41
 Source: Lean Manufacturing Website, <http://www.pqa.net/ProdServices/leanmfg/lean.html>.   
42
 Source: Loch et al. “Making Sense of Business Process Reengineering.” 
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(3) Minimizing reconciliation – Means reducing the number of different external contact points of 
information and influence for a process.  This greatly reduces the risk of inconsistent information 
interfering with the process. 
(4) Task combination – Assigns several tasks to one worker, thus eliminating handoffs and the 
associated errors, delays, and rework.  The most basic feature of BPR is the absence of an 
assembly line.  
(5) Workers making decisions – Integrates formerly managerial activities into everyone’s work by 
delegating a certain degree of decision-making, and thus, further eliminating non-value-added 
tasks in the process. 
(6) Multiple process versions – Allow a single process to be tuned to the differing requirements of 
different market segments.  Thus, specialized resources might be assigned to tasks for difficult 
cases, allowing generalized resources to be used for standard cases. 
(7) Having work done “where it makes the most sense” – Shifts activities to external departments, 
customers, and suppliers whenever efficiencies can be gained. 
(8) Hybrid centralization / decentralization – Allows local decision-making while at the same time 
maintaining global information updates and control. 
(9) The case manager – Provides a single coordinating interface to the customer, behaving as if he 
or she were responsible for the whole process, even though that is not the actual case. 
 
7.3 Implementation Goals 
As mentioned in Section 6.3, the four most important of the “managed in” sources of quality problems – 
DNA sample mix-ups, improper procedures, undetected equipment failures, and lab disorganization and 
uncleanliness – were classic problems addressed in lean manufacturing and process reengineering 
implementations.  The opportunity to use lean and process reengineering in MBPG was quickly identified 
near the beginning of this thesis work and was considered the highest importance work.  Thus, a five-
month long lean implementation was kicked off in July 2004 in MBPG.  
 
During the project initiation phase of the lean implementation, meetings were held with the MBPG 
manager and coordinators as well as the director of sequencing operations.  These four Broad Institute 
employees, along with the author, formed the core leadership team for the lean manufacturing project.  
These project initiation meetings created the following five high-level goals for the MBPG lean 
manufacturing implementation: 
 
Goal # 1 -  Eliminate all possible chances for mixing up of DNA tubes and samples from different 
genomes, projects, and libraries. 
 
Goal # 2 -  Create personal workstations with a full set of equipment and materials per workstation 
(enabling equipment to employee to product traceability). 
 
Goal # 3 -  Minimize travel – for both people and DNA samples. 
 
Goal # 4 -  Improve and standardize the material flow of (1) replenishment of materials to lab mini-
marts from the Materials department, and (2) stocking of materials to workstations from 
lab mini-marts on a daily basis. 
 
Goal # 5 -  Clean up and organize the MBPG laboratory area.  Recover unused or poorly used space. 
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7.4 Implementation Methodology 
The lean manufacturing implementation was completed over a five-month period from July through 
November of 2004.  The first three months were spent on the core implementation of 5S, workstations, 
kanban, and process reengineering.  The final two months were spent on maintaining the implementation 
and formalizing a permanent sustainability of the project’s success.  The methodology utilized during the 
MBPG lean manufacturing implementation is described below and summarized in Table 3. 
 
From a staffing perspective, a leadership team was quickly formed at the beginning of the project.  This 
team consisted of the sequencing operations director (and LFM thesis sponsor), MBPG manager, MBPG 
ligation and transformation coordinators, and the thesis author (LFM intern working in MBPG).  This 
team established the project goals described above in Section 7.3 and provided weekly decision making 
over the next steps in the implementation.  Within this leadership team, the sequencing operations director 
held the final decision making authority, and the thesis author served in the role of project manager. 
 
In addition to this leadership team, a core implementation team was formed to lead the hands-on work in 
the laboratory area.  This core team initially consisted of the thesis author and a senior technician from the 
Ligation team.  This senior technician was reassigned from her normal work to fully support the lean 
manufacturing implementation for its first two months.  This reassignment of a critical resource to the 
project was a key factor in the success of the project, as this technician had been in MBPG for a very long 
time and had a great deal of peer respect and influence.  The core team was eventually expanded to 
include another senior technician from the Ligation team who was one of the most active supporters of 
the lean implementation from the beginning. 
 
From a perspective of the actual lean and process reengineering work completed, the implementation 
followed a five step process.   
 
(1) Core implementation in the MBPG lab area was led on a daily basis by a team of the LFM intern 
and two technicians. 
 
(2) Weekly leadership team meetings were held to review progress to date and determine the lean 
work to be completed in the next week. 
 
(3) Hands-on implementation in the MBPG lab area was completed one workstation at a time, 
eventually working a way through the entire lab. 
 
(4) A “train by example” approach was taken to ensure the involvement of all employees in MBPG.  
The 5S work on the first three lean workstations was completed by the core implementation team.  
All subsequent workstations were lead by one of the members of the core team along with two 
other people in MBPG, ensuring that each MBPG employee got hands-on 5S experience. 
 
(5) Employee-created checklists were utilized to sustain 5S in the MBPG lab area.  These checklists 
were created and maintained by the MBPG employees who will be held directly accountable for 
sustaining the lean manufacturing implementation in the future. 
 
Finally, from a training perspective, the implementation methodology relied on an initial formal training 
and ongoing informal training.  The initial formal training was delivered by the thesis author to the 
leadership team and core implementation team to teach them the basics of basics of 5S, workstations, 
kanbans, and process reengineering.  The ongoing informal training was provided to all MBPG 
employees through the “train by example” approach described above in step 4 of the five step 
implementation process.   
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Table 3.  Summary of MBPG learn manufacturing implementation methodology. 
Implementation Characteristic Methodology Selected 
Project Timeline - Core Implementation = July thru September of 2004 
- Sustain Implementation = October and November of 2004 
Leadership Team - Sequencing Operations Director 
- MBPG Manager 
- MBPG Ligation Coordinator 
- MBPG Transformation Coordinator 
- LFM Intern from MIT (thesis author) 
Core Implementation Team - Technician from Ligation Team 
- Technician from Ligation Team 
- LFM Intern from MIT (thesis author) 
Implementation Process (1) Core implementation team of LFM intern and two technicians 
(2) Weekly leadership team meetings  
(3) Hands-on implementation one workstation at a time 
(4) “Train by example” involvement of extended team 
(5) Utilize employee-created checklists to sustain 5S 
Training – Project Initiation LFM Intern trained leadership team and lead technicians on the 
basics of 5S, workstations, kanbans, and process reengineering 
Training – During Project LFM Intern and two lead technicians delivered “training by 
example” to all employees in MBPG 
  
7.5 Results 
The results of the lean manufacturing implementation in MBPG at the Broad Institute were very 
successful and well received.  While much initial skepticism existed as to the applicability of an 
operations management tool developed in automobile manufacturing to the new world of biotechnology 
R&D, the results of this implementation quickly and resoundingly quieted this skepticism.   
 
The lean manufacturing successes in MBPG touched all three teams – ligation, transformation, and DNA 
preparation – as well as the supporting Materials department.  To summarize the results from a high level, 
the lean manufacturing implementation in MBPG created the following:   
 
• 10 Individual Workstations 
• 15 Group Workstations 
• 6 Material Mini-Marts 
• 9 Improved Workflows 
• 1 Master 5S Checklist 
• 2 Individual Workstation Checklists 
• 15 Group Workstation Checklists 
• Capital Investment in New Equipment of ~$168,000 
 
The remaining parts of this section describe some of these specific results in much greater detail.  Those 
results not discussed in this section can be found in Appendix B at the end of this thesis. 
 
7.5.1 Ligation Workstations and Workflow Improvement 
The initial focus of the MBPG lean manufacturing implementation was to drastically redesign and 
improve the ligation workstations and workflow.  The ligation process was initially targeted as it 
contained the highest number of opportunities for DNA sample mix-ups, the most concerning of the 
“managed in” sources of quality problems. 
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The first step taken in improving the ligation workstations and workflows was to gain hands-on 
experience in the process.  Thus, the thesis author spent two weeks working with a senior technician in 
the ligation team, learning the entire process and creating his own DNA libraries.  During these two 
weeks of hands-on process work, the technician and thesis author spent time each day documenting 
problems and improvement ideas for the ligation process and workstations.  The primary problems with 
the ligation workstation were identified as the following (see Figure 29): 
 
• Few pieces of dedicated equipment located in the workstation.  It is very difficult to track which 
equipment was used to process each DNA library. 
• Most equipment located in other parts of the MBPG lab.  Employees and DNA samples travel 
around a lot in the lab area.  Common equipment is not assigned and used on a first-come, first-
serve basis. 
• No local stock of consumables.  These materials are retrieved in a just-as-needed fashion from the 
mini-marts in the lab. 
• No visual separation between two side-by-side ligation workstations.   
• Workstations are very messy, disorganized, and unsightly.  The MBPG lab area was known as the 
most disorganized at the Broad Institute. 
 
The second step taken in improving the ligation workstations and workflows was to fully characterize the 
process.  The following tools were used in this process characterization step: 
 
• Hand-Drawn Process Travel Maps – Each technician on the Ligation team was given a printed 
out floor plan of the MBPG lab and asked to draw out the travel path they took while completing 
the ligation process.  An example of one of these travel maps appears in Figure 27. 
• Cycle Time Measurement – The thesis author and lead technician took cycle time measurements 
of each step in the ligation process.  This data appears in Table 4. 
• Process Equipment List – A list was created of all the equipment and consumables used in the 
ligation process.  Each item’s location was noted.  This data appears in Appendix B in Section 16. 
 
 
Table 4.  Cycle time measurements of the ligation process before and after the lean manufacturing implementation. 
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Figure 27. Hand-draw travel map of the ligation workflow before the lean manufacturing implementation. 
 
With the primary process problems identified and the process fully characterized, the next step was to 
design a prototype lean workstation for the ligation team.  The lead technician volunteered her 
workstation as the prototype, and over the course of a week, the technician and thesis author designed a 
new lean workstation.  This new workstation was organized with the 5S methodology, and enabled the 
technicians to complete one full DNA library (1-1.5 weeks of work) with minimal need to retrieve 
permanent equipment and room-temperature consumables.  Extra equipment was ordered and dedicated 
to this workstation, as compared to being commonly available to all employees in the lab.  The 
workstation enabled daily restocking of materials from the MBPG mini-marts and eliminated the majority 
of opportunities to mix up DNA samples from different genomes, projects, and libraries.   
 
The prototype workstation was used by another ligation technician for two weeks, and further 
improvements were documented and implemented.  The leadership team for the lean implementation then 
all agreed to the final design of the new ligation workstation, and orders were placed for the additional 
equipment needed for all six workstations.  Once this equipment arrived, the final version of the ligation 
workstation, pictured in Figure 30, was implemented for all six members of the ligation team.  Each 
workstation was identified with its own unique color, providing better visual management in the lab.  
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Figure 28. Hand-draw travel map of the ligation workflow after the lean manufacturing implementation. 
 
The final step in improving the ligation workstations and workflows was to re-characterize the process 
with the new lean workstations.  The hand-drawn process travel maps were re-created, showing a 
significantly streamlined workflow (see Figure 28).  The cycle time measurements were also done again, 
showing a 4.4% reduction in the total ligation process cycle time and a 34.2% reduction in the manual 
cycle time (the actual hands-on time in the process as compared to machine processing time).  This cycle 
time data appears in Table 4. 
 
As this example shows, significant process improvements in a biotech research laboratory can be gained 
from the implementation of basic lean manufacturing and process re-engineering tools.  The 
improvements in cycle time allowed the ligation employees to dedicate more time to quality and process 
improvement work.  The cycle time reduction also helped the MBPG team absorb the loss of one 
technician to another job without a fall-off in team production. Most importantly, all the ligation 
employees expressed significantly increased job satisfaction in having more dedicated equipment, better 
working conditions, and less walking around during their work day.   
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Figure 29. Picture of two ligation workstations before the lean manufacturing implementation. 
 
 
 
Figure 30. Picture of two ligation workstations after the lean manufacturing implementation. 
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7.5.2 Ligation Reagent Kits 
In addition to the improvements described in the previous section to the ligation workstations and 
workflow, the lean manufacturing implementation also significantly improved materials management for 
the ligation process.  For the critical room temperature reagents used in the process, the ligation 
technicians had previously retrieved these from a mini-mart in the MBPG lab area one at a time as they 
were needed.  This material management process had the following problems: 
 
• Multiple, repetitive trips to the material mini-mart during the ligation process, resulting in 
wasteful motion for the technicians 
• Requirement that technicians remember from memory or refer to the process protocol before 
pulling a specific material from the mini-mart. 
• Potential recognition in the middle of the ligation process that a key material is not in stock in the 
material mini-mart.  This problem could result in delayed processing or, worse, the need to scrap 
an entire DNA library because a time-sensitive reaction step could not be completed. 
• No management visibility into the progress of the week-long ligation process from viewing the 
consumption of materials in each process step. 
 
To address these problems, the core lean implementation team designed reagent kits for use during the 
ligation process.  These kits were designed to hold all the materials needed to complete a library, and one 
kit was created for each temperature the materials are stored at – room temperature, +4°C, and -20°C.  
Plastic test tube holders used in MBPG were modified to create these kits, and each reagent had a labeled 
location in the kit.  The reagent kits for each workstation were made in the same color as the rest of the 
items in the workstation.  Figure 32 shows close-up pictures of the reagent kits, and Figure 31 shows all 
the reagent kits for all six workstations. 
 
Prior to beginning a DNA library, each ligation technician takes an empty reagent kit to the material mini-
marts, fills up the designated spots with the correct materials, and then brings the kit back to his/her 
ligation workstation or freezer space.  The kit remains at the workstation throughout the duration of the 
ligation process, eliminating the need for multiple trips to the mini-marts. 
 
 
Figure 31. Six sets of color-coded reagent kits used in the ligation workstations. 
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Figure 32. Close-up pictures of the three reagent kits used in each ligation workstation. 
 
In addition to cutting down on wasted motion, the ligation reagent kits have several other advantages.  
They force the ligation technician to plan out his/her material consumption at the beginning of the 
process, preventing unforeseen process delays or failures due to material unavailability.  The item and 
quantity labels on the kits also ensure that the technician is using the correct materials in the process.  
Finally, the kits provide a very simple yet powerful visual management tool – the MBPG managers can 
quickly gage the progress of each technician’s progress by simply looking at what materials have been 
consumed out of the reagent kits.   
 
7.5.3 Transformation Workstations and Workflow Improvement 
The improvement process applied to the ligation workflow discussed in Section 7.5.1 above was also 
applied at the same time to the transformation workflow.  Since the coordinator of the transformation 
group had many years of experience in the process and team, she took the lean implementation leadership 
role for this area with the thesis author acting as an advisor.  Given the coordinator’s experience in the 
process, the implementation went straight to the second step of characterizing the process.  The primary 
tool used in this process characterization was the Hand-Drawn Process Travel Map, which the coordinator 
drew out in an electronic format.  This travel map appears in Figure 33. 
 
Before designing a lean transformation workstation, the first improvement efforts were placed on the 
overall workflow.  As shown in the travel map in Figure 33, the transformation team did a significant 
amount of walking around during their process.  Two simple process changes alleviated this problem.  
First, the travel maps showed how the ligation team was moving their plates in and out of a cold room and 
warm room located two hallways away from the MBPG lab area. Another set of warm and cold rooms  
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Figure 33. Travel map of the transformation workflow before the lean manufacturing implementation. 
 
were located only one hallway away and were not being used due to an old allocation of space for other 
departments.  Thus, the MBPG leadership team quickly won approval to use these closer warm and clean 
rooms, which drastically cut down on the travel distance in the transformation workflow.  The second 
process change was the investment in two table-top incubators to replace the use of the warm room during 
a 45-minute heating step in the transformation process.  These incubators were located very close to the 
transformation workstations and further cut down on unnecessary travel in the workflow.  These changes 
can be seen in the “after” state travel map shown in Figure 34. 
 
After these overall process improvements were implemented, focus turned to improving the 
transformation workstations.  The main goal was to place a full set of dedicated equipment and a full 
day’s stock of consumables in each workstation. Previously, all workstations had to share two critical 
pieces of equipment called electroporators, leading to poor equipment-to-product traceability and waiting 
for equipment availability.  Figure 34 illustrates the old design of the workstations.  Thus, additional 
electroporators were ordered, and four new transformation workstations were designed around them. 
 
The evolution of the design of the lean transformation workstation demonstrates how the culture in 
MBPG eventually embraced the concepts of 5S, lean, and process re-engineering.  The transformation 
process follows three main steps – (1) set-up, (2) shock, and (3) plate. The first lean workstation, shown 
in Figure 36, was designed by the team coordinator and thesis author and was a significant improvement 
with its dedicated equipment, extra working space, and full stock of consumables.  This first workstation 
was successfully used for a few weeks of regular transformation production work, with the technicians on 
the team taking notes for future areas of improvement. 
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Figure 34. Travel map of the transformation workflow after the lean manufacturing implementation. 
 
This final lean transformation workstation design was created when the extra electroporator arrived for 
the other three workstations.  When this equipment arrived, the team coordinator and thesis author asked 
the transformation team and one of the lead technicians from the ligation team to set up the other three 
workstations in the same manner as the first lean workstation.  As they went about this work, they 
reviewed their notes from using the first design and determined that a better design was possible.  Placing 
the electroporator in the middle of the workstation allowed a right-to-left flow for the three steps of the 
transformation process (see Figure 37).  The whole team eagerly endorsed this new design, demonstrated 
it to the thesis author and team coordinator, and implemented the new design after getting enthusiastic 
support from the coordinator and author.   
 
Transforming a workplace culture is usually the most difficult part of a lean manufacturing and process 
reengineering implementation.  Prior to this work with the transformation workstations and workflow, the 
lean project was viewed by the MBPG employees as a top-down management initiative being lead by the 
thesis author.  However, with this project and specifically with the final design of the transformation 
workstation, the lean culture started to take hold and sink into the “organizational DNA” of MBPG.  After 
this point, small self-initiated lean projects began to be completed by the technicians in MBPG. 
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Figure 35. Picture of a transformation workstation before the lean manufacturing implementation. 
 
 
 
Figure 36. Picture of the first prototype of the lean transformation workstation. 
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Figure 37. Picture of the final version of the lean transformation workstation. 
 
7.5.4 Gel Workflow Improvement 
Both the Ligation and DNA Preparation teams run a sub-process called a fractionation gel (see Section 
4.1.1).  The whole process for running a fractionation gel is called the “gel workflow” in MBPG.  The 
same lean manufacturing improvement process applied to transformation and ligation was applied to this 
workflow.  The entire workflow was first mapped, helping to identify areas of improvement (see Figure 
38).  The gel workflow utilizes many different workstations which had been built up in various parts of 
the MBPG lab area on a space availability basis.  No holistic view had ever been taken of the end-to-end 
gel workflow, resulting in the scattered process shown in Figure 38 that used nine work locations, five 
rooms, six material inventory locations, and eight long walks for the MBPG employees.   
 
Using a combination of designing lean workstations (see Appendix B, Section 16.4) and physical 
rearranging the locations of some workstations, a significantly streamlined gel workflow was created in 
MBPG (see Figure 39).  This new workflow contained the process mostly to one room (except for a dark-
room that could not be moved in the building), and had the process smoothly flow in a streamlined “U” 
shape.  Almost two-thirds of the MBPG employees were involved in the hands-on implementation of the 
new gel workflow and lean workstations, and they enthusiastically embraced the improvements.   
 
The gel workflow area is the most heavily used and most externally visible part of the MBPG lab area and 
had previously been the messiest and most disorganized lab area in the entire Broad Institute.  This lean 
manufacturing implementation successfully transitioned the gel workflow into a showcase laboratory 
space for MBPG and source of pride for the entire team.  When external visitors were given a tour of the 
Broad Institute’s sequencing operations, the MBPG lab area containing the gel workflow became one of 
the focal points of the standard tour given by the director of sequencing operations. 
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Figure 38. Travel map of the gel workflow before the lean manufacturing implementation. 
 
 
Figure 39. Travel map of the gel workflow after the lean manufacturing implementation. 
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7.5.5 Material Mini-Marts 
A final example of success from the lean manufacturing implementation in MBPG is the expansion and 
improvement of the materials mini-marts.  While some mini-marts were already in use in MBPG prior to 
this project, their scope, effectiveness, and standardization were greatly expanded.  An analysis of the 
initial state of the MBPG material mini-marts identified the following problems: 
 
• Partial Coverage of MBPG Material Needs – Not all of the materials used in MBPG were 
being supplied by the Materials department to the mini-marts.  Some materials were being 
retrieved by MBPG employees from far away Materials department labs, and other materials 
were being directly ordered, received, and inventoried by the MBPG coordinators. 
• Poor Labeling – The mini-marts were not properly labeled with all the items they were supposed 
to contain, the target inventory levels of each item, and the stocking location of each item. 
• No Agreed-Upon Specifications – None of the mini-marts had documented agreed-upon 
specifications between the MBPG and Materials departments.  The items in each mini-mart had 
built up over time through email and in-person requests.  No formal process existed to add, 
remove, or change items in a mini-mart. 
 
To address these problems, the 5S and process reengineering tools were used to optimize the mini-marts 
in MBPG.  Each mini-mart was taken apart, cleaned up, re-labeled, and re-stocked according to the 
current needs in MBPG.  Several mini-marts were consolidated together, and a few new ones were 
created.  The overriding principle was to balance the MBPG team’s desire to have materials stocked close 
to their point-of-use with the Material team’s desire to stock to as few locations as possible.  Both teams 
settled on a total of six material mini-marts in the end.  See Figure 40 for examples of these mini-marts. 
 
For each of the six mini-marts, the MBPG team evaluated the optimal desired inventory level.  Since none 
of the MBPG materials are very expensive or take up much shelf space, the team decided to not utilize a 
sophisticated safety stock inventory level calculation.  Rather, the team judged their actual use over the 
last few months along with a safety stock level they felt was reasonable to determine the desired 
inventory level in each mini-mart.  These inventory levels were then specified on each material’s label in 
the mini-mart (for example, the “50” represents a desired inventory level of 50 units in the label “EDTA 
0.5M (x50)”). 
 
The final step in the improvement of the materials mini-marts was to create a detailed specification for 
each mini-mart.  This specification served as the official request from MBPG to the Materials department 
for the exact items that belonged in each mini-mart, along with the item’s size and quantity.  Figure 41 
contains an example of one mini-mart specification.  All future mini-mart change requests from MBPG to 
the Materials department will be sent in the form of an updated specification. 
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Figure 40. Example of material mini-marts used in MBPG. 
 
MBPG Mini-Mart Inventory Specification
Mini-Mart:    Glass Bottles & Graduated Cylinders
Material Size Quantity
Glass Bottle 1000 ml 12
Glass Bottle 500 ml 21
Glass Bottle 250 ml 4
Graduated Cylinder 2000 ml 2
Graduated Cylinder 1000 ml 4
Graduated Cylinder 500 ml 4
Graduated Cylinder 100 ml 4
Aluminum Foil Small (25 in2) 9
Aluminum Foil Large (18"x500') 2
Toothpick, round, sterile (500/beaker) Beaker of 500 8
Scalpels (Bard-Parker #10) Case of 100 2
Replenishment Frequency: 2-3x per Week
 
Figure 41. Example of a material mini-mart specification given by MBPG to the Materials department. 
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7.6 Strategy to Sustain Results 
The most critical and difficult part of implementing the 5S methodology of lean manufacturing is the fifth 
“S” – sustain.  After the success of MBPG’s lean manufacturing implementation in the first three months, 
the second two months were spent on maintaining and formalizing the permanent sustainability of this 
success.  This goal was achieved through the implementation of a formal “5S Sustain Strategy” in MBPG. 
 
Three types of checklists were used in this 5S Sustain Strategy to help the MBPG management and 
employees self-regulate how well its lean manufacturing success is being sustained in the future.  The 
design and role of each of these checklists is described below and in Figure 44. 
 
• 5S Master Checklist – Based on best-practice 5S checklists from Honeywell and Intel, a 5S 
Master Checklist was created for MBPG.  This monthly checklist has a total score out of 100, and 
each of the five S’s contains five check items (25 check items in total) that are scored on a scale 
of 0-4 points.  This master checklist is scored once per month by the three managers in the Broad 
Institute’s sequencing operations (including the MBPG manager), and the score for MBPG is 
tracked by the director of sequencing operations.  This checklist was scored for the first time in 
November 2004 with a score of 65 out of 100.  The monthly results of this checklist are posted in 
a prominent location in the MBPG lab area.  See Figure 43 for an example of this checklist. 
 
• Individual Workstation Checklist – To drive performance on the monthly 5S Master Checklist, 
detailed weekly checklists were created for the two types of individual workstations – one for the 
ligation team and one for the transformation team.  These checklists are used every week by the 
technicians and coordinators to keep the workstations in order, and the results from these weekly 
checklists will be used as part of each employee’s year-end HR performance review.  Figure 45 
shows an example of an individual workstation checklist. 
 
• Group Workstation Checklist – To drive performance on the monthly 5S Master Checklist, 
detailed weekly checklists were created for all fifteen group workstations.  Each employee is 
assigned responsibility for one or two workstations, and these assignments are rotated every two 
months.  These checklists are used every week by the technicians and coordinators to keep the 
workstations in order, and the results from these weekly checklists will be used as part of each 
employee’s year-end HR performance review.  Figure 43 shows an example of a group 
workstation checklist. 
 
Both the individual and group workstation checklists were created by the MBPG employees themselves, 
ensuring their input into the system for which they will be held accountable.  These checklists and the 
entire 5S Sustain Strategy were formally rolled out to the MBPG team in November 2004, and the system 
was successfully used during the remaining two month of this LFM internship and thesis work.  The 
future success of this 5S Sustain Strategy will depend on MBPG management’s commitment to 
encouraging and enforcing the use of these checklists. 
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Figure 42. Description of the MBPG 5S Sustain Strategy implemented in November 2004. 
 
 
Figure 43. Example of a Group Workstation Checklist used as part of the 5S Sustain Strategy. 
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Figure 44. 5S Master Checklist used in MBPG. The actual scored checklist from November 2004 is shown. 
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Figure 45. Example of an Individual Workstation Checklist used as part of the 5S Sustain Strategy. 
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7.7 Metrics 
The leadership team for the MBPG lean manufacturing implementation identified metrics for the project 
in the four areas of quality, productivity, material efficiency, and capital productivity.  Given MBPG’s 
operations strategy to maximize quality, the quality metrics were the most important in this 
implementation along with the quality-related benefits from improvements in the other metric areas.  This 
section discusses each metric and how it was impacted over the course of this thesis work.  Table 5 
summarizes the baseline (May 2004) and project end (November 2004) level of the most important 
metrics, and Table 6 tracks each metric over each month of the internship. 
 
7.7.1 Quality Metrics 
The primary quality metric of concern was the number of potential sample mix-up points in the MBPG 
processes.  This metric was measured through observations taken by the thesis author and was agreed 
upon by the project leadership team.  Prior to the lean manufacturing implementation, 71 potential sample 
mix-up points existed in MBPG, and this number was cut by 49% to 35 points by the end of the project.  
While data on the actual number of sample mix-ups was not available or known, this significant reduction 
in the number of sample mix-up points greatly reduced the probability of a sample mix-up occurring, and 
directly addresses the most important source of quality problems in MBPG identified in Section 6.2. 
 
Another key quality metric was the 5S Master Checklist score for MBPG.  Since this checklist was not 
implemented until November, no performance trend could be determined during the internship.  However, 
in the months after the completion of the internship, the 5S Master Checklist score showed great 
improvements with scores of 65 in January 2005, 80 in February 2005, and 78 in March 2005. 
 
The final key quality metrics were the passing rates of the two main MBPG products – DNA libraries and 
agar plates.  The library pass rate is defined as the number of passed libraries in a month divided by the 
total number of libraries produced that month.  The agar plate pass rate is defined as the number of passed 
plates in a month divided by the total number of plates produced that month.  Since both of these metrics 
were already tracking high and this project did not address any of the intrinsic process variability that 
mostly drives these metrics, neither passing rate changed much during the lean implementation. 
 
Table 5.  Summary of key MBPG lean manufacturing metrics at the beginning and end of the implementation. 
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7.7.2 Productivity Metrics 
Productivity metrics in terms of products per person per month were tracked for both the ligation and 
transformation teams.  Total team output was also tracked for each team along with the cycle time and 
individual capacity for the ligation team.   
 
The productivity metrics for the ligation team improved significantly, increasing by 73% by the end of the 
project.  This improvement directly shows the impact of the ligation workstation and workflow 
improvements described in Section 7.5, which resulted in much lower ligation process cycle times as 
measured before and after the lean implementation by the thesis author.  These data provide great 
evidence of the significant opportunity for implementing lean manufacturing in high throughput 
biotechnology laboratories such as MBPG. 
 
On the other hand, the productivity for the transformation team decreased during this project.  Special 
causes other than the lean manufacturing implementation explain this decrease.  The transformation team 
has the ability to self accelerate and decelerate their process based on the downstream demand they 
receive for agar plates.  In other words, the transformation team closely matches its output and rate of 
production to that of the Core Sequencing team (conversely, the ligation team can not do this self-
regulation of production rate due to the precise reaction times required in the ligation process).  At the 
beginning of this project, this downstream demand was very high and the transformation team had 
accelerated their process.  Towards the end of this project, the demand from Core Sequencing was not as 
high, so the transformation team slowed its production (while still using the same number of people), 
resulting in the decreased productivity metrics. 
 
7.7.3 Material Efficiency Metrics 
Material efficiency metrics were utilized to measure how much waste was being removed in the flow of 
materials into and through MBPG.  Prior to the improvements in the material mini-marts and reagent kits, 
MBPG had a great deal of inventory sitting around the lab.  These high levels of inventory were not only 
costly but potential detriments to quality.  Many of the reagents begin to go bad after a few weeks or 
months, so MBPG was potentially using bad or expired reagents in its processes.  Also, process protocols 
in MBPG change quite frequently, and ensuring proper compliance with any material changes was very 
difficult with so much excess inventory in the lab. 
 
Overall monthly material consumption in MBPG dropped by 20% during the lean implementation, saving 
the Broad Institute $10,000 to $30,000 each month.  This actual material consumption was compared each 
month to the required material consumption to measure the efficiency in which MBPG was using the 
items it received.  This required materials consumption was calculated by multiplying the actual ligation 
and transformation output in a month by the bill of materials (BOM) costs for these products.  As the data 
shows, MBPG become significantly less wasteful in using its materials, improving this ratio by 28%.  
More importantly, quality is also improved from improvements in material efficiency through the use of 
more “fresh” reagents (i.e. less likely to be expired) and a reduction in the likelihood of using the wrong 
reagent in a MBPG process. 
 
Additional material efficiency measurements include the number of inventory locations and material 
replenishment locations in MBPG.  Reductions in these numbers illustrate the streamlining and 
rationalization of MBPG’s workflows from the lean implementation.  Finally, the number of labels in the 
MBPG lab area was hand counted each month to demonstrate how much more visual and organized the 
lab had become from 5S in particular.  A large number of labels also represents a quality improvement 
from reducing the likelihood of an employee using the wrong reagent or sample in a MBPG process due 
to inadequate or non-existent labeling on the reagent or sample. 
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7.7.4 Capital Productivity Metrics 
A well-known benefit of 5S is the freeing up of poorly used floor space for other useful purposes.  MBPG 
tracked this benefit by measuring the cumulative amount of recovered floor space.  Over 141 square feet 
was freed up from the 5S implementation, representing over 5% of the total MBPG lab space and over 
$6000 in annual capital costs. The overall demand and throughput in MBPG was not significantly 
different during the course of the lean manufacturing implementation, so the implementation team was 
assured that this reduction in floor space was a result of the 5S work and not a drop-off in demand. With 
this free space, MBPG was able to install a piece of automation equipment (that would not have fit in the 
MBPG lab area before the lean manufacturing implementation) to be used for future workflow 
improvements. 
 
7.7.5 Employee Safety 
While none of the metrics tracked for the MBPG lean manufacturing implementation focused on 
employee safety, it is still useful to comment on the impact in this important area.  These comments are 
based on colloquial data gathered by the thesis author.  Employee safety was greatly improved due to the 
reduction in inventory of hazardous chemicals, discarding of old chemicals and samples that were no 
longer in use, and better signage and labeling of safety showers, eye washes, and biological waste 
collection areas.  The onsite safety coordinator at the Broad Institute was brought into the lean 
manufacturing implementation several times to provide advice on the safety impact of various 5S related 
ideas.  Finally, the increase in the number of labels in the MBPG lab area discussed in Section 7.7.3 was 
beneficial from a safety perspective in increasing the ease with which fire fighters, emergency medical 
technicians, and safety workers could operate in the MBPG area in the event of a major safety incident 
MIT Thesis – Matthew R. Vokoun  Page 74 of 132 
 
 
 
 
 
 
 
 
 
MIT Thesis – Matthew R. Vokoun  Page 75 of 132 
8 Production Forecasting Implementation  
 
This chapter describes a three-month long production forecasting implementation in MBPG.  The need 
for forecasting in MBPG is first discussed.  Then, the application of forecasting tools to improvements in 
inventory management, materials requirement planning (MRP), labor utilization, and supply chain 
visibility is described.  The objective of this chapter is to explain to the reader why a new forecasting tool 
is now being successfully used in MBPG. 
 
8.1 Need for Forecasting in MBPG 
As mentioned in Section 6.2, the fifth most concerning source of potential quality problems in MBPG 
was priority and schedule changes.  Frequent changes in the MBPG production schedule led employees to 
waste effort and materials on unneeded work, release work downstream in the incorrect order, and 
experience unnecessary process disruptions and instability.  These frequent changes also made it difficult 
for the Materials department to effectively supply materials in the timeframe and quantities needed.   
 
As mentioned in Section 5.4, the forecasting and scheduling systems in MBPG prior to this thesis work 
were very minimal. For the most part, the managers in MBPG manually forecasted and scheduled the 
work that needed to be completed for the next one to two weeks.  Very little visibility into future MBPG 
demand and production schedules were known within the department or communicated to the supporting 
Materials department.  Given that the transformation team had fairly adequate forecasts from their 
connection with the downstream core sequencing production schedule, these priority and schedule 
changes had little impact on the transformation process. 
 
However, the manually planned ligation and DNA preparation process felt significant impact from these 
priority and scheduling changes.  The MBPG manager and coordinators were repeatedly challenged with 
determining which DNA libraries and preparation work to perform in a given week.  As the Broad 
Institute moved away from sequencing just human DNA during the HGP towards running multiple 
genome sequencing projects at the same time, this scheduling challenge grew significantly.  Each of these 
sequencing projects competed for top priority each week, and MBPG had to react quickly to changes in 
priority determined by upper management.  Additionally, in any given week different material 
availability, equipment capacity, and personnel capacity constraints existed in MBPG and were difficult 
to consider in the production forecasts.  Finally, stringent quality  control policies, such as the requirement 
that one employee work on only one DNA sample at a time (i.e. no parallel processing in one 
workstation), further complicated the production forecasting process. 
 
Outside MBPG, the Materials department also felt significant pain from these priority and schedule 
changes.  Materials places orders with suppliers, receives and inspects the material shipped from 
suppliers, performs value-added processing, and then delivers material to inventory mini-marts in MBPG.  
To properly manage this inventory, Materials needs an accurate forecast from MBPG of its expected 
future material needs.  However, no updated forecasts were ever given to Materials from MBPG for the 
ligation and DNA preparation processes.  Instead, Materials used a “standard” forecast for these processes 
that is consistently inaccurate.   
 
The inaccurate forecasts have caused several large problems in the past for the Materials Department.  A 
few days of stopped production in MBPG have occurred in the past due to material unavailability.  A 
larger problem has arisen from the Materials department placing orders too soon or in too high of 
quantities in anticipation of MBPG demand that never materialized.  These problems have resulted in 
losses of several tens of thousands of dollars of expired reagents and/or in the use of “aged” reagents in 
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MBPG which could have a significant impact in quality.  While these problems have not been well 
documented in terms of monetary losses, they have proven to be a divisive issue between MBPG and the 
Materials department, leading to poorer work relationships between these two departments. 
 
As this section has clearly shown, the lack of a standardized forecasting process has lead to significant 
challenges for both MBPG and the Materials department.  This thesis work brought most of these 
problems to light and identified an opportunity to address them with a simple production forecasting 
process and tool.  The remaining sections in this chapter describe the implementation of this solution. 
 
8.2 Implementation Goals 
The same core leadership team for the MBPG lean manufacturing implementation was also responsible 
for setting the goals and scope for the production forecasting implementation.  This team kicked off a 
three-month long project for this implementation in October 2004.  The thesis author was solely 
responsible for the core hands-on work in the implementation. 
 
The scope of the production forecasting implementation was defined as creating a tool for MBPG that 
allows it to easily create a manual realistic forecast of its future ligation and DNA preparation production 
schedules taking into account the following – (1) prioritized sequencing project demands; (2) important 
material, equipment, and personnel constraints; and (3) quality assurance policies.  The primary users for 
this new production forecasting tool would be the MBPG manager and ligation team coordinator.  The 
output of this tool would provide benefits to the following constituents: 
 
• MBPG Management Team – Saved time and increased accuracy in its production forecasting 
process. 
• MBPG Employees – More accurate and realistic work assignment schedules. 
• Materials Department Manager – More accurate MBPG forecast, allowing Materials to 
improve its materials requirement planning and inventory management processes. 
• Sequencing Operations Director – Improved visibility into MBPG’s future production plans. 
  
To accomplish the implementation of this project scope, the MBPG leadership team identified three 
specific goals and deliverables for the production forecasting implementation: 
 
Goal # 1 -  Create a data map of product definitions to bills of materials (BOMs) to process 
protocols.  This data map will create consistent definitions across the entire MBPG and 
Materials teams about what exactly each MBPG product means, how its BOM is 
represented in the ERP system, and how its process is defined in the scientific protocols.  
 
Goal # 2 -  Create a simple production forecasting tool in a Microsoft Excel spreadsheet for use by 
the MBPG manager and ligation team coordinator. 
 
Goal # 3 -  Define and implement a weekly process for creating a production forecast in MBPG and 
communicating this forecast to the Materials department. 
 
8.3 New Product Data Map 
Before an effective production forecasting process or tool could be developed, the MBPG and Materials 
teams needed to standardize its information about the products and processes in MBPG.  Much confusion 
existed about what all the “standard products” actually were in the ligation and DNA preparation 
workflows.  Additionally, further confusion existed over the exact names, definitions, batch sizes, and 
MIT Thesis – Matthew R. Vokoun  Page 77 of 132 
units for each standard product.  Therefore, MBPG spent the first week of this implementation agreeing 
upon exactly how each of its products would be defined.  These product definitions focused on (1) 
creating a whole list of products, (2) naming each product, and (3) clarifying the units for each product.    
Table 7 below shows the final list of product definitions.  Using the metaphor of a restaurant, these 
product definitions represent the meals on a menu. 
 
Now that MBPG had settled on its exact definitions of the products it would forecast for the ligation and 
DNA preparation workflows, the next step was to sync this information up with the two other main 
sources of product information at the Broad Institute.  In addition to the product definitions in MBPG, a 
wealth of product and process information resided in the Bills of Materials (BOMs) in the Broad 
Institute’s ERP system (referred to as “OPM” which stands for “Oracle Process Manufacturing”) and also 
in the process protocols created by the Molecular Biology Development group, the R&D arm of MBPG.   
 
A BOM is a list of components, ingredients, or materials needed to manufacture a product.  It includes the 
hierarchy of materials making up a product or sub-product including the proper ratios of quantities of 
each item.  Referring again to the restaurant metaphor, a BOM represent the list of ingredients in a meal.  
Standard ERP systems such as OPM provide rich functionality for creating and updating BOMs, and the 
Materials department had ownership over access and control of OPM including the BOMs.  However, 
since the exact processes and products in ligation and DNA preparation were much lower in volume and 
much less understand than other parts of the DNA sequencing process, Materials had not defined many 
BOMs yet for MBPG.  A lack of priority or focus in MBPG to provide Materials with the required 
information also contributed to this incomplete state of MBPG BOMs. 
 
Table 7.  Definitions of terminology and units for each Ligation and DNA Preparation product made in MBPG. 
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Figure 46. The MBPG product data map, created to link product forecasts to BOMs to process protocols. 
 
Process protocols are in-depth scientific documents created by the Molecular Biology Development 
(MBD) group to specify exactly how each step in a MBPG workflow is to be performed.  These protocols 
are created by the highest ranking molecular biologist at the Broad Institute, the MBD manager, and their 
purpose is to train each employee in MBPG how to perform their work.  MBPG employees also refer to 
physical copies of these protocols while performing their work.  Referring one last time to the restaurant 
metaphor, the process protocol represents the recipe a chef uses to make a meal.  The MBD group has 
ownership over the publication and modification of all process protocols in MBPG.   
 
Unfortunately, as described above, these three sources of information – product forecasts, BOMs, and 
protocols – were all owned by different organizations at the Broad Institute.  Consequently, they were 
never in sync with one another, leading to confusion in both MBPG and Materials as to what exactly was 
needed on a given day to complete the work at hand.  This confusion could lead to both quality and 
productivity problems in MBPG, and syncing up these three sources of information was critical to the 
successful implementation of a production forecasting process. 
 
To tie together the product forecasts, BOMs, and protocols, a cross-functional team was created from the 
MBPG, Materials, and MBD departments.  This team was given the responsibility to create a new Product 
Data Map for MBPG.  On this map, links were created between the products being forecasted and the 
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BOMs and protocols that corresponded to them.  Missing BOMs and protocols were then identified, and 
team members were assigned to create them.  Finally, outdated BOMs and protocols were also identified 
and addressed so that the actual content in each mapped link was the same.  The latest version of the 
Product Data Map for MBPG is show in Figure 46, and this tool proved to be very effective for driving an 
ongoing data maintenance process across the MBPG, Materials, and MBD departments. 
 
8.4 New Forecasting Tool 
With solutions in place for the data requirements of an improved production forecasting process in 
MBPG, the next step in the implementation was to build a forecasting tool.  The thesis author led this 
effort and created a simple production forecasting tool in a Microsoft Excel spreadsheet.  The primary 
users for this forecasting tool were the MBPG manager and ligation team coordinator. 
 
The new MBPG production forecasting tool, pictured in Figure 47, contains the following features: 
 
• Weekly forecasting buckets for each product 
• Rolling two-month (eight-week) forecast for all products 
• Quarterly and annual forecast totals for each product 
• Labor capacity utilization calculations for each week for the ligation and DNA preparation teams 
 
 
 
Figure 47. Screen-shot of the MBPG production forecasting tool built in a Microsoft Excel spreadsheet. 
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Table 8.  Definitions of cycle time for each Ligation and DNA Preparation product made in MBPG. 
 
 
The labor capacity utilizations are calculated by comparing the available labor hours in the ligation and 
DNA preparation departments with the scheduled labor hours.  These scheduled labor hours were 
computed by multiplying the weekly forecast of each product by its estimated cycle time.  These cycle 
times, shown above in Table 8, were determined by the thesis author through interviews and process time 
measurements with the MBPG employees.  The labor capacity utilization calculations are beneficial to the 
users of the production forecasting tool as it allows them to quickly determine if their weekly forecasts 
are realistic given their current labor pool. 
 
8.5 New Forecasting Process 
The last step in the production forecasting implementation in MBPG was to define a weekly process for 
the use of the forecasting tool and the communication of its contents within the Broad Institute.  After a 
few meetings between MBPG and Materials, the following process was agreed upon: 
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(1) MBPG manager and ligation team coordinator meet each week on Friday afternoon to update the 
production forecast for the following two months. 
 
(2) MBPG manager emails a copy of the updated production forecasting tool to the Materials 
department manager and the director of sequencing operations. 
 
(3) Materials department manager receives updated MBPG forecast and uses it in his weekly MRP 
and inventory management processes. 
 
(4) Director of sequencing operations receives updated MBPG forecast and uses it in his weekly 
production plan for the entire DNA sequencing operation. 
 
This new forecasting process was successfully deployed in November 2004, and both the MBPG and 
Materials department managers expressed high satisfaction with the process and tool.  This 
implementation of information clarity and organization, simple and defined processes, and basic 
forecasting techniques had a profound impact on the ability of the Broad Institute to plan its production, 
materials requirements, and inventory levels for MBPG. 
 
While no metrics were formally developed during this thesis work for the new production forecasting 
process in MBPG, the Broad Institute should look into implementing forecasting related metrics in the 
near future.  The following metrics are recommended: 
 
• Forecast Accuracy – The actual production in a given week should be compared to the 
forecasted production in MBPG.  This ratio represents the accuracy of MBPG’s forecasts and can 
be used by the leadership team in MBPG to improve future forecasts.  This forecast accuracy can 
also be used by the Materials department to represent the expected variance in the average MBPG 
production levels from which Materials will perform its MRP and inventory level calculations. 
 
• Inventory Levels of MBPG Items held by Materials – The implementation of production 
forecasting should allow Materials to better plan for the materials needs of MBPG.  These better 
plans should result in lower safety stock inventory levels for MBPG items held by Materials. 
 
• Days of MBPG Production on Hand – With the improved BOMs and production forecasts, the 
Materials department will have a much better understanding of how many days of MBPG 
production they can support with the items they have in stock at the Broad Institute.  This 
information should be presented out to the organization with a metric that represents “Days of 
MBPG Production on Hand.” 
 
• Expired Reagents – One problem that occurred before the implementation or production 
forecasting in MBPG was the periodic expiration of large batches of reagents that Materials had 
procured for MBPG but were then never used by MBPG.  The dollar amount of these expired 
reagents should be tracked going forward on a monthly basis, and it is expected that this amount 
will go down in the future as production forecasting is used in MBPG. 
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9 Opportunities for Six Sigma  
 
This chapter provides a brief overview of Six Sigma and then identifies future implementation 
opportunities for Six Sigma in the Molecular Biology Production Group at the Broad Institute.  These Six 
Sigma opportunities are all focused on further improvements in quality and are directly in line with the 
MBPG operations strategy defined in Section 6.1.  This work was originally in the scope of this LFM 
internship. However, the Six Sigma work was never fully started as it was not as high of a priority as the 
lean manufacturing and production forecasting implementations discussed in Sections 7 and 8 of this 
thesis.  The objective of this chapter is to demonstrate how the Six Sigma approach is needed to 
understand and reduce the intrinsic process variability in the molecular biology processes used at a 
genome sequencing center. 
 
9.1 Six Sigma Overview 
Six Sigma is a quality management system focused on accomplishing "six sigma" levels of quality in 
organizational processes. It was originally developed at Motorola in the 1980's and has become one of the 
most widely discussed and reported trends in business over the past several years.  Six Sigma owes its 
phenomenal success predominately to its widespread use at one of the world's most successful companies, 
GE. The company credits the program with millions of dollars in annual cost savings and product quality 
improvements.  From its historical base is manufacturing, Six Sigma has successfully spread to call 
centers, sales and marketing, supply chain management, product development, and project management.44 
 
Six Sigma aims to have the total number of failures in quality occur beyond the sixth sigma (standard 
deviation) of likelihood in a normal distribution.  Designing processes with tolerances of at least six 
standard deviations will yield fewer than 3.4 defects in one million.  Many organizations had previously 
believed that six-sigma quality was impossible and settled for three to four sigmas. However, industry 
leaders have reached six sigma levels of measurement in many, many processes.43 
 
The Six Sigma methodology improves any existing business process by constantly reviewing and re-
tuning the process.  To achieve this, Six Sigma uses a methodology known as DMAIC:43 
• Define out of tolerance range.  
• Measure key internal processes critical to quality.  
• Analyze why defects occur.  
• Improve the process to stay within tolerance.  
• Control the process to stay within goals. 
 
Experts in Six Sigma, called Green Belts and Black Belts, evaluate a business process and determine 
ways to improve upon the existing process. Six Sigma experts can also design a brand new business 
process using DFSS (Design For Six Sigma) principles.  Six Sigma incorporates the basic principles and 
techniques from the three core elements of business, statistics, and engineering.  Six Sigma improves the 
process performance, decreases variation, and maintains consistent quality of the process output. These 
improvements lead to defect reduction and increases in profits, product quality and customer 
satisfaction.44   
 
                                                 
43
 Source: Wikipedia Dictionary.  “Six Sigma” dictionary entry. 
44
 Source: Pande et al. The Six Sigma Way: How GE, Motorola, and Other Top Companies are Honing Their 
Performance. 
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9.2 Future Opportunities in MBPG 
The primary opportunity for the application of Six Sigma in MBPG is in understanding and reducing 
variability in the ligation process.  This process is discussed in detail in Sections 2.3 and 4.1 of this thesis, 
and it is also illustrated in Appendix A.  The ligation process introduces the most variability into genome 
sequencing operations and is also the least understood process at the Broad Insitute.  Now that lean 
manufacturing has been successfully used in MBPG to remove the sources of variability managed into the 
process, Six Sigma can be used to understand and reduce the intrinsic variability in the process.  Figure 47 
below shows which set of potential quality problems could be addressed by Six Sigma. 
 
 
Figure 48. Potential quality problems in MBPG. Six Sigma can address the five problems on the right. 
 
9.2.1 Update of Historical Production Data Analysis  
Section 5.1 briefly described a historical production data analysis performed for MBPG in June 2004. 
This analysis focused on creating 2004 4kb production control charts for white counts and glycerol yield.  
The results of this analysis showed that the MBPG ligation and transformation processes are not well 
controlled or understood.  While most of the consequences and ramifications of this work are not 
discussed in this thesis, this analysis will provide a good starting point for future Six Sigma work in 
MBPG.  Another intern from the LFM Class of 2006 will be working in MBPG in 2005-2006 and will 
focus on expanding this initial historical production data analysis. 
 
9.2.2 Continuation of DOEs on Competent Cell Volume Reduction 
A series of designed experiments (DOEs) were performed in the spring and summer of 2004 to reduce the 
volume of competent cells used in the transformation process, a change that could potentially result in 
over $100,000 savings in annual purchased material costs.  The details of these DOEs are outside the 
MIT Thesis – Matthew R. Vokoun  Page 84 of 132 
scope of this thesis.  This opportunity was identified from experimental results that showed competent 
cell volume as an insignificant variable with respect to the white count measurement.  Unfortunately, a 
production verification experiment at the lower volume showed that the white counts were lowered by a 
statistically significant amount.  However, other transformation process variables could be used to bring 
the white count values back up higher while still using the lower competent cell volume.  Thus, it is too 
soon to eliminate the possibility of lowering the cell volume and extracting the $100,000 savings.  
Detailed reports and statistical analysis of these experiments were passed on to the follow-on LFM intern 
in MBPG who will complete the remaining experimentation on this opportunity in 2005. 
 
9.2.3 Gage R&R Study on Pico Green QC Test 
As described in Section 4.1.1, the Pico Green test is the most common QC tool used in MBPG to quantify 
the exact amount of DNA in a sample.  This test is critical to almost every process performed in MBPG, 
and its results are used to calibrate reaction volumes at several steps in each process.  However, a gage 
R&R study has never been performed on the Pico Green test to understand its reproducibility and 
repeatability.  The results of this study will be needed before any future DOEs and Statistical Process 
Control (SPC) can be conducted for any part of the process where the DNA quantity is a critical variable. 
 
9.2.4 DOE on Hydroshearing Process 
As described in Section 4.1.1, the hydroshearing process is run by the DNA preparation team to create the 
sheared DNA raw material for the ligation process.  The hydroshear equipment has been known to 
produce highly variable sheared DNA in terms of the distribution of molecule lengths, especially for 
different types of organisms.  While some work has been performed in the past to define the optimal 
hydroshear settings for each organism, no true DOE approach has been taken to understand and minimize 
the hydroshear’s variability.  Such work would be critical to reducing the variability in the ligation 
process as it would better standardize one of the key inputs to ligation. 
 
9.2.5 DOE on Each Step in Ligation Process 
DOEs should be conducted to determine the critical process parameters for each of the reaction steps in 
the week-long ligation process.  Each of the following steps in the ligation process need to be analyzed 
for their critical input and process variables. 
• EtOH Precipitation & Resuspension 
• End Repair 
• Reaction Clean-Up 
• BstXI Linker Ligation 
• Size Fractionation 
• Fragment Purification 
• Fragment-Vector Ligation 
 
9.2.6 DNA Yield Analysis on the Ligation Process 
Several years of historical production data on the ligation process exists in laboratory notebooks and 
spreadsheets in MBPG.  This data should be analyzed to determine the actual DNA yield in each step of 
the ligation process.  The DNA quantity should have been measured and known at the beginning and end 
of each process step.  Actual data from past libraries can be analyzed to determine the following: 
• Average and standard deviation for DNA Yield (Ending DNA / Beginning DNA) on each step. 
• Which step has the largest average DNA loss (i.e. lowest yield)?  What is the root cause of this? 
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• Which step has the most highly variable DNA loss (i.e. largest standard deviation)?  What is the 
root cause of this? 
 
9.2.7 Stoichiometric Model of Ligation Process 
Once all of the above Six Sigma work is completed, the MBPG team should be in a position to build a 
theoretical stoichiometric model of the ligation process from beginning to end.  This model would take 
into account the kinetics and mass balance of each reaction in the ligation process and predict an expected 
DNA yield at the end of the process.  This model can then point out what parts of the protocol must be 
adjusted to either increase or decrease the ratio of excess reagents to DNA to potentially increase the 
DNA yield throughout the process (i.e. drive each reaction step more towards completion maximizing the 
DNA output).   
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10 Opportunities for RFID  
 
This chapter provides a brief overview of radio frequency identification (RFID) technology.  Future 
implementation opportunities for RFID at the Broad Institute are then described.  These RFID 
opportunities are important as they focus on further improvements in quality and are directly in line with 
the operations strategy for MBPG described in Section 6.1. This work was originally scoped out during 
this LFM internship and thesis work, but an RFID implementation was never fully started due to resource 
constraints.  The objective of this chapter is to demonstrate how this new technology can be utilized to 
further improve operations at the Broad Institute. 
 
10.1 RFID Overview 
Radio frequency identification (RFID) is an information technology that holds the promise of widespread 
and major impact on supply chains, business processes, and inventory management.  This technology is 
based on a method of remotely storing and retrieving data using devices called RFID tags. An RFID tag is 
a small object, such as a plastic chip or adhesive sticker, which can be attached to a product. Antennas on 
the RFID tags enable them to receive and respond to radio-frequency queries from an RFID transceiver.45 
 
RFID tags come in either the active or passive type.  Passive RFID tags have no internal power supply; 
instead, the tiny electrical current induced in the antenna by the radio-frequency signal provides the power 
for the tag. Lack of its own power supply results in passive RFID tags being quite small.  Currently, the 
smallest such devices commercially available measure 0.4mm by 0.4mm and are thinner than a sheet of 
paper. The read ranges of passive RFID tags vary from about 10mm up to about 5m.45 
 
Active RFID tags, on the other hand, contain their own internal power source, have longer ranges and 
larger memories than passive tags, and possess the ability to store additional information sent by the 
transceiver.  Currently, the smallest active tags are about the size of a penny. Active RFID tags have read 
ranges of tens of meters and a battery life of several years. 45 
 
Since passive tags are much cheaper to manufacture and do not depend on a battery, the vast majority of 
RFID tags used today are passive. Currently, the average cost of a tag is approximately $0.40. The goal 
for the future is to produce tags for less than $0.05 to make widespread RFID deployment commercially 
viable. Analysts from Gartner and Forrester Research agree price levels under $0.10 are not achievable 
until 6-8 years from now, creating a potential hurdle to widespread adoption of passive RFID. 45 
 
A complete RFID system consists of several components – tags, tag readers, tag programming stations, 
circulation readers, sorting equipment, and tag inventory wands. In this system, individual objects are 
equipped with a small, inexpensive tag. The tag contains a digital memory chip that holds a unique 
electronic product code. The RFID transceiver or reader emits a signal activating the RFID tag so it can 
read and write data to it. When an RFID tag passes through the signal zone, it detects the reader's 
activation signal. The reader decodes the data encoded in the tag, and the data is passed to a computer for 
processing. The data transmitted by the tag may provide identification or location information, or 
specifics about the product tagged, such as price, color, or date of purchase. 45 
 
RFID tags are often envisioned as a replacement for UPC bar-codes, having several advantages over this 
older technology. However, it is unlikely that RFID tags will fully replace barcodes and will instead be 
used as a complementary technology for two main reasons – (1) cost of tags and (2) necessity to 
                                                 
45
 Source: Wikipedia Dictionary.  “RFID” dictionary entry 
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individually recognize an individual item. The cost of a tag is still relatively high, but in time this will 
reduce due to manufacturing economies of scale. However, it is unlikely that lower value items will ever 
justify any cost associated to RFID tagging it. Also the unique nature of each RFID tag may be 
considered to be overkill in being able to track the final consumer of every bottle of soda.46 
 
Despite these issues with replacing barcodes, RFID technology has found widespread use in other 
application area.  Low-frequency RFID tags are commonly used for animal identification and automobile 
key-and-lock systems. High-frequency RFID tags are used in pallet tracking, building access control, 
airline baggage tracking, and identification badges.  Microwave RFID tags are used in long range access 
control for vehicles, such as General Motors' OnStar system.  Several toll booths, such as California's 
FasTrak and Massachusetts’s FastLane systems, use RFID tags for electronic toll collection.46 
 
An organization called EPCglobal is working on an international standard for the use of RFID and the 
Electronic Product Code (EPC) in the identification of any item in the supply chain for companies in any 
industry, anywhere in the world. The organization's board of governors includes representatives from 
Procter & Gamble, Wal-Mart, Hewlett-Packard, Johnson & Johnson, and Auto-ID Labs.46 
 
Finally, the Food and Drug Administration (FDA) recently began reviewing whether hospitals can use 
RFID systems to identify patients and/or permit relevant hospital staff to access medical records.  The 
FDA is also looking to use RFID tags in pharmaceutical supply chains to fight drug counterfeiting.  
Finally, the FDA recently approved the country's first RFID chips that can be implanted in humans, which 
will be used to save lives and limit injuries from errors in medical treatments.46 
 
10.2 Workflow Management Opportunities for RFID 
The primary opportunity for the application of RFID technology at the Broad Institute is in workflow 
management and tracking for the ligation and DNA preparation processes in MBPG.  These processes are 
discussed in detail in Sections 4.1 and 4.2 of this thesis, and Appendix A illustrates these processes. Both 
the ligation and DNA preparation teams have a highly hands-on, high-laboratory-skill work model, and 
the products they handle and produce are very small in nature (i.e. small 1.5ml tubes filled with DNA).  
Due to these work style challenges, no effective IT system has ever been deployed at the Broad Institute 
for tracking and controlling the workflow in these processes.  The current practice is for MBPG 
employees to manually enter process data into the OPM (Oracle Process Manufacturing) and LIMS 
(Library Information Management Systems) applications after the workflow is completed.  Figure 49 
below maps out how these IT systems relate to the physical genome sequencing process. 
 
The traditional solution of barcode labels and scanners used in other parts of the Broad’s sequencing 
process would not work in these two MBPG groups as the scanning action and labels would interfere with 
the molecular biology techniques being performed by the technicians.  In addition, any such scanning 
based system would suffer from low compliance as it relies on manual data entry as compared to 
automated in-line scanning.  Thus, the amount of workflow data currently extracted from the ligation and 
DNA preparation processes is fairly minimal and not of high quality, which is a major concern given that 
the Broad Institute’s final product is purely informational in nature (i.e. a genome database). 
 
Every manufacturing process seeks the goal of tightly coupling its physical work processes to its 
information processes.  The need for this tight coupling is only growing in importance today with the 
advent of lean manufacturing, global supply bases, internet-based supply chain systems, and build-to-
order business models.  The Broad Institute’s genome sequencing operation sits at the far extreme of this  
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 Figure 49. Information to physical process coupling used at the Broad Institute.   
  The area of opportunity for RFID in MBPG is highlighted. 
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need to tightly couple physical processes to information processes.  It literally throws away its entire 
physical product at the end of the process and ONLY retains the information as its final product.  Thus, 
the information from all steps of the sequencing process at the Broad is of highest importance.  In 
evaluating the information-to-physical coupling techniques used throughout the sequencing process, the 
only gaping hole is in MBPG’s ligation and DNA preparation workflows (see Figure 49).  As explained 
above, the traditional barcode label and scanner solution will not work for these workflows.  RFID, with 
its non-invasive and remote data gathering capabilities, is the only technology that can effectively fill this 
information-to-physical process gap for the Broad Institute. 
 
Any RFID-based workflow tracking solution for MBPG’s ligation and DNA preparation workflows 
should have the following features: 
 
• Hardware Requirements 
o RFID reader integrated into standard lab bench workstations 
o Flat and touch screen computer monitors integrated into standard lab bench workstation 
o Wireless keyboard and mouse integrated into standard lab bench workstation 
o Passive RFID tags integrated into standard tubes and plates used in MBPG workflows.  
These tags must be able to withstand temperatures as low as -20°C. 
 
• Software Requirements 
o Workflow tracking system showing process steps and required fields of data entry for all 
ligation and DNA preparation workflows 
o Ability to track “in-process DNA” in all tubes and plates it passes through in a workflow 
o Ability to scan workstation for all reagents and “assign” those reagents as being 
consumed against the DNA libraries or samples currently being worked on 
o Ability to track the important process variables throughout a workflow – for example, the 
Pico Green test results showing the amount of DNA at specific points in the workflow 
o Ability to scan workstation and alert employee if another DNA sample enters the 
workstation other than the one the employee is supposed to be working on 
o Ability to track cycle times on each ligation and DNA preparation workflow 
o Full integration to OPM, the ERP system at the Broad 
o Full integration to SQUID, the LIMS system at the Broad 
 
10.3 Inventory Management Opportunities for RFID 
A secondary opportunity for the application of RFID technology at the Broad Institute is in inventory 
management for both MBPG and the Materials group.  The Broad Institute operates a very large and 
complex supply chain encompassing over 1000 different items from over 50 different vendors.  Most of 
the materials that flow through the genome sequencing process are very small in nature and very high in 
dollar value.  In addition, many of these materials are extremely temperature sensitive and must be stored 
in large freezers held at either -80°C, -20°C, or +4°C.  Thus, RFID holds the potential for significant cost 
savings and material quality improvement for the Broad Institute. 
 
The Materials organization manages all aspects of the supply chain of raw materials into the various 
departments at the Broad Institute.  This group must perform periodic manual audits of its on-hand 
inventory, and this task is very difficult to accomplish because (1) materials are small, hard-to-handle, and 
easy-to-misplace, and (2) materials must be removed from freezers for counting, putting their quality in 
jeopardy.  In some instances, the Materials group may have several freezers containing over $5M in 
inventory that it must hand-count.  Thus, the Materials group would benefit from an RFID solution that 
could integrate into its current inventory-holding freezers.  Each item placed in the freezer would have an 
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RFID tag placed onto it, and the freezer would be set up with an RFID reader inside of it.  Then, the RFID 
reader could perform real-time inventory audits for the Materials group, eliminating the need to hand-
count and the risk of exposing materials to higher temperatures during the audit.  This RFID solution 
could also be replicated in other departments that hold their own local inventory of similar high-value, 
temperature-sensitive materials. 
 
Within MBPG, the application of RFID to its DNA sample tracking presents a huge improvement 
opportunity.  MBPG handles hundreds of DNA samples each year, with each sample having the potential 
to support several months of sequencing work and several millions of dollars in grants.  MBPG is 
currently working with the bioinformatics team at the Broad Institute to implement a significantly 
improved DNA sample tracking system.  This system will provide improved workflows for requesting 
DNA samples from external collaborators, physically receiving these DNA samples at the Broad, and 
then storing these samples in pre-assigned locations in an organized set of freezers.  The traceability in 
this system currently relies on bar-coded labels on the DNA samples that must be manually scanned each 
time the samples are moved.  Thus, MBPG would benefit from an RFID solution to replace the bar-codes 
used in this system.  RFID tags would be used in place of the bar-codes to significantly improve the ease-
of-use of the system and expand the amount of building space in which the DNA samples could be 
tracked (other than in their storage freezers).  In addition, RFID tags could be used to track the 
temperature and humidity profiles experienced by the DNA samples as they are sent from external 
collaborators back to the Broad Institute. 
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11 Organizational Change and Leadership Analysis 
 
This chapter uses the results from the lean manufacturing and production forecasting implementations to 
perform an organizational change and leadership analysis for MBPG and the Broad Institute.  This thesis 
work is first examined from the three perspectives of organizational processes (also referred to as 
organizational behavior) for analyzing organizational change – strategic design, political, and cultural.  
An assessment is then made of the leadership style used by the thesis author while leading this work in 
MBPG, focusing on the leadership “change signature” framework.  Finally, the chapter concludes with an 
evaluation of the change process in MBPG, as well as several recommendations for continued success at 
the Broad Institute. 
 
11.1 Using the Three Perspectives on Organizational Processes 
The ultimate success of the organizational change brought about in MBPG from the lean manufacturing 
and production forecasting implementations can be evaluated using the three perspectives or lenses 
framework from the MIT Sloan Organizational Processes (OP) class.  These three perspectives – strategic 
design, political, and cultural – provide a well-rounded view of the Broad Institute, MBPG, and the 
organizational change from this thesis work.  In performing the following analysis, the author was able to 
not only pull from the current LFM thesis work, but also from three other LFM theses based on work at 
the Broad Institute (Scott Rosenberg in 2003, Julia Chang in 2004, and Kazunori Maruyama in 2005) and 
from two MIT Sloan OP Class Projects completed over the last two years in MBPG.  One of these OP 
Class Projects, completed during the fall of 2004, specifically focused on the organizational impact in 
MBPG of the lean manufacturing implementation described in Chapter 7. 
 
11.1.1 Strategic Design 
The strategic design perspective assumes that organizations are a kind of machine that has been designed 
to achieve goals by carrying out tasks.  This perspective is highly rational and analytical and believes 
organizations are designed with a strategy or purpose based on a rational analysis of capabilities and 
opportunities.  Within this strategic viewpoint, alignment mechanisms are structured to motivate 
employees towards the organization’s common goals. 
 
The strategic advantage of the Broad Institute’s sequencing operation has been its ability to rapidly scale-
up or industrialize the DNA sequencing process.  In order to achieve scale, speed, and efficiency, the 
sequencing process was decomposed into many simpler, repetitive steps, utilizing high-volume process 
automation and operations management tools.  Complementing this work design, the organization divided 
itself around individual processes, with many sub-teams performing small, repetitive pieces of the larger 
process.  The resulting organization consisted of a layered reporting hierarchy of departments and sub-
departments traditionally found in most manufacturing plants.  
 
Each sequencing operations department has a manager, and most of the sub-departments have a 
coordinator or supervisor. The technicians, who are analogous to floor-level operators in a manufacturing 
plant, work closely together and report up to these coordinators and managers.  However, due to the 
reporting structure, facility layout, and job design, teams and sub-teams interact infrequently, resulting in 
weak relationships across groups.  In Chapter 3, Figure 12 shows the organizational design of the Broad 
Institute, and Figure 13 shows the organization chart for sequencing operations, including MBPG. 
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While most of the other departments at the Broad Institute had already been highly industrialized, MBPG 
had not yet undergone such a transformation and still operated more like a laboratory than a 
manufacturing group.  Thus, a project was needed to transform MBPG into an operations-minded 
production group and align it with the Broad’s strategy for industrial-scale biotechnology research.  Given 
the close physical ties between MBPG and the other departments, the lack of a production environment in 
MBPG propagated quality issues, variability, and poor inter-department relationships throughout the 
organization.  Whereas manufacturing management tools such as assembly line material flow, process 
automation, and theory of constraints had been used to effectively design the other departments, these 
tools were not useful in MBPG given its lower volumes and higher content of skilled labor.  Lean 
manufacturing was identified during this project as the most proper tool for MBPG, and implementing it 
allowed MBPG to align better with the Broad’s strategy, formal structure, and operating environment. 
 
The Broad’s process-oriented department structure was a project enabler in that it allowed MBPG to 
experiment on its own with lean manufacturing since its outputs to the downstream department were 
already well defined.  In other words, MBPG could be treated as a “black box” in which a different 
manufacturing style (lean) and a different operations strategy (maximize quality) could be implemented 
from the rest of the departments.  Thus, MBPG could better align its very different technical processes to 
the overall Broad strategy, something not possibly if MBPG tried to operate like every other department. 
 
Conversely, the Broad’s process-oriented departments were a hindrance for implementing improved 
inventory management and a spirit of continuous innovation in MBPG.  Since the Materials department 
was tasked with supply chain management, it was difficult to initiate inventory and material flow 
improvements from inside MBPG.  Very weak linking mechanisms existed between MBPG and 
Materials, mostly relying on word-of-mouth communication.  To ensure project success, these links were 
significantly strengthened to include formal inventory specifications, forecasts, and collaborative projects.  
As the LFM intern in MBPG, the thesis author primarily served as this strong linking mechanism since he 
could speak both the “scientific language” of MBPG and the “operations language” of Materials.  Upon 
completion of the internship, the improved communication mechanisms and linking processes are 
providing an ongoing significant improvement in the linking between MBPG and Materials. 
 
Developing a spirit of continuous innovation was a challenge due to the existence of the Molecular 
Biology Development (MBD) group and also the strict definition of three sub-teams within MBPG.  
MBD had been created about a year before this thesis work and was tasked with developing next 
generation technologies for MBPG.  The manager of MBD had formerly been the MBPG manager and 
was the most senior molecular biologist at the Broad.  Thus, MBPG tended to look to MBD for all its 
innovations and simply did what they were told per the current process standards.  Compounding this 
challenge was the sub-team structure within MBPG where each employee only worked on ligation, 
transformation, or DNA preparation processes.  While needed for specialization in complex technologies, 
this structure hindered cross-team collaboration, respect for common work spaces, and an end-to-end 
process mindset.  The lean manufacturing implementation was a success partly because it addressed these 
structural challenges.  It convinced MBPG to embrace a new form of innovation, process improvement, as 
its own specialty separate from MBD, and it also get all three sub-teams to work together to improve the 
physical space and workflows within MBPG. 
 
To support the implementation process, formal coordination was primarily made the responsibility of the 
thesis author.  While the author worked inside the MBPG team, he formally reported to the director of 
sequencing operations who took great interest in the internship, giving the author an organizational 
position to impact change across MBPG, MBD, and Materials.  A formal project leadership team was 
created including the operations director, MBPG manager, both MBPG coordinators, and author, and they 
met on a weekly basis to review project status and define next steps.  A dedicated resource was also 
assigned to work for the thesis author for two months on the project, and the person selected was a well-
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respected and experienced MBPG employee.  Another part-time resource was also assigned to the 
author’s project after it showed success in the first month.  The combination of these two employees’ 
process knowledge, the author’s coordination position and operations domain expertise, and the director’s 
personal involvement made for a powerful and well-designed project team. 
 
This analysis of the project’s strategic design points out several areas of concern and possible 
improvements to ensure the continued success of lean manufacturing in MBPG.  With the departure of the 
author from the organization, a void was left in the critical project coordination mechanism and process 
improvement driving force.  A short-term solution to this issue was the hiring of a new intern from the 
LFM Class of 2006 to continue and expand this thesis work.  However, a long-term solution is needed 
where the job responsibilities for the MBPG manager and coordinators are modified to include continuous 
process improvement.  Currently, these MBPG leaders are over-burdened with administrative duties and 
interfacing tasks with the other departments, leaving them little time to spend in the laboratory working 
with employees on process improvement, teamwork, and training.  Other project-related responsibilities 
such as formally working with Materials and MBD on process improvement should be delegated to senior 
technical people in MBPG who are now well-trained in 5S and other lean tools.  The innovation 
responsibilities of MBD (science) and MBPG (process, workspace, and workflow) must also be formally 
defined and enforced by the sequencing operations director. 
 
Finally, incentive structures for MBPG employees should be tied to their process improvement 
contributions.  5S checklists were created during the project, and their results will be used during each 
employee’s annual performance review.  Additional incentives are needed beyond this such as bonuses 
that share in savings from process improvements and certifications for different levels of lean 
manufacturing expertise.  A set of 5S metrics was also tracked during the project, and it is critical that the 
MBPG leadership team continue to update, evaluate, and communicate these metrics in the future.  The 
director of sequencing operations will be critical in this area as he can hold MBPG accountable to these 
metrics, checklists, and incentives going forward.  Without such emphasis on continuing the lean 
manufacturing related measurements in MBPG, the project success will fade and the group will resort to 
its prior state. 
 
11.1.2 Political 
The political perspective assumes that organizations are contested struggles for power among 
stakeholders with different goals and underlying interests.  Organizations form combinations of interest 
groups that advocate their side of important issues.  From the political perspective, power is the ability to 
get things done, and major organizational changes are not simply rational moves to accomplish goals, but 
are also threats to those who hold power and opportunities for those who want more power.  
 
With respect to the operations of its sequencing process, power at the Broad Institute has historically 
come from three main sources – hierarchy, educational background, and the LFM program.  The Broad is 
a strongly hierarchical organization with power and decisions passed down from the top.  The heads of 
the scientific programs (equivalent to business unit managers) hold the most power in the organization, as 
they lead the major areas of study that attract government funding and press notoriety.  The platform 
heads (equivalent to plant managers) then hold the next level of power as they run the operations that 
provide the required data to the scientific programs.  Within the genome sequencing platform, the most 
powerful figure is the director of sequencing operations, an alumnus of the LFM Program, followed by 
the department managers.  This hierarchical power structure is emphasized by the physical layout of the 
building where senior management sits upstairs in a nice office area and line managers, coordinators, and 
employees sit downstairs in the crowded, loud laboratory areas. 
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Education provides another source of power at the Broad, and this behavior is consistent with the entire 
biotech industry.  Given the cutting edge nature of this field, most biotech organizations are dominated on 
the technical and business sides by people with prestigious PhDs and Post-Docs in engineering and the 
sciences.  The quality of a person’s degrees and universities serve as a barrier to entry for employment in 
the industry as well as a criterion for career advancement.  The Broad Institute emphasizes this 
educational power source to an even greater extent than biotech companies given its academic and 
government ties and inability to provide large financial rewards.  The only caveat on the education source 
of power at the Broad Institute is that it can be augmented by the tacit knowledge of key sequencing 
operations employees.  Their amount of work experience at the Broad Institute has provided them with 
knowledge of its operations that very few other employees possess or even understand.  Thus, a few 
notable people have risen to significant levels of power in the organization despite their lack of a 
traditional prestigious biotechnology education. 
 
A final source of power in the Broad’s sequencing operations is the LFM program.  Given the Broad’s 
close ties to MIT, competitive strategy of “industrial scale biology,” and hiring of an LFM alumnus as its 
sequencing operations director, the LFM program is held in high regard in the organization.  The Broad 
uses LFM internships for their true purpose of solving critical operations problems (as compared to 
recruiting or university relationship reasons), and each of the past LFM internships before this one had 
been a great success.  Thus, the organization has learned that whatever the current LFM intern is working 
on is a very clear signal of a high importance project in the mind of the director of sequencing operations.  
The thesis author was very appreciative of this political aspect of the organization, as the author instantly 
had a high level of credibility and power at the Broad Institute. 
 
These sources of power at the Broad Institute were evident among the different stakeholders in the lean 
manufacturing and production forecasting implementations in MBPG.  Table 9 below lists these 
stakeholders, their interests, and what each stood to gain or lose from the project, and Figure 50 maps out 
these stakeholders with indications of the extent to which they were for or against the project. 
 
 
Figure 50. Stakeholder map of the LFM thesis work in MBPG at the Broad Institute. 
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Table 9.  Summary of key stakeholders in the LFM thesis work in MBPG at the Broad Institute. 
Stakeholder Interests Gain from Project Loss from Project For or Against? 
Operations 
Director 
- High quality product 
from MBPG 
- Operations mindset 
instilled in MBPG 
- LFM Project 
Success 
- Less time spent 
dealing with MBPG  
- 5S catalyst for all other 
departments 
- Proof of value of LFM 
program 
- Project failure would 
reflect on him as the 
LFM project sponsor 
STRONGLY FOR 
MBPG 
Manager 
 
- Clean up lab space 
- Improve operations 
& quality in MBPG 
- Improve morale in 
MBPG 
- Better operations & 
quality which she is 
accountable for 
- Lab cleanliness in line 
with her standards 
- Greater exposure to 
senior management 
- Loss of daily operations 
power to LFM intern 
- Loss of educational power 
to operations skills 
- Scrutiny on failure of past 
improvement projects 
NEUTRAL  
(FOR on some 
dimensions & 
AGAINST on other 
dimensions) 
Ligation 
Coordinator 
- Increase ability to 
lead  his team 
- Improve morale 
- Learn ops. mgmt 
tools  
- Better operations & 
quality  
- Lab cleanliness 
- New mgmt capability 
- Loss of daily ops. power 
to LFM intern 
- Loss of power for cont. 
improvement to lab 
employees 
FOR 
Transformation 
Coordinator 
- Clean up lab space 
- Improve workspace 
and reputation  
for  team 
- Lab cleanliness 
- Higher visibility for 
transformation team  
- Better equipment 
- None STRONGLY 
FOR 
Ligation Team 
 
- Better workflows 
and work areas 
- Less boredom  
- Learning opps. 
- Leadership opps. 
- Better equipment and 
work conditions 
- Chance to lead 
innovation 
- Loss of freedom from 
standardization 
 
STRONGLY 
FOR 
(except for one 
member of the team) 
Lead 
Technicians 
- Learning opps. 
- Leadership opps. 
- Leadership Role 
- Mgmt. recognition 
- Responsibility if project 
fails 
STRONGLY 
FOR 
Transformation 
Team 
- Better workflows 
and work areas 
- Learning opps. 
- Leadership opps. 
- Better equipment and 
work conditions 
- Chance to lead 
innovation 
- Loss of freedom from 
standardization 
 
FOR 
DNA Prep 
Team 
- Better workflows 
and work areas 
- Be left alone to do 
their work (very 
introverted team) 
- Better equipment and 
workstations 
- Improved work 
conditions 
- Not as strong of a fit to 
Lean with their high 
process mix 
- Feeling neglected in being 
last area of focus 
NEUTRAL  
(FOR on some 
dimensions & 
AGAINST on other 
dimensions) 
MBD (R&D) 
Manager 
- Strict adherence to 
process protocols 
- Leadership of all 
MBPG innovation 
- Improved adherence to 
MBPG protocols 
- Loss of power for 
innovation 
- Loss of informal MBPG 
leadership role 
AGAINST 
Materials 
Department 
- Better workflows 
- Better MBPG 
communication 
- Better inventory 
management 
- Better MBPG info. 
- Loss of control in 
inventory decisions 
STRONGLY 
FOR 
LFM Intern 
(Thesis Author) 
- Successful project 
- Learn about Lean 
- Mgmt. recognition 
- Team recognition 
- Lean skills 
- Project failure falls 
largely on LFM intern 
- No or bad LFM thesis 
STRONGLY 
FOR 
 
As the stakeholder analysis table and map show, most of the interests in the project are fairly compatible.  
Most of the stakeholders saw value in the project and recognized it had some benefits that were directly in 
line with their interests.  Where interest misalignment did exist, the thesis author and the rest of the 
MBPG leadership team found a few mechanisms to address these areas of concern.   
 
The project was unique in that it had a strong amount of bottom and upper level support, but not as much 
middle level support, specifically from the MBPG and MBD managers.  The political concerns of the 
MBPG manager centered on loss of daily operations power, loss of educational power from her scientific 
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background to the project’s operations management focus, and potential scrutiny on why past 
improvement projects had failed and this one succeeded.  To address these concerns, the author used the 
techniques of leadership partnering, sharing power, and sharing recognition with the manager.  While the 
author initially took a stronger leadership role at the project start, he began to back off this position during 
the project to hand more leadership back to the MBPG manager. This leadership transition was critical to 
setting up the future sustainability of the project’s success.  However, in reflection, not enough project 
leadership power was transferred away from the thesis author and to the MBPG manager by the end of the 
project, and this concern was evident in a moderate fall-off in the “5S state” of MBPG in the month after 
the end of the internship. 
 
With regard to the lack of project support from the MBD manager, the challenge faced during this thesis 
work was just one small instance of an overall power challenge inside MBPG.  The MBD manager still 
held a significant amount of power over MBPG given her former role as its manager and her continuing 
role as the most educated and experienced molecular biologist at the Broad.  Thus, the author consulted 
with the director of sequencing operations on how to best address the situation, and they decided the best 
approach was to position the project with a purely operations focus and not a technical focus to avoid 
stepping into the core of the MBD manager’s power.  It was also agreed to mostly not involve the MBD 
manager in the lean manufacturing implementation, except for requiring that her space be optimized 
along with the MBPG area.  This last requirement was acceptable to the MBD manager as it resulted in 
her obtaining newer equipment, a larger amount of equipment, and a larger amount of lab space.   
 
Within the ligation team, all the technicians except one were very supportive of the project.  The one 
unsupportive person was a very experienced technician who had a strong individualistic personality and 
work attitude.  Thus, he was not happy about an outsider coming in and reorganizing the workflows and 
physical layout of MBPG.  To address this issue, the leadership team decided to initially leave his 
workstation out of the 5S effort.  All of the other workstations around him were improved with 
significantly better pieces of dedicated equipment, more space for stocking consumables, and more 
management praise.  Eventually, this unsupportive technician realized that his workstation was now not 
nearly as nice as it could be, and he finally requested the author to “5S” his work area.  This political 
move of initially ignoring the malcontent proved to be a very powerful way of gaining project support. 
 
A final area of interest misalignment was in the DNA preparation team.  The workflows in this team are 
much more variable and non-standardized than those of the ligation and transformation teams.  Thus, 
implementing lean manufacturing in this area was more difficult than the other two and was left until the 
end.  While deferring the DNA preparation team work until the end allowed the implementation to build 
up a great deal of early success, it somewhat alienated this team and created some tension in MBPG.  
Once the leadership team realized this mistake, they quickly moved to implement 5S in DNA preparation 
and more heavily involve the team.  However, the author fears that some long-term damage was done, so 
getting full support for lean from DNA preparation will continue to be a challenge in the future. 
 
Separate from these challenges due to interest misalignment, a final project challenge from the political 
perspective was in the history of poor relations between the technicians and the MBPG manager and 
coordinators.  The employees in MBPG had experienced a great deal of management turnover in the last 
few years, and the current manager had only been with the group for a little over a year.  Also, the 
coordinators had formerly been part of the teams they supervised, leading to a small level of resentment 
between the employees and coordinators around this career advancement.  Therefore, prior to the lean 
manufacturing implementation, a fair level of “us vs. them” political tension existed between the 
employees and their management, with lab cleanliness and quality being two of the most divisive issues.  
While the lean manufacturing work did not fully ease this political tension, it did unite the employees and 
management together toward common goals and solutions in MBPG.  One of the reasons for this success 
was that the project went against the traditional power structure in the organization in that it was not 
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performed in a top-down, educational-superior fashion.  A key takeaway from this insight is that MBPG 
and the Broad Institute should push for more bottoms-up innovation and project leadership in the future. 
 
In summary, from the political perspective this project leveraged one source of power – the LFM program 
– to enable the MBPG employers to drive continuous process innovation, improve their operations, and 
raise their standing in the organization relative to the other departments.  The hierarchical source of power 
was both leveraged – having director-level support – and resisted – the project was not managed in a top-
down manager-to-coordinator-to-employee fashion.  Most importantly, the educational power source was 
resisted in this project, allowing the lowest-level technical people in the organization to provide a 
significant innovation for the Broad’s “industrial scale biology” competitive strategy.  
 
11.1.3 Cultural 
The cultural perspective takes the view that people in organizations take action as a function of the 
meanings they assign to situations.  Cultures develop over time as organizations solve important 
problems, pass on their traditions, and develop shared symbols, stories, and experiences.  Culture is the 
way of life in an organization – it is “what we do around here and why we do it.”  From a cultural 
perspective, organizations are social systems in which people must work and live together, and, therefore, 
the management of meaning during an organizational change is as critical as the management of money 
and production. 
 
The most defining feature of the culture at the Broad Institute was and still is the Human Genome Project.  
Though it was completed over two years ago, the HGP is still the cultural icon in the organization and 
represents the over-riding purpose of the Broad Institute’s work – bettering human health through the 
advancement of genomic sciences.  The HGP is considered by many experts to be one of the greatest 
scientific achievements of all time, and it brought a great deal of prestige to the Broad Institute, including 
articles in national newspapers, a visit from the Dali Lama, and a trip for the Broad’s management to meet 
the President at the White House.  The resulting culture at the Broad is characterized by an intense belief 
in the higher purpose of their work and pride in their world-class scientific capabilities. 
 
However, with the completion of the HGP, a few cultural problems have been created.  The Broad’s 
culture suffers from a loss of identity and focus now that it operates in the post-HGP world.  Sequencing 
the genomes of armadillos and mosquitoes just can’t come close to the cultural significance of the HGP.  
While the boring, repetitive work that goes into the daily sequencing of a genome was tolerable during the 
world famous HGP, employees at the Broad struggle now to find satisfaction and excitement in their 
work, and overall employee morale is low in the sequencing operations area.   
 
A second defining feature of the Broad Institute is its strong “scientist” culture, and MBPG held this 
culture stronger than most other departments.  A classic scientist goes through many years of apprentice-
style training and is used to a great deal of autonomy in doing his/her own work, and many of the MBPG 
employees have come from such a background.  The culture in MBPG had been highly individualistic and 
non-standardized – lab employees were given freedom to set-up their workstations and perform their 
processes as they wanted.  Much of their equipment was shared, and employees mostly dealt directly with 
Materials to supply them on an as-needed basis.  The result of this individualistic culture was misplaced 
equipment, uneven material flow, and occasional sample mix-ups.  This culture also led to a diluted sense 
of accountability because few mistakes could be traced to specific individuals and processes.  While the 
rest of the Broad Institute had instilled a good amount of “industrial operations” culture to balance this 
“scientist” culture, MBPG had not yet achieved such a cultural balance. 
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This thesis work was both a reinforcement and change agent for elements of the Broad Institute’s culture.  
It reinforced the overall culture of “industrial scale biology” by instilling more of an “industrial 
operations” culture in its traditional “scientist” culture.  However, the project was aimed at MBPG where 
this cultural balance had not been achieved, so it was a direct challenge to MBPG’s culture.  By the end, 
the lean manufacturing and production forecasting implementations proved successful in turning MBPG 
into more of a production group than a laboratory group and better aligned the culture inside MBPG with 
the culture inside the rest of the Broad Institute.  Employees, though accustomed to working in traditional 
labs, were aware that this was a necessary cultural thrust and overall welcomed the changes. 
 
This thesis work was also a cultural success in partially addressing the loss of morale and focus since the 
completion of the HGP.  As scientists, employees at the Broad Institute inherently love learning and 
having new equipment (or toys) to work with (much like engineers).  Therefore, the author presented lean 
manufacturing as a new tool or skill set that employees could learn and also used the project as a 
mechanism to get more and better equipment for MBPG.  The author spent a great deal of time in both 
meetings and on the laboratory floor talking about the theory behind 5S and lean manufacturing, its 
history in Japan and the automotive industry, and stories of how it had been successfully applied in other 
industries and on other LFM internships.  Most of the MBPG employees became excited about having 
something new to learn and work on outside of their monotonous laboratory processes, and the project 
benefited from tapping into this learning curiosity inherent in the culture.   
 
The lean manufacturing and production forecasting implementations involved the use of many tools from 
the LFM skill set.  However, the thesis author and project leadership team recognized that MBPG was 
still very new to most operations management ideas and would get confused by the use of too many LFM 
“buzz words” during the project.  Therefore, all aspects of the thesis work were packaged up as simply 
part of “5S.”  Everything implemented on the project was tied back to one or more of the 5S’s, and the 
operations strategy of maximizing quality in MBPG was reinforced over and over again.  Any time the 
project ran into a snag or employees questioned its purpose, the author referred back to three concepts – 
(1) the pareto diagram of the quality problems in MBPG shown in Figure 25, (2) the definition of 5S, and 
(3) the goals of the 5S implementation in MBPG.  These concepts were the three “messages” for the 
project, and both the director of sequencing operations and author consistently referred back to them over 
and over again.  The leadership team knew the culture in MBPG had been positively changed when 
employees started using the phrase “to 5S” as a saying for cleaning up work areas and improving process 
flows.  This phrase eventually spread outside of MBPG to other departments who sought out the MBPG 
team’s help in “5S-ing” their areas. 
 
At the end of this thesis work, it was still too early to determine the extent to which the culture of MBPG 
has been changed.  If the culture of an organization is broken down into three layers – basic assumptions, 
espoused values, and artifacts – then the change that was mostly observed in MBPG is a change in the 
artifacts of the lab (its physical design and environment).  The other two layers of culture are much harder 
to see and measure and also take much longer to change.  Ultimately, as 5S takes root in the espoused 
values of MBPG, its basic assumptions will begin to shift to understand how manufacturing ideas can 
compliment the operations of a lab.  This process will take time and strong leadership. 
 
Culturally, MBPG management has already embraced the espoused values and basic assumptions of the 
lean manufacturing project.  However, in their continued work, the manager of MBPG, director of 
sequencing operations, and next LFM intern must act as “leaders of meaning” and continue to 
communicate with MBPG employees by providing positive reinforcement of the change through the 
language and the framing of successes and challenges.  They must also continually respond to the 
concerns and contributions of the team and provide employees with a sense of influence over the goals 
and incentives for sustaining the project.   
 
MIT Thesis – Matthew R. Vokoun  Page 99 of 132 
In summary, the lean manufacturing implementation has successful pushed the culture of MBPG in the 
direction that management and employees agree it should go.  However, this cultural change is not yet 
fully complete, and strong ongoing leadership is required to sustain the cultural change and prevent 
MBPG from slipping back into its old cultural ways. 
 
11.1.4 Summary of the Three Perspectives 
To summarize this section, the top four insights from each of the three organizational processes 
perspectives are summarized below in Table 10. 
 
Table 10.  Summary of top four insights from the three OP perspectives. 
Strategic Design Political Cultural 
Broad consists of process-
oriented departments that have 
“industrialized” sequencing 
Three sources of power – 
hierarchy, educational 
background, and LFM Program 
Human Genome Project is a 
cultural icon and source of an 
identify crisis 
Department structure enabled 
project in allowing MBPG to 
have its own operations strategy 
Interests of most stakeholders 
were well aligned with project 
5S was a tool for pushing an 
“operations” culture into 
MBPG’s “scientist” culture 
Department structure hindered 
improvements in materials flow 
and innovation process 
Mechanisms were successfully 
found to address areas of interest 
mis-alignment 
Project success through 
leveraging the learning culture in 
MBPG 
Project leadership void was left 
with LFM intern’s departure 
from MBPG 
Project leveraged LFM power to 
enable low-level employees to 
lead critical innovation 
Cultural change in MBPG has 
started but is not yet complete 
 
 
11.2 Leadership of the Change Process 
The purpose of this section is to evaluate the leadership role of the author in the lean manufacturing and 
production forecasting change process in MBPG, focusing on what this experience illustrated about the 
author’s leadership “change signature.”  As described in the previous sections, the author held a 
significant transformational leadership position on this project and held a powerful position in the 
organization as the LFM intern.  In performing the operations strategy work, the author identified lean as 
the most appropriate tool for the thesis work and then sold the project idea to senior management, MBPG 
management, and MBPG employees.  Once the project was approved, the author led both the project 
leadership team and the hands-on project implementation team. 
 
This project was a successful “shop floor transformational” leadership experience for the author and was 
similar to other leadership experiences prior to attending the LFM program.  New leadership insights 
were formed mostly in the project formation and championing areas, as previous experiences were mostly 
in the implementation area.  Therefore, a few dimensions were added to the thesis author’s personal 
leadership change signature and enhanced the dimensions already developed before LFM.  The following 
eight leadership behaviors characterize the leadership change signature demonstrated by the author during 
this thesis work in MBPG at the Broad Institute: 
 
• Management By Walking Around – Ever since reading the book “The HP Way: How Bill 
Hewlett and I Built Our Company” by David Packard about seven years ago, the author has been 
a strong believer in the idea of “management by walking around.”  This leadership trait is marked 
by personal involvement, good listening skills, and the recognition that everyone in an 
organization wants to do a good job. The author made sure to practice this style of leadership 
every day at the Broad Institute by spending a great deal of time in the MBPG and Materials lab 
areas.  As an analytical engineer by background, the author’s natural comfort zone is sitting at a 
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desk in front of a computer, so the author always needed to force himself to not do this as a leader 
and use the “management by walking around” concept as motivation. 
 
• Lead by Example – A leader must get in the trenches with the team and help them implement 
any “shop floor transformation” program.  No team will be inspired or follow a leader who 
simply shares words and concepts, but no actions.  Thus, the author spent several weeks learning 
how to perform all the MBPG processes and then did a great majority of the hands-on 5S 
implementation work with the team.  In simply doing things like moving heavy equipment or 
scrubbing down a dirty work area, the author found the MBPG employees much more willing to 
buy into the thesis work. 
 
• Sell, Sell, Sell – A leader must take any chance to sell the benefits of what he/she is trying to 
accomplish, whether this includes formal presentations, two-minute conversations on the shop 
floor, or getting people to help you with some hands-on project work for thirty minutes every day.  
While this may sound like the behavior of a politician, a leader must get his/her “messaging” 
straight, concise, and clear and then repeat it over and over again to anyone that wants to listen.  
The author practiced this leadership trait by continually selling the MBPG operations strategy and 
lean manufacturing project on a daily basis up and down the organization. 
 
• Be Ultra-Responsive to Improvement Ideas from the Project Team – If someone comes to a 
leader with an improvement idea for the project, the leader should quickly evaluate it, try to 
implement it if possible, and then tell the employee what he/she did.  If the idea is not 
implemented, the leader must still make sure to explain the reasons for this to the person who 
generated the idea.  Quick responses to ideas will make employees much more receptive to what 
a leader is doing, especially at the start of the project.  The author put this leadership trait to 
practice by keeping a written log of all improvement ideas and holding himself to a two-day 
timeline for getting back to MBPG employees on their ideas. 
 
• Be Nice and Legitimately Interested in Coworkers – Leadership starts with actually caring 
about people, their lives, and their job satisfaction.  To be an effective leader, one needs to get to 
know people first and talk to them about their families, hobbies, and backgrounds.  If a leader 
cares about getting to know people as much as he/she cares about implementing the project, the 
leader will find others much more receptive to working with him/her. 
 
• Go Around Project Obstacles – Any project will have people that oppose it, but a leader does 
not let these obstacles block the progress of the project if the team knows the project is the right 
thing to do.  In the MBPG lean manufacturing implementation, the author could tell that one 
employee was very against it.  So, the team implemented 5S all around this employee’s 
workstation first, and then the employee saw all the extra new equipment each 5S’d area now 
had.  He eventually came to the author and requested the team to “5S” his workstation. 
 
• Utilize the Project Champion – Sometimes it is not possible to go around all the project 
obstacles.  An effective leader must be able to identify those problems where his/her strategic and 
political role in the organization can not let him/her address the problem.  In these situations, a 
leader should leverage the executive who sponsored the project to help clear obstacles.  The 
author used this approach at the Broad Institute to get assistance from the director of sequencing 
operations to overcome leadership challenges that spanned across departments into the Materials, 
Core Sequencing, and MBD groups. 
 
MIT Thesis – Matthew R. Vokoun  Page 101 of 132 
• Commit to the Small Conversations – The author found this leadership behavior to be the 
MOST IMPORTANT on this project.  Leadership of “shop-floor” operational transformations 
requires a commitment to the thousands of daily five-minute conversations rather than the one, 
big-audience, hour-long formal presentation.  The people who need to really adopt the project are 
rarely in the conference room with the leaders for the presentation.  They are the people the leader 
talks to for a few minutes every day on the shop floor. 
 
11.3 Evaluation of the Change Process 
The results and metrics of this thesis work were strongly aligned with the goals of the lean manufacturing 
and production forecasting implementations and the interests of the key project stakeholders.  Everyone 
involved with the project at the Broad Institute and MIT felt the project was a resounding success and a 
great example of how manufacturing management tools can be applied in the relatively new field of large-
scale biotechnology R&D.   
 
To evaluate the thesis work as a change process, the following five issues were considered.  They show 
how the thesis work was a large success in MBPG, except for the concern of how the organization can 
sustain this success in the future: 
 
• Acceptance of Findings and Recommendations  VERY STRONG.  The decision to 
implement lean manufacturing in MBPG as part of its strategy to maximize quality was very well 
accepted at all levels of the organization.  The project had a solid blend of operations strategy 
frameworks, proven operations management tools, hands-on implementations involving an 
extended team, and metrics that showed improvement throughout the project.  One signal of the 
high project acceptance was the decision by the Broad Institute to hire another LFM intern to 
follow on in MBPG after the completion of this thesis work to continue the implementation of the 
findings and recommendations. 
 
• Implementation and Follow-Through  VERY STRONG.  A significant strength of the 
Broad Institute is its relative small size and fast decision making ability.  Thus, this project was 
able to go from initiation to implementation within only a few weeks, and the project team was 
able to follow-through on fully implementing the first wave of lean manufacturing and production 
forecasting tools in MBPG before the end of the LFM internship.   
 
• Sustainability of Changes Implemented  CONCERN.  The most common statement in 
MBPG by the end of this thesis work was “what are we going to do when the LFM intern leaves.”  
These statements were signals that the sustainability of the lean manufacturing and production 
forecasting work in MBPG was a significant concern, as the project was still highly identified 
with the thesis author and not with the team.  In reflection, too much time was spent by the thesis 
author working with the laboratory employees and not with the MBPG managers and 
coordinators during the project implementation.  While this assured a high project acceptance, it 
did not build long-term leadership capability in MBPG to sustain the project at the management 
level.  To address this challenge, it will be critical for the director of sequencing operations and 
next LFM intern to continue actively pushing lean manufacturing forward in MBPG, allowing its 
managers more time to take on the ongoing project leadership responsibilities. 
 
• Organizational Learning from the Project  VERY HIGH.  As mentioned previously in this 
chapter, one of the keys to success for this project was tapping into the Broad’s learning culture.  
Lean manufacturing was positioned as a new tool for employees to learn, and most of them 
eagerly dove into learning and applying this new skill.  A great deal of the author’s time was 
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spent educating people throughout the organization on lean manufacturing.  Additionally, lean 
manufacturing had never been tried at the Broad Institute or any other large-scale biotech R&D 
facility, so a great deal of learning was generated from this unique application. 
 
• Diffusion of Learning to Other Units in the Organization  HIGH.  Prior to this project, the 
MBPG lab had been the most disorganized, cluttered, and uncleanly area in the Broad Institute.  
After the project, the MBPG lab area was the best on these dimensions, and its use of 5S became 
a highlight of the many lab tours given at the Broad Institute.  The other departments quickly saw 
this very visible success and became interested in applying 5S and other lean tools in their area.  
Several other departments had the thesis author give educational presentations on lean to them 
near the end of the LFM internship, and these departments are now actively implementing 5S in 
their areas with the help of some employees from MBPG. 
 
11.4 Recommendations for Continued Success 
To conclude this chapter, a few comments and recommendations are provided to MBPG, the Broad 
Institute, and any other organizations that might attempt a similar project to this thesis work.  These 
recommendations focus on what parts of these efforts should be replicated and what should be done 
differently.   
 
• Significant value can be delivered in high-throughput biotech R&D organizations through the 
application of traditional manufacturing management tools such as Lean Manufacturing, 
Production Forecasting, RFID, and Six Sigma.  
 
• Embracing operational excellence is a source of competitive advantage in the biotech industry as 
demonstrated by the Broad Institute's success against other public and private genome sequencing 
centers.  
 
• A traditional “operations management” mindset is very different from a traditional “laboratory 
management” mindset, and blending the two mindsets is a challenge to the biotech industry as it 
scales-up its R&D processes.  Both mindsets have a desire to learn and innovate at their core, and 
these similarities should be leveraged as an organization blends the two mindsets together. 
 
• The “basics” of Lean Manufacturing (5S, workstations, mini-marts, kanban, etc.) are a must-have 
in any operations organization.  They provide the baseline mindset from which all other sources 
of operational excellence are created.  
 
• Develop and communicate effective alignment mechanisms. – Management must clearly and 
frequently articulate how the use of 5S allows MBPG to align itself more closely with the goals 
of the organization.  In developing alignment mechanisms, management should provide team 
members with a sense of influence over the team goals and incentives.  Their buy-in on the 
appropriate alignment mechanisms will be critical to sustaining the change. 
 
• Measure and communicate process improvements from 5S. – The comprehensive set of metrics 
related to the 5S project was a useful tool in evaluating and driving improvement in MBPG.  
Leaders must take the time at the beginning of a project to identify the key metrics and then 
prioritize time during a project to gather and analyze the data needed to update these metrics. 
 
• Develop a formalized process for feedback. – During this project, the thesis author served as this 
feedback process, and a structural hole was left in MBPG with the completion of this internship.  
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MBPG management should place drop boxes in the lab area for suggestions and also provide 
rewards and incentives to employees who make suggestions that are implemented and have 
significantly contributed to improvements. 
 
• Plan for project sustainability from the beginning, and make sure an individual leader is not the 
primary sustaining mechanism. – This mistake was made during this thesis work in having the 
sustainability of the project rely too much on the presence and leadership of the author who is 
now no longer part of the MBPG organization at the Broad Institute. 
 
• True leadership is all about the thousands of daily five-minute conversations rather than the one, 
big-audience, hour-long formal presentation.  Commit to the small conversations! 
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12 Conclusions 
 
This chapter ties together the results and discussion of the preceding chapters, highlighting the key 
conclusions of the thesis.  The chapter also offers some perspectives on how the framework developed in 
this thesis can be applied to the operations capability improvement of any high-throughput laboratory in 
the biotechnology and pharmaceutical industry.  
 
With the completion of the Human Genome Project in 2003 and the continuing introduction of novel 
medical therapies, the biotechnology and pharmaceutical industry is in the middle of an era of 
unprecedented scientific achievement.  However, these breakthroughs are not enough to satisfy the 
world’s ever growing needs for more affordable, available, safe, and individualized medical treatments.  
The biopharma industry must continue pushing forward towards the goal of “personalized medicine” in 
which diseases are redefined on the molecular level so that diagnostics and therapeutics can be targeted to 
specific patient populations, offering the right treatment to the right patient at the right time.  The industry 
must also significantly reduce the cost to develop a new drug, which currently stands at $802 million on 
average according to the Tufts Center for the Study of Drug Development.47 
 
To address these challenges, the biopharma industry must continue to rapidly scale up and industrialize its 
R&D processes.  Further improvements in the cost to sequence a genome will eventually open the door 
for every person to have his or her own genome sequenced, enabling the critical data needed for the 
personalized medicine vision.  Efficiency gains in the operations of high throughput R&D laboratories in 
biopharma companies will help address the rising costs of developing new drugs.  The effective 
application of operations strategy and use of operations management tools such as Lean Manufacturing 
and Six Sigma will be critical in allowing biopharma R&D operations to meet these requirements. 
 
The Broad Institute has been on the forefront of addressing these new management challenges given its 
role in creating the first example of “industrial scale biology” with the genome sequencing operations it 
created for the HGP.  This thesis work in the Molecular Biology Production Group is a further example of 
the Broad Institute’s role of teaching its industry how to apply traditional operations management tools to 
the effective operation of high throughput laboratories.  MBPG had not yet undergone the same industrial 
transformation as the rest of the groups at the Broad Institute, so this thesis is an excellent case study of 
how to “industrialize” a biopharma R&D laboratory.  Additionally, this thesis is unique in that it 
demonstrates how operations management tools can be used to increase quality, as compared to the more 
traditional goals of increasing throughput and reducing costs. 
 
This thesis has sought to define a framework for improving the operations capability of a molecular 
biology laboratory in a high throughput genome sequencing center.  Chapters 4 and 5 provided a 
description of MBPG and described an initial audit of its operations capability.  Chapter 6 defined 
maximizing quality as the operations strategy for MBPG and then showed how lean manufacturing, 
production forecasting, and Six Sigma can be used to address different areas of operations capability 
improvement.  Chapter 7 described a lean manufacturing implementation that resulted in significant 
improvements in quality, Chapter 8 described a production forecasting implementation that significantly 
improved the operations of MBPG, and then future quality-focused applications of Six Sigma and RFID 
are described in Chapters 9 and 10.  Finally, Chapter 11 examines this thesis work from the three 
perspectives of organizational processes and also provides a project leadership assessment, evaluation of 
the change process, and recommendations for continued success in MBPG. 
 
                                                 
47
 Source: Tufts Center for the Study of Drug Develop
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In summary, the key conclusions of this thesis are: 
 
• Operations has an important role in biopharma R&D. – Significant value can be delivered in 
high-throughput biotech R&D organizations through the application of traditional manufacturing 
management tools such as Lean Manufacturing, Production Forecasting, Six Sigma, and RFID. 
This thesis provides a case study of how these tools have been used in a molecular biology 
laboratory in a high throughput genome sequencing center, and the Broad Institute demonstrates 
how operational excellence is a source of competitive advantage in biopharma R&D. 
 
• A laboratory must define its operations strategy. – A critical first step in “industrializing” a 
laboratory is defining its operations strategy as one or more of the following: (1) minimize cost, 
(2) maximize throughput, (3) maximize flexibility, or (4) maximize quality.  To select the 
appropriate strategy, the laboratory’s capacity, material costs, capital costs, position relative to the 
process bottleneck, and impact on final R&D product quality must be considered. 
 
• In a high throughput operation, not all groups must be focused on throughput. – In the 
Broad Institute’s high throughput genome sequencing center, MBPG has very low relative 
material and capital costs and excess capacity, is upstream of the bottleneck, and has a large 
impact on final product quality.  Therefore, its operations strategy must be to maximize quality in 
order to allow the Broad Institute to achieve its operations strategy of drastically reducing the cost 
to sequence a genome. 
 
• Lean Manufacturing can address “managed in” sources of quality problems. – In MBPG, 
the most concerning sources of quality problems (DNA sample mix-ups, improper procedures, 
undetected equipment failures, lab disorganization and uncleanliness, and priority and schedule 
changes) had nothing to due with the actual molecular biology processes performed but rather 
were managed into the process by the policies, workflow design, and organizational design of 
MBPG.  This thesis demonstrated how the basic tools of Lean Manufacturing (5S, workstations, 
etc.) can be used to solve these “managed in” sources of quality problems. 
 
• Operational excellence starts with the basics. – This thesis demonstrated how the use of rather 
basic operations management tools can have dramatic improvements on the operations capability 
of an organization.  In this thesis, very simple lean manufacturing tools and a very basic 
spreadsheet-based production forecasting tool were used to transform MBPG from a laboratory 
group into a production group similar to those found in traditional manufacturing plants. 
 
• Leadership of operational transformations requires a commitment to small conversations. – 
True leadership is all about the thousands of daily five-minute conversations rather than the one, 
big-audience, hour-long formal presentation.  The people who need to really adopt the project are 
rarely in the conference room with the leaders for the presentation.  They are the people the leader 
talks to for a few minutes every day on the shop floor. 
 
This thesis work resulted in significant quality improvements in MBPG as well as a much more industrial 
approach to the management of its operations.  It also resulted in an understanding across the Broad 
Institute that the operations strategy of MBPG should be to maximize quality, and that all subsequent 
operations capability improvement projects in MBPG should be performed with this sole objective in 
mind.  Finally, this thesis work served as an introduction of lean manufacturing to the Broad Institute’s 
genome sequencing operations, and this methodology has now taken hold in the organization and spread 
to other groups beyond MBPG. 
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More broadly, the results of this thesis work can be applied to the operations capability improvement of 
any high throughput laboratory in the biotechnology and pharmaceutical industry.  As an increasing 
number of high throughput technologies are introduced into biopharma R&D organizations, many 
managers are challenged with how to operate their laboratories like a production group in a traditional 
manufacturing plant.  To assist in this new management challenge, the results of this thesis have been 
used to create a general framework for selecting the correct operations strategy and operations 
management tools for a biopharma R&D manager that is seeking to improve the operations capability of 
any laboratory.  This framework appears below in Table 11. 
 
Table 11.  Framework for selecting the operations strategy and management tools for a biopharma laboratory. 
 
Laboratory Characteristics 
 
Costs  
(Relative to 
the Whole) 
 
Capacity  
(Relative to the 
Bottleneck) 
 
Impact on 
Quality of 
Final Output 
Operations 
Strategy 
Operations 
Management Tools 
Example(s) 
 
Low 
 
 
Excess 
 
High 
Maximize  
Quality 
Lean Manufacturing, 
Six Sigma 
MBPG at 
Broad 
 
Low 
 
 
Excess 
 
Low 
Minimize  
Cost 
Process Automation, 
Outsourcing 
None available 
 
Low 
 
 
Bottleneck 
 
High 
Maximize 
Throughput 
Theory of Constraints, 
Scheduling, Six Sigma 
Finishing 
Group at Broad  
 
Low 
 
 
Bottleneck 
 
Low 
Maximize 
Throughput 
Theory of Constraints, 
Scheduling, Process 
Re-Engineering 
Report Writing 
Group Inside a 
Laboratory 
 
High 
 
 
Excess 
 
High 
Minimize Cost, 
Maximize Quality 
Six Sigma, Lean 
Manufacturing 
Core Seq. 
Group at Broad 
 
High 
 
 
Excess 
 
Low 
Minimize  
Cost 
Process Automation, 
Outsourcing, Lean 
Manufacturing 
Materials Dept. 
Agar Plate 
Mfg. at Broad 
 
High 
 
 
Bottleneck 
 
High 
Maximize 
Throughput, 
Maximize Quality 
Theory of Constraints, 
Six Sigma 
Detection 
Group at Broad  
 
High 
 
 
Bottleneck 
 
Low 
Maximize 
Throughput, 
Minimize Cost 
Theory of Constraints, 
Lean Manufacturing 
None available 
 
 
In closing, it is valuable to refer back to the mission of the Broad Institute described in the introduction to 
this thesis – “(1) create tools for genomic medicine and make them broadly available to the scientific 
community and (2) apply these tools to propel the understanding and treatment of disease.” While this 
statement typically refers to scientific tools, this thesis is consistent with the Broad Institute’s mission in 
creating a new operations management tool for improving the capability of a biotechnology laboratory 
and then applying this tool to the Molecular Biology Production Group.  The knowledge created by this 
thesis is now available to the broader scientific community, with the hope that it can provide a positive 
impact on the ability of R&D organizations in the biotechnology and pharmaceutical industry to create 
the life enhancing innovations we all hope and pray for. 
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15 Appendix A – Process Flow Diagrams 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Process flow diagram for the DNA Preparation team in MBPG. 
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Figure 52. Level 2 process flow diagram for the Ligation team in MBPG. 
MIT Thesis – Matthew R. Vokoun  Page 114 of 132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. Level 3 process flow diagram for the Ligation team in MBPG. 
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Figure 54. Process flow diagram for the Transformation team in MBPG. 
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16 Appendix B – Lean Manufacturing Implementation Results 
 
This appendix contains pictures and diagrams illustrating the results of the MBPG lean manufacturing 
implementation.  This information was not discussed or covered in Section 7.5 of this thesis and is 
included here as additional information for the reader. 
 
16.1 MBPG Lab Floor Layout 
The MBPG lean manufacturing implementation utilized both a “before” and “after” floor layout of the 
MBPG lab area to guide the progress of the implementation.    
 
 
Figure 55. MBPG lab floor layout prior to the lean manufacturing implementation. 
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Figure 56. MBPG lab floor layout after the lean manufacturing implementation. 
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16.2 Gel Buffer Reagent Kanban 
The MBPG lean manufacturing implementation utilized one kanban system for the materials 
replenishment of two buffer reagents used in the gel workflow.  These buffer reagents had previously 
been created from concentrated solutions by the MBPG team on an as-needed basis.  This work was 
transitioned to the Materials department who then operated a two-cart kanban loop.  
 
In this kanban system, one cart was placed in the MBPG lab area with “in use” carboys filled with the two 
buffer reagents.  The other cart was kept in the Materials department lab area where it was cleaned out, 
refilled, and placed in waiting until the cart in MBPG became empty.  The empty carboys on the cart in 
MBPG were the visual signal to the technicians to push the empty cart back to the Materials lab and bring 
back the filled cart.  One of the carts used in this gel buffer reagent kanban is pictured below along with 
some of its benefits. 
 
 
 
 
 
Figure 57. Gel buffer kanban cart used in the MBPG gel workflow area. 
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16.3 Ligation Workstation Equipment Lists 
Section 7.5.1 discusses the vast improvements to the ligation workflow and workstations.  One of the 
process characterization tools used in this improvement project were lists of equipment and consumables 
used in the ligation process.  These lists appear in this section. 
 
 
Figure 58. List of permanent equipment used in the MBPG ligation process. 
 
 
Figure 59. List of consumables used in the MBPG ligation process. 
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16.4 Gel Workstations 
Section 7.5.4 discusses the vast improvements in the fractionation gel workflow in MBPG.  This section 
contains “before” and “after” pictures of some of the workstations built for the gel workflow. 
 
 
Figure 60. Before pictures of the Gel Making Workstation in MBPG. 
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Figure 61. After pictures of the Gel Making Workstation in MBPG. 
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Figure 62. Before picture of the Large Gel Box Workstations in MBPG. 
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Figure 63. After pictures of the Large Gel Box Workstations in MBPG. 
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Figure 64. Before picture of the Gel Staining and Imaging Workstation in MBPG. 
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Figure 65. After picture of the Gel Staining and Imaging Workstation in MBPG. 
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16.5 DNA Preparation Workflow Improvement 
Section 7.5 discusses the vast improvements to the ligation and transformation workflows and 
workstations.  Improvements were also made in the DNA preparation workflow and workstations, and 
this section contains “before” and “after” process flow diagrams for DNA Preparation. 
 
 
Figure 66. DNA Preparation workflow prior to the lean manufacturing implementation. 
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Figure 67. DNA Preparation workflow after the lean manufacturing implementation. 
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17 Appendix C – Lean Manufacturing Metrics Calculations 
 
This appendix contains the detailed calculations behind the lean manufacturing metrics described in 
Section 7.7. 
 
17.1 Sample Mix-up Points 
The data behind the sample mix-up points metric for the first and last month of the project are below. 
 
Table 12.  Data gathered in June 2004 for the potential sample mix-up points metric. 
Month = Jun-04
Cumulative # Potential Sample Mix-Up Points 71
Area Bay # No. Mix-Up Points
Common-Use Transformation Benches (2) 2 3
Common-Use Electroporators (3) 2 3
Refrigerator (-20 C) for Transformers & Ligators 2 1
Refrigerator (-80 C) for Transformers & Ligators 2 1
Warm Room 1
Cold Room 1
Incubator for Transformers 2 0
Refrigerator (+4 C) for Ligators, Reagents 1 1
Refrigerator (+4 C) for Ligators, Pico & SyBR 1 1
Invertor for Falcon Tubes 1 1
Invertor for Epp. Tubes 1 1
Common-Use Thermal Cyclers 2 5
Common-Use Cold Centrifuges 1 & 2 3
Beckman Centrifuges 2 & 3 2
Common-Use Water Bath, Small 2 1
Common-Use Water Bath, Large (gel area) 1 1
FluorImager - Gel Imaging only 2 1
FluorImager - Gel Imaging + Pico 1
Common-Use Large Gel Boxes 1 10
Common-Use SC Gel Boxes 1 8
Common-Use Pulse Field Gel Boxes 1 2
Common-Use Small Gel Boxes 1 16
Microwaves 1 2
Shaker Tables (2) 2 2
Common-Use Dry Heating Blocks 1 & 2 3
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Table 13.  Data gathered in November 2004 for the potential sample mix-up points metric. 
Month = Nov. 2004
Cumulative # Potential Sample Mix-Up Points 36
Area Bay # No. Mix-Up Points
Common-Use Transformation Benches (2) 2 0
Common-Use Electroporators (3) 2 0
Refrigerator (-20 C) for Transformers & Ligators 2 0
Refrigerator (-80 C) for Transformers & Ligators 2 1
Warm Room 1
Cold Room 1
Incubator for Transformers 2 2
Refrigerator (+4 C) for Ligators, Reagents 1 0
Refrigerator (+4 C) for Ligators, Pico & SyBR 1 0
Invertor for All Tubes 1 3
Invertor for Epp. Tubes 1 0
Common-Use Thermal Cyclers 2 0
Common-Use Cold Centrifuges 1 & 2 0
Beckman Centrifuges 2 & 3 2
Common-Use Water Bath, Small 2 0
Common-Use Water Bath, Large (gel area) 1 2
FluorImager - Gel Imaging only 2 0
FluorImager - Gel Imaging + Pico 1 0
Dedicated Large Gel Boxes 1 0
Common-Use SC Gel Boxes 1 8
Common-Use Pulse Field Gel Boxes 1 4
Common-Use Small Gel Boxes 1 8
Microwaves 1 2
Shaker Tables (2) 2 2
Common-Use Dry Heating Blocks 1 & 2 0
 
 
MIT Thesis – Matthew R. Vokoun  Page 130 of 132 
17.2 Ligation Productivity and Quality Metrics 
The data behind the ligation productivity and quality metrics for all months of the project are below. 
 
Table 14.  Data gathered for the ligation productivity and quality metrics. 
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Table 15.  Ligation capacity calculations for June through November of 2004. 
June July August Sept. Oct. Nov.
Number of Ligators 6 5 4 4 3.25 4
Hours Worked per Month 167 167 167 167 167 167
Total Monthly Ligator Capacity (person-hours) 1000 833 667 667 542 667
Cycle Time per Library Attempt (person-hours) 56.25 56.25 53.08 53.08 53.08 53.08
Available Ligation Capacity (library attempts per month) 17.8 14.8 12.6 12.6 10.2 12.6
Individual Ligation Capacity (library attempts / month / person) 2.96 2.96 3.14 3.14 3.14 3.14
Library Capacity
Ligation Process Step
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17.3 Floor Space Metrics 
The data behind the recovered floor space metrics for the final month of the project are below. 
 
Table 16.  Data gathered in November 2004 for the recovered floor space metric. 
Month = Nov-04
Cum. Rec. Space (sq.ft.)= 141.2
Recovered Area Bay # Floor Space (sq. ft.)
Extra Gel Table 1 10.6
Old Microwave Space 1 6.0
Old Core Sequencing Bench Space 1 11.4
Spot for Boxes next to -20 Fridge 1 4.0
Replace Big Gel Table with Small Gel Table 1 0.2
1 Shelf --> Above Scales & Agarose Area 1
4 Shelves --> Old CS Area 1
Set of Drawers --> Old Storage of Gel Combs, Dams 1 4.7
Set of Drawers --> Old CS Area 1
Extra Transformer Table 2 10.6
Footspace --> Under Room Temp. Mini-Mart 2
Footspace --> Under DNA Prep Bench 3
Footspace --> Under DNA Prep Bench against Wall 3
Old Bench Space for Broken Therm Cyc & Shearer 3 16.3
4 Shelves --> Above New Gel Staining/Imaging WS 1
Set of Drawers --> New Pico WS 1
Footspace --> Old Pico Drum Storage Spot 1
Moved Gel Imaging Computer off of Benchtop 1 4.3
2 Shelves --> Above Nathan & Andy Bench 1
4 Shelves --> Old location for Tips Mini-Mart 1
Space for 2 old fridges in DNA Prep area 3 14.5
Space for DNA Extraction oven 3 5.6
Reducing from 2 benches to 1 for Gel Shaking & Imaging 2 11.2
Table now used for Transformer Plate QC 2 10.6
Table now used for Transformer Common Equipment 2 10.6
Table now used for Transformer Common Equipment 2 10.6
Spot for New Microwave Stand behind QPIX 1 6.3
Old spot for 1 cart in walkway by ligator benches 2 3.8
 
